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Abstract
Modified vaccinia virus Ankara (MVA) is a highly attenuated, replication defective strain of 
Vaccinia virus with the attributes of an optimal viral vaccine delivery system.
An improved vaccine for the prevention of tuberculosis (TB) is urgently required and until 
recently, the most advanced clinical candidate under development for use against TB was 
based on MVA vectoring a single mycobacterial antigen (MVA85A). Unfortunately, pre- 
clinical efficacy and potent immunogenicity in humans did not lead to improved protection 
in BCG vaccinated infants.
There are a number of design features to consider in the development of a recombinant 
MVA (rMVA)-based vaccine. The current study undertook to assess how these might 
impact upon the immunological potency of MVA vectoring TB antigens. Specifically, the 
influence of vaccinia promoter selection and leader sequences was assessed.
Vaccinia promoter selection influences antigen transcription and thereby expression. The 
relationship between antigen production, murine immunogenicity and protective efficacy 
was evaluated. The results support the conclusion that vaccinia promoter optimisation can 
increase immunological potency and efficacy.
Virally vectored antigens can be fused to sorting signals for optimised intracellular 
processing. The immunomodulatory effects of two leader sequences were compared. The 
results suggest that the sorting signal currently incorporated in virally vectored TB 
candidates, such as MVA85A, might be subject to further optimisation for the induction of 
enhanced T cell responses.
Overall, the results demonstrate that rMVA immunogenicity is intrinsically linked to the
precise nature of transgene insertion. The value of an optimised vaccinia promoter might
be to reduce the dose of rMVA required. Leader sequences represent an opportunity to
enhance the quality of the antigen-specific response for improved protection. It is
VI
concluded that both vaccinia promoter selection and leader sequence optimisation should 
be a feature of future rMVATB vaccine development.
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Chapter 1 Introduction
1.1 Vaccination
In 1798, Edward Jenner published his research describing inoculation with cowpox lesion 
matter to confer protection against smallpox (Jenner, 1798). At the end of the last century, 
live Vaccinia virus, a very close relative of cowpox virus was used as the vaccine in the 
World Health Organisation's Smallpox Eradication Programme (1966 -  1980). Jenner 
introduced the noun 'vaccine' to describe the cowpox material used as his inoculum, and 
subsequent use of the words 'vaccine', 'vaccination' and 'vaccinology' pay homage to his 
pioneering studies; vacca is Latin for cow. Jenner may not have been the first to use 
cowpox to achieve protection against smallpox; there is anecdotal evidence that an English 
farmer, named Benjamin Jesty, protected his family from smallpox via the same means 20 
years earlier. The practice of variolation (inoculation with smallpox lesion matter) had also 
been widely implemented and can be traced back to the ancient Chinese. Jenner, however, 
was the first to subject the phenomenon of immunisation to scientific investigation and 
reporting. In the subsequent 200 years of vaccinology research there have been many 
significant developments.
1.1.1 Major advances in the development of novel vaccines
The history of vaccination, and findings in the related fields of bacteriology, virology and 
immunology that have been pivotal to vaccine development, has been reviewed (Plotkin, 
2014; Plotkin and Plotkin, 2011). A brief overview is provided here and is summarised in 
Figure 1.1.
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In his publications relating to smallpox, Edward Jenner described the capacity for a 
naturally occurring, less virulent infection to confer protection against a related, but more 
deadly disease. Eighty years later, Louis Pasteur demonstrated that the same phenomenon 
could occur following artificial attenuation of the disease-causing agent; chickens were 
protected against cholera and cattle against anthrax. In 1885, the Pasteur laboratory 
applied induced attenuation to produce a rabies vaccine for post-exposure use in humans.
Fundamental to the development of vaccines has been the discovery of their causative 
agents. In 1877, Robert Koch published discussions on the causative agents of disease, 
giving rise to Koch's postulates: a set of 4 criteria through which to confirm the relationship 
between a microbe and an infectious disease. Between 1876 and 1884, Robert Koch 
identified the bacteria responsible for anthrax, tuberculosis (TB) and cholera. The discovery 
of these and other causative agents of disease was an important precursor to the 
development of effective vaccines; after the artificial attenuation work of Pasteur came the 
finding that whole-cell preparations of dead bacteria, killed by heat or chemical treatment, 
could be safely administered to confer protection against their live counterpart. In the late 
19th century, this process gave rise to bacterial vaccines against typhoid, cholera and 
plague.
Towards the turn of the 20th century, it was discovered that the bacterium responsible for 
diphtheria infection produced a toxin and that anti-toxin, i.e. the serum of a toxin- 
inoculated animal, was protective upon transfer to another animal. In 1907, Emil von 
Behring demonstrated improved efficacy with toxin - anti-toxin (TAT) mixtures and this was 
implemented for human use. In 1923, TAT was superseded by the use of formalin- 
inactivated toxin, or 'toxoid', the immunogenicity of which was later shown to be enhanced 
by the addition of aluminium salts (Glenny et o/., 1926). This was the first example of an 
adjuvanted vaccine, i.e. a vaccine to which a substance had been added to potentiate the 
immune response evoked to it.
The artificial attenuation work of Pasteur had been achieved using exposure to adverse 
conditions such as oxygen and/or heat. The first example of attenuation achieved via serial 
passage was provided by scientists Albert Calmette and Camille Guerin, who grew 
Mycobacterium bovis on artificial medium. After 230 passages, performed over a period of 
14 years, the bacillus of Calmette and Guerin (BCG) was less virulent and provided 
protection against M. tuberculosis in animal models. The M. bovis BCG vaccine strain was 
first used in humans in 1927 and later, evidence for its protective efficacy in children was 
described (Calmette, 1931).
The first viral vaccine to be attenuated by serial passage was a vaccine for Yellow Fever 
virus (Theiler and Smith, 1937). Viral vaccine development was later accelerated by the 
advent of methodology for large-scale propagation of viruses in vitro (Enders et al., 1949); 
the development of these improved tissue culture techniques led to the production of live 
attenuated vaccines against poliovirus, measles, rubella and mumps. A further 
development related to the culture of viruses in vitro was the ability to induce attenuation 
of RNA viruses via reassortment. This process was applied in the generation of vaccines 
against influenza and rotavirus, and more recently a new rotavirus vaccine (Clark et al., 
1996).
An alternative to the use of whole cell preparations has been the development of vaccines 
based on individual components of the disease-causing organism. The first examples of 
'subunit' vaccines were based on inactivated toxin (diphtheria and tetanus toxoid). More 
recent examples based on isolated proteins include vaccines for use against anthrax, 
pertussis and hepatitis B. There are also vaccines based on polysaccharides, e.g. for 
meningococci and pneumococci, which have been improved by conjugation to protein 
antigens. Another subunit combination, developed for use against cholera, comprises a 
killed whole cell (WC) preparation in combination with a cholera protein. Some virus
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proteins, e.g. the LI protein of human papilloma virus (HPV), have increased 
immunogenicity on account of forming virus-like particles (VLP).
The most recent general development to impact on the field of vaccinology is the 
advancement of techniques related to genetic engineering. This has made possible the 
production of recombinant protein, as first demonstrated for hepatitis B surface antigen 
(Valenzuela et al., 1982). It has also been possible to deliver a subunit antigen for one 
infectious disease target using an unrelated organism as a recombinant delivery system. 
Thus far, one example has been licensed: a Yellow Fever Virus (YFV) carrying a Japanese 
encephalitis (JE) antigen.
An important consideration for more recent vaccine development efforts is safety. To date, 
smallpox remains the only disease to have been eradicated via vaccination; eradication was 
declared in 1979 (Fenner et al., 1988). Live Vaccinia virus was used as the vaccine and 
whilst clearly efficacious, it was observed to cause severe complications in some individuals, 
for example those with immunological disorders (Lane et al., 1969). Therefore, a safer 
alternative was required. Vaccinia virus Ankara was attenuated via serial passage on chick 
embryo fibroblast (CEF) cells. After more than 500 passages, the resultant strain was 
replication-defective in mammalian cells and non-pathogenic in animal models and was re­
named Modified Vaccinia virus Ankara (MVA) (Mayr et al., 1978). Later, genomic analysis 
and marker rescue revealed the attenuation to be the result of multiple deletions and 
mutations (Meyer et al., 1991; Wyatt et al., 1998), all of which were confirmed when the 
MVA genome was sequenced (Antoine et al., 1998). Towards the end of the smallpox 
campaign, MVA was used to vaccinate over 120,000 individuals without the complications 
observed for the parent strain. Whilst the contribution of MVA to the eradication campaign 
may be unclear, it was demonstrated to be safe in all groups. Recently, MVA has been 
licensed for use as a smallpox vaccine in Europe (IMVANEX®, Bavarian Nordic) and Canada 
(IMVAMUNE, Bavarian Nordic).
1.1.2 Future goals for vaccinology research
As described above, there are now many effective vaccines available for the prevention of 
important human diseases and these are used in the World Health Organisation's Expanded 
Programme of Immunisation (EPI) (see Figure 1.1). However, vaccines are still required for 
prevention of the three biggest causes of morbidity and mortality: TB, HIV/AIDS and 
malaria. There are also vaccines under development for the immunotherapeutic treatment 
of cancers.
A vaccine forTB (M. bovis BCG) was developed and remains in use, but is now recognised to 
be only partially effective beyond adolescence and so an alternative is required (discussed 
further, below). It now known that for the majority of the vaccines successfully 
implemented to date, protective immunity is achieved via the induction of humoral 
responses, i.e. protective antibodies (Plotkin, 2010). For the outstanding vaccine targets, 
for which antigenic diversity and complexity of the pathogen/stages of the infectious 
disease are an issue, greater levels of cellular immunity are believed to be required. As 
such, it has become apparent that a thorough understanding of the protective immune 
response is an essential aspect of vaccinology research.
Humoral immunity
That an immunological component (antibodies) existed in blood serum became evident in 
1890, when von Behring and Kitasato performed serum transfer studies to confer 
protection against diphtheria. In 1931, Theiler demonstrated the neutralising properties of 
this component with regards to viral infectivity. Then in 1939, Tiselius and Kabat identified 
antibodies as gamma globulins.
Immunoglobulins (Ig) are produced by B cells - lymphocytes that mature in the bone 
marrow. They are glycoproteins comprising heavy and light chain elements the structure of 
which form a variable, antibody binding fragment (Fab) and a crystallisable fragment (Fc) 
which is constant (Schroeder and Cavacini, 2010). A schematic is shown in Figure 1.2A.
Variable region
Constant region
IFNy
TNFa
IFNy IL-4 IL-17 IL-10
TNFa IL-5 IL-22 TGFP
IL-2 IL-10
Figure 1.2 Components of the adaptive immune system. A) The structure o f 
immunoglobulin comprising heavy (red) and light (orange) chains. B) Principal T-cell 
subsets and the cytokines they secrete (IFNy; interferon gamma, TNFa; tum our 
necrosis factor alpha, IL; interleukin).
For the most part, Ig molecules are secreted, but they can also serve as a B cell surface 
receptor. Antibodies function by binding antigen at the variable region and then 
stimulating immunological pathways via Fc receptors (FcR); the m ajority o f cells 
contributing to  immune function expressed FcR. Five main classes o f Ig have been 
categorised based on differences in the structure o f the Fc fragment, tw o o f which (IgG and 
IgA) have sub-classes, also referred to  as isotypes (see Table 1.1). For each Fc type there is 
a complementary FcR capable o f activating or inhibiting immunological responses. 
Differences in the heavy chain confer differences in biological activity, since it is the heavy 
chain which defines the Fc portion, and thereby the FcR tha t w ill be bound and the role o f 
the Ig molecule w ith in  the immune system.
Arguably the most im portant class o f antibody, in the context o f vaccine induced
protection, is IgG. It is the most abundant and induction o f antigen-specific IgG is a
correlate o f protection fo r many vaccines (Plotkin, 2010). In addition to  influencing
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immune pathways, a vital role for IgG (as well as IgA) is to bind directly to toxins and 
viruses, thereby neutralising them by impeding subsequent interaction with the host.
Table 1.1 The 5 classes of immunoglobulin. A summary of the main characteristics 
and biological functions of human Ig classes. IgG and IgA are present as one of 4 and 
2 isotypes, respectively (Arnold et al., 2007; Schroeder and Cavacini, 2010).
■g
Heavy
chain
Function and characteristics
IgG y l Neutralises toxins and viruses.
y2 Binds complement; a serum enzyme system leading to 
pathogen destruction.
y3 Is the most abundant serum Ig, circulating at 10-15 mg/ml. 
Can be transferred across the placenta.
y4 As above, but does not bind complement.
IgA Secretory forms (IgAl and lgA2) provide mucosal immunity.
a l ,  a l Both associated with mucosal epithelia, tears, saliva and 
milk. Serum IgA consists predominantly of IgAl ( ~ 1 mg/ml).
IgM Associated with primary immune response.
Binds complement.
Serum Ig has a pentameric structure (~ 2.5 mg/ml). 
Also serves as a B cell receptor.
IgD
6
Low abundance in serum (< 30 pg/ml).
Is expressed on immature (differentiating) B cells, with IgM.
IgE Least abundant serum Ig (<  1 pg/ml).
e Associated with hypersensitivity, allergy and parasitic 
infections.
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Cell mediated immunity
It became apparent in the 1940's that some infectious diseases were not preventable by 
induction of antibody responses; it was shown that the delayed type hypersensitivity (DTH) 
reaction associated with skin tests could be induced after transfer of cells, but not by 
serum. In 1968, the T-cell lymphocyte was identified as having cell-cytotoxic properties 
that were induced upon cellular infection.
/
T cells are lymphocytes that mature in the thymus. They are diverse and are characterised 
by T-cell antigen surface receptors (TCR). The essential role of T cells is to recognise antigen 
that has been processed within a host cell; T cell receptors are only able to bind antigen in 
the form of a peptide fragment bound to a major histocompatibility complex (MHC) 
molecule.
There are two classes of MHC molecule. All cells, except for red blood cells, express MHC 
Class I. The role of this molecule is to bind antigen encountered within the cell, i.e. 
following infection with an intracellular pathogen. MHC Class II molecules bind antigen that 
has been endocytosed by the cell. They are expressed by 'professional' antigen presenting 
cells (APC) such as dendritic cells (DC), macrophages and B cells.
There are 2 main types of T cell, defined by the MHC receptors that they express. T cells 
expressing CD8 (CD8+ T cells) bind MHC Class I molecules. Upon activation, CD8+ T cells are 
effective in lysing infected cells directly and so are called cytotoxic T lymphocytes (CTL). T 
cells expressing CD4 (CD4+ T cells) bind MHC Class II. The role of CD4+ T cells, upon 
activation, is to release cytokines -  cell signalling molecules that stimulate further T cell 
function, macrophage activation and B cell antibody production. Thus, they are also known 
as T helper (Th) cells and can be further subdivided into Th-1, Th-2 and Th-17 subsets based 
on their cytokine secretory profile. Th-1 and Th-17 enhance inflammatory immune 
responses, while Th-2 promotes non-inflammatory responses. An essential contributor to 
the regulation of inflammation are another subset of CD4+ helper cells called regulatory T
cells (Treg) (Vignali et al., 2008). As well as lysing antigen-bearing cells directly, cytotoxic 
CD8+ cells are also able to release the effector cytokines IFNy and TNFa. A summary is 
shown in Figure 1.2B.
Each T cell subset can be further categorised according to its state of activation (Broere et 
al., 2011). 'Naive' T cells, having matured in the thymus, reside in the spleen and lymph 
nodes. Upon infection, antigen-loaded APC migrate to the lymphoid tissues where TCR and 
MHC-bound antigen interact. This leads to T cell activation and in this state T cells become 
effector cells (TE). Critical to the principle of vaccine-induced T cell immunity is the ability of 
some effector T cells to remain beyond antigen elimination, as these long-lasting 
populations contribute to immunological memory.
Effector memory cells (TEM) remain at the periphery, including mucosal sites, where they 
are able to encounter secondary infection and develop immediate effector function. 
Central memory cells (TCM) reside in the secondary lymphoid tissue (spleen and lymph 
nodes) where they can mount a recall response, which although delayed in terms of 
mounting effector functions has greater proliferative potential (Sallusto et al., 2010).
Induction of cell mediated immunity
For the outstanding vaccine targets, humoral responses may remain important for 
prevention of initial infection, but induction of cell-mediated immunity is now believed to 
be essential for effective infection control (Plotkin, 2010). Further, protection may depend 
upon the activation of particular T cell subsets, specifically, the induction of T cells offering 
protective effector function within which are subsets that will be programmed to have both 
effector memory and central memory function.
For any given vaccine target, antigen discovery is important; antigen-specific responses 
must confer protection. Sophisticated transcriptomic, proteomic and reverse vaccinology 
{in silico) approaches are being applied to identify novel vaccine antigens. However,
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beyond antigen selection, it is vaccine formulation and/or the delivery system employed 
that will determine the type of immune response that is promoted, thereby impacting on 
the potential success of the vaccine.
Adjuvant research has identified a number of compounds that can evoke humoral and 
cellular immunity; however, the ability to promote robust cellular immunity without 
adverse effects is a challenge (Reed et al., 2013). An alternative to adjuvanting protein 
subunits is to apply genetic engineering to the challenge of antigen delivery. There are 
vaccines under clinical development based on plasmid DNA and many recombinant 
organisms. In these vaccines the genetic code for the vaccine antigen is delivered for 
expression in the host, i.e. the vaccine recipient. This gives rise to intracellular 
manifestation of antigen, as would occur in intracellular pathogen infection. Thus, plasmid 
DNA and recombinant viral and bacterial vaccines are able to induce effective CD8+ CTL 
responses.
Plasmid DNA vaccines are simple to produce and induce both CD4+ and CD8+ T cell 
immunity (Maecker et al., 1998). The first demonstration of protective DNA vaccination 
was performed in mice immunised with an influenza antigen (Ulmer et al., 1993). Plasmid 
DNA vaccines have proved to be an excellent tool in pre-clinical research, and there are 
some examples licensed for veterinary use (Draper and Heeney, 2010). However, plasmid 
DNA alone has been found to be less immunogenic in larger animals and strategies are 
required for enhancing their efficacy (Saade and Petrovsky, 2012).
Responses to DNA-vectored antigen can be enhanced by co-administration with adjuvants,
or by advanced delivery techniques, e.g. gene gun technology. It is also possible to increase
T cell responses via heterologous prime-boosting. This was first demonstrated following a
DNA prime and MVA boost protocol in mice, which provided protection against malaria
(Schneider et al., 1998). High levels of antigen-specific CD8+ T cells were observed and
induction of similarly enhanced T cell responses were subsequently demonstrated in
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humans (McConkey et al., 2003). Currently, a vaccine candidate based on DNA-MVA 
immunisation is under clinical development for HIV (Munseri et al., 2015).
The benefit of recombinant bacterial or viral vectors is that, relative to plasmid DNA or 
protein subunits, they are antigenically diverse and highly immunogenic, without the need 
for additional adjuvants or specialised delivery methods. There are vaccines based on 
recombinant bacteria and viruses in clinical trials, but as yet, the only licensed vaccine is a 
recombinant YFV -  JE chimera. That bacterial vaccine vectors might not be as advanced as 
viral vectors may stem from their complexity and the need to render them safe for use in 
human subjects and concomitant release to the environment (da Silva et al., 2014). A 
greater number of viral vectored vaccines, meanwhile, are under development.
1.1.3 Viral Vector vaccines
A summary of the principal viral vaccine vectors currently under investigation is 
summarized in Table 1.2. As shown, a number of viral vectors are based on poxviruses.
The first viral vectored vaccines were based on live Vaccinia virus. Following the 
eradication of smallpox, and supported by recent advances in genetic engineering, Vaccinia 
virus was investigated as a tool for recombinant antigen expression. In the first instance, it 
was shown to be possible to introduce and express foreign genes in recombinant Vaccinia 
virus (rVV) (Mackett et al., 1982; Panicali and Paoletti, 1982). Soon after it was 
demonstrated that rVV could evoke protective, antigen-specific immune responses in an 
animal model of hepatitis B (Moss et al., 1984). Later, MVA was turned to as an alternative 
viral vector with an improved safety profile and was also demonstrated to be effective pre- 
clinically (Sutter et al., 1994).
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Table 1.2 Viruses used as vaccine vectors. The principal viral vector platforms under 
investigation for the development of novel vaccines.
Virus Family Viral Vector(s) Advantages and disadvantages*
DNA viruses
Poxviridae Vaccinia virus, Genome 130 -  280 kb.
MVA, NYVAC, Large capacity for foreign DNA (>25 kb).
ALVAC and FPV Safe history of use in humans/veterinary
applications.
Established platforms for product development.
fAnti-vector immunity may arise.
Adenoviridae Adenovirus Genome 36 -  38 kb.
Capacity for 7-8 kb foreign DNA.
Safe history of use in humans/veterinary 
applications.
Established platforms for product development. 
+Possible interference from pre-existing immunity.
RNA viruses
Rhabdoviridae VSV Genome 13 - 1 6  kb
+Limited capacity for foreign inserts.
Abbreviations: MVA, modified Vaccinia virus Ankara; NYVAC, Vaccinia virus 
attenuated via the deletion of 18 open reading frames; ALVAC, attenuated canarypox 
virus; FPV, fowlpox virus; VSV, Vesicular stomatitis virus.
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Vaccinia virus (VV) is a member of the orthopoxvirus genus within the Poxviridae family. 
Other poxviruses in use as viral vectors include attenuated canarypox virus (ALVAC), 
fowlpox virus (FPV) and a strain of W  attenuated by genetic manipulation (NYVAC). While 
none of these vectors have been licensed for human use, Phase I -  III clinical studies for a 
range of disease targets and cancer are ongoing, and there are examples of licensed 
veterinary vaccines based on ALVAC, FPV and VV (Draper and Heeney, 2010). Thus, 
poxviruses are an effective vaccine delivery platform and are amenable to large-scale 
production.
After poxviruses, the most commonly employed viral vector platform for the development 
of novel vaccines is adenovirus (Ad). Adenovirus naturally infects humans resulting in a 
range of clinical outcomes. The infection can be asymptomatic, cause common cold 
symptoms or, in some cases, severe respiratory disease. In common with poxviruses, 
Adenovirus exhibits a broad tropism, i.e. can infect a range of cell types. Like poxviruses, 
there are examples of rAd under Phase I -  III clinical development for bacterial, viral and 
parasitic diseases, as well as for cancer immunotherapy (Rollier et al., 2011). The capacity 
of recombinant poxviruses to carry foreign DNA may be greater, but the pay load for rAd 
may still amount to several antigens. In Ad vector methodology, genes are removed from 
the virus in order to render it replication deficient. A 'gutless' Ad vector may accommodate 
up to 8 kb of foreign DNA. To date, the most commonly used Ad virus serotype has been 
human Ad virus serotype 5 (AdHu5). Pre-existing immunity may be a disadvantage for this 
vector, but more recently this has been circumvented by using chimpanzee serotypes.
There are fewer examples of other viruses that have been used as viral vaccine vectors. A 
relatively recent example to come to prominence is based on Vesicular stomatitis virus 
(VSV). VSV is a member of the Rhabdoviridae family of viruses. It infects animals of 
agricultural importance (horses, cattle, pigs) and can cause a flu-like illness in humans. The 
virulence of VSV is associated with its glycoprotein (G). Cleverly, VSV G can be replaced
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with an alternative antigen with the effect that the virus is attenuated, induces little 
neutralising immunity against itself while promoting strong humoral and cell-mediated 
responses against a recombinant antigen (Roberts et al., 1999). Most recently, VSV viral 
vector technology has been implemented in a Phase III trial against Ebola virus disease 
(Camacho et al., 2015).
There are other viral vaccine vectors under investigation for which there is currently less 
clinical data through which to establish safety and efficacy. For each of these, there may 
also be other disadvantages such as potential to integrate into the human genome, reduced 
tropism and pre-existing immunity. They include Adeno-associated virus, Measles virus, 
Sendai virus and Baculovirus and have been subject to review (Brave et al., 2007; Liu, 2010; 
Tripp and Tompkins, 2014; Lira et al., 2014).
With many examples of MVA and Adenovirus having been tested in clinical studies, there is 
now detailed evidence for the type of T cell immunity they induce. Both are able to induce 
CD8+ responses that include effector memory and central memory functions (Rollier et al.,
2011). Thus, the responses are encouraging from the perspective of novel vaccine 
development.
1.1.4 Prospects and progress for MVA based vaccines
MVA is a highly attenuated, replication defective strain of vaccinia virus with attributes of
an optimal viral delivery system including; large capacity for foreign DNA, proven clinical
safety and ability to induce potent and long-lasting humoral and cell-mediated immune
responses which can be further complemented in heterologous prime-boost regimens.
Efficacy of rMVA based vaccines has been demonstrated in numerous pre-clinical and
clinical studies against a range of targets including HIV, malaria, tuberculosis and an array of
tumour associated antigens (Gomez et al., 2008; Harrop and Carroll, 2006). In addition to
its proven clinical safety and ability to elicit protective immunological responses, the
advantages of rMVA as a viral vaccine vector now extend to include established
15
manufacturing processes (compliant with Good Manufacturing Practice; GMP), low costs of 
goods, ease of storage and clear requirements for regulatory submission (Hall and Carroll,
2012). That rMVA based vaccines are a reliable prospect is evident from the number of 
candidates in clinical development, with a number of institutions committed to rMVA based 
research (see Table 1.3).
Pre-existing and anti-vector immunity
As stated above (Table 1.2), anti-vector immunity may be the biggest disadvantage 
presented by the use of MVA as a viral vaccine vector. Pre-existing immunity has the 
potential to limit the efficacy of a viral vector and, following the eradication of smallpox, 
there was a widespread population with humoral immunity to vaccinia virus. However, 
with the cessation of global vaccination, this population has halved (Bray, 2003) and is 
decreasing. Even so, the effects of pre-existing vector immunity still require consideration 
in the context of multiple-immunisation regimes and in light of the number of rMVA 
vaccines under clinical study.
Pre-clinically, MVA has been shown to evoke less potent vector-specific immune responses 
than replication competent vaccinia, without compromising the strength of immune 
response elicited against a foreign antigen (Ramirez et al., 2000a). Recombinant MVA has 
also been shown to be effective under conditions of pre-existing immunity to the vector 
(Ramirez et al., 2000b; Redchenko et al., 2004). There are now clinical examples for 
immunogenic vaccine antigen delivery by rMVA against a background of MVA-specific 
antibody, pre-existing, or induced through repeated rMVA immunisation (Harrop et al., 
2007). rMVA's ability to induce transgene responses in the presence of pre-exiting MVA 
immunity in homologous prime boost regimens may be due in part to the rapid expression 
kinetics of Vaccinia virus promoters and a lack of requirement for cell to cell spread of the 
vector. For each novel rMVA product, however, the impact of pre-existing immunity on 
rMVA efficacy should be evaluated (Kannanganat et al., 2010).
16
Table 1.3 Recombinant MVA in clinical development. Examples of clinical candidates 
under development by institutes active in the field of rMVA research.
Target Vaccine(s) Antigens
Clinical
Phase
Ref
University of Oxford (UK)
Tuberculosis MVA85A Ag85A II (Sheehan et 
al., 2015)
Seasonal MVA-NP+M1 NP+M1 II (Berthoud et
Influenza al., 2011)
Malaria MVA ME-TRAP ME-TRAP Mb (Sebastian and
MVAMSP1, MVA MSP1, AMA1, CS lla Gilbert, 2015)
AMA1, MVA CS
MVARH5, MVA PvDBP RH5, PvDBP la
HIV infection M VA.H IVconsv 14 conserved regions lb (Letourneau
(Clades A, B, C of the HIV-1 etal., 2007)
and D) proteome
Bavarian Nordic (Denmark)
Respiratory MVA-BN RSV RSV F, GP (x2), N, M2 1 NCT
Syncytial Virus 02419391
Ebola/Marburg MVA-BN Filo Zaire Ebola virus GP, III (Tapia et al.,
Virus Disease Sudan Ebola virus GP, 
Marburg virus GP, 
and Tai-Forest Ebola 
virus NP
2015)
Transgene (France)
Cancer; lung TG4010 MUC1 and IL-2 Mb (Quoix et al., 
2011)
HPV - induced TG4001 HPV16 E6, E7 and IL- lib (Brun et al.,
disease 2 2011)
Oxford Biomedica (UK)
Cancer; TroVax® 5T4 II (Harrop et al.,
colorectal, 2012)
mesothelioma,
ovarian.
National Institute of Health (USA)
Ebola Virus MVA Ebola Z Zaire Ebola virus GP lb (Zhou and
Disease Sullivan, 2015)
HIV MVA-CMDR
CRF01_AE gag, env 
and pol
1
(Earl et al., 
2009)
Abbreviations: Ag85A, mycobacterial mycolyl transferase 85A; AMA-1, apical membrane 
antigen 1; CMDR, Chiang Mai Double Recombinant; GP, glycoprotein; HPV, human 
papilloma virus; IL-2, interleukin 2; M l, matrix 1 protein; ME-TRAP, multiple epitope string 
fused to thrombospondin-related adhesion protein; MSP-1, merozoite surface protein 1; 
MUC1, mucin 1; NP, nucleoprotein; PvDBP, Plasmodium vivax Duffy-binding protein; RH5, 
reticulocyte binding protein-like homologue 5; RSV F, G, N, M2, respiratory syncytial virus 
fusion protein, nucleoprotein, and matrix protein 2; NCT02419391; clinical trial ID for a 
Phase I Trial to Evaluate Safety, Tolerability and Immunogenicity in Healthy Adult Subjects.
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Heterologous prime-boost regimens
The potential for heterologous prime-boosting to enhance rMVA efficacy, particularly for 
the improvement of immunisation strategies which require cell mediated immunity, is now 
well established. Recombinant MVA administered in prime-boost regimens involving 
plasmid DNA or alternative viral vectors has been demonstrated to drive strong T cell 
responses (McConkey et al., 2003) and may be more effective when rMVA boosts non-MVA 
prime (Vuola et al., 2005), although this may differ between vaccine targets. Heterologous 
prime-boost regimens are being pursued in a clinical setting for vaccines targeted against 
HIV (Iyer and Amara, 2014), malaria (Hill et al., 2010) and tuberculosis (Ottenhoff and 
Kaufmann, 2012).
Immunisation route
Route of administration is sometimes thought to be another feature of the immunisation 
protocol that can influence rMVA efficacy. Intramuscular (i.m) and intradermal (i.d) 
delivery are commonly used for rMVA delivery with the latter leading to higher immune 
responses in some pre-clinical studies, which is evidently a result of the increased number 
of professional antigen-presenting cell encountered at this site (Abadie et al., 2009). 
However, any benefit conferred by i.d immunisation is outweighed by its reduced 
practicality in the clinic and tendency for localised reaction. In any event, clinical 
comparison of rMVA i.d and i.m administration demonstrates no significant difference in 
immunogenicity (Berthoud et al., 2011; Harrop et al., 2006). Mucosal delivery may be 
advantageous for diseases in which the pathogen is first encountered at the mucosa and 
this is under investigation for rMVA targeting HIV (Maeto et al., 2014) and tuberculosis 
(Satti et al., 2014).
Summary
In conclusion, while vector immunity must remain a consideration for MVA-based vaccines, 
there are many more favourable characteristics and the opportunity to optimise its use.
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There are now a number of vaccines under clinical study and there have been 
developments in manufacturing platforms and bespoke cell lines for manufacture.
1.2 Rational design of recombinant MVA
The principal feature of a vaccine based on a recombinant MVA virus is the antigen, or 
antigens, it has been engineered to deliver. For a given target disease, these antigens must 
be capable of evoking an immune response that imparts long-lasting, protective immunity, 
otherwise the vaccine will not be effective. As described below, there are aspects of rMVA 
construction that may impact upon the ability of the vectored antigen(s) to achieve this. 
The development of optimised rMVA is, therefore, very important. Our current 
understanding of rMVA design and optimisation has been honed over three decades of 
recombinant Vaccinia virus research. Underpinning the research are background 
knowledge in poxvirus biology and advances in genetic engineering.
1.2.1 MVA life cycle and gene expression
MVA is a member of the orthopoxvirus genus within the Poxviridae family. The virus 
contains a single copy of double stranded DNA genome, approximately 178 kb in length 
(Antoine et al., 1998). Unlike other DNA viruses, vaccinia replication occurs exclusively in 
the host cell cytoplasm and uses virus encoded polymerases and transcription factors. In 
common with most other viruses, replication is controlled via tight temporal regulation of 
gene expression falling into specific categories - early, intermediate and late (Broyles, 
2003), with an additional, immediate-early class of genes more recently described 
(Assarsson et al., 2008; Yang et al., 2010). The infectious virion has packaged within it 
enzymes and transcription factors required for early gene expression so that viral 
messenger RNA (mRNA) transcripts are detectable within 20 minutes post-infection 
(Baldick and Moss, 1993). Under the tight regulation of vaccinia transcriptional promoters, 
the first genes to be expressed code for immune modulators and for enzymes and 
transcriptional factors required for intermediate expression. After viral DNA replication,
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intermediate gene transcription is activated and viral late gene transcription factors are 
expressed to enable subsequent late gene expression to occur. The proteins and enzymes 
required for early transcription are expressed at late times so that they are encapsulated 
into progeny virus ready for the next round of replication. The majority of virus particles 
are then released during cell lysis. The tightly regulated cascade of viral early, intermediate 
and late transcription is shown in Figure 1.3. Also shown is the point at which replication is 
defective for MVA infecting non-permissive cell types.
Figure 1.3. MVA life cycle. The infectious MVA virion enters the cell and 
undergoes replication prior to the release of viral progeny. In non-permissive 
cells, there is a block in MVA replication.
As MVA replication is blocked in the final step of virus particle maturation, authentic gene
expression is still able to occur at all stages, a feature confirmed for high level expression of
recombinant genes (Sutter and Moss, 1992) capable of evoking an effective immune
response (Sutter et al., 1994). That MVA replicates in the host-cell cytoplasm with relative
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autonomy from the host cell nucleus represents another favourable characteristic of rMVA- 
based vaccines from the perspective of GM safety i.e. the lack of opportunity for insertion 
of viral DNA into the host genome.
Host range restriction
During the course of its attenuation in primary chick embryo fibroblasts (CEF), 
approximately 30 kb of the parent vaccinia genome was deleted rendering MVA replication 
defective in human and most other mammalian cells. Whilst the genetic basis for host 
range restriction has not been fully elucidated, it is known to involve multiple gene defects 
(Meyer et al., 1991; Wyatt et al., 1998). Initially, propagation of MVA was thought to 
require culture in CEF, but later other non-human cell lines permissive to MVA growth were 
identified, and one in particular, baby hamster kidney cells (BHK-21) were found to support 
efficient replication (Carroll and Moss, 1997; Drexler et al., 1998; Okeke et al., 2006) and 
production of rMVA (Carroll and Moss, 1997). The most common cell cultures now in use 
for in vitro manipulation of MVA are primary CEF and BHK-21. Additional designer avian 
cell lines have been developed for optimised scalability and robustness for product-scale 
amplification of MVA (Brown and Mehtali, 2010; Jordan et al., 2011; Jordan et al., 2009).
1.2.2 The first recombinant Vaccinia viruses
The first examples of recombinant Vaccinia virus used homologous recombination as the 
mechanism for gene transfer (Mackett et al., 1982; Panicali and Paoletti, 1982) and this is 
still the most widely used technique for generation of rMVA. Methods for constructing 
rMVA are discussed in more detail in Section 1.3. Briefly, MVA permissive cells are infected 
with wild type virus and then transfected with a transfer plasmid vectoring exogenous DNA. 
Homologous recombination into a specific site of the MVA genome is mediated by 
homologous sequences flanking the transgene (Earl et al., 2001b). In addition to the gene 
of interest, the transfer plasmid contains a vaccinia promoter for control of its expression 
and, dependent upon the precise nature of the protocol, a selection marker to aid isolation
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of recombinant virus. An example based on transient expression o f green fluorescent 
protein (GFP) (W yatt et al., 2008b) is shown in Figure 1.4. During MVA replication, 
homologous recombination between genomic and transfer plasmid DNA occurs at a 
frequency o f approximately 1:1000 (Kremer et al., 2012). Thus, when genomic DNA is 
repackaged to yield MVA progeny, a proportion o f the population, reflective o f this 
frequency, is recombinant. Purified recombinant virus must subsequently be prepared 
through a process enabling selective enrichment.
MVA R FlankMVA L Flank GFPDR DR.
Transfection with 
transfer plasmid DNA
Infection 
with MVA
Flost cell 
nucleus
Host cell 
cytoplasm Homologous
recombination
Virus
assembly
r Serial . 
\  passage f y
Recombinant MVA with Markerless
GFP and Ag recombinant MVA
Figure 1.4 Generation of rMVA. Permissive cells are infected w ith  MVA and then 
transfected w ith  transfer plasmid DNA carrying a recombinant cassette. In addition 
to  the antigen o f interest (Ag), the cassette contains a selection marker (GFP), 
vaccinia promoters fo r transgene expression (P) and left (L) and right (R) MVA 
homologous flanks through w ith  recombination into the MVA genome is mediated. 
Direct repeat (DR) sequences flanking GFP lead to  transient expression o f the marker.
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1.2.3 Selection markers
Since the first rVACV were generated in the early 1980s, there have been many technical 
advances relating to construction and isolation of recombinants. Early methods relied on 
insertion of the foreign gene into the thymidine kinase (TK) coding sequence via 
homologous recombination and enrichment on the basis of a TK-phenotype selected by 
using bromodeoxyuridine (Brdll) (Mackett et al., 1982, 1984; Panicali and Paoletti, 1982). 
Later, this method was combined with simultaneous insertion of the Escherichia coli Lac Z 
gene, coding for (3-galactosidase, so that recombinants could be further distinguished from 
TK-mutants arising under the cytotoxic influence of BrdU; lac Z recombinant plaques turn 
blue when grown in the presence of X-gal (Chakrabarti et al., 1985). Other genes added to 
transfer vectors to improve versatility in recombinant isolation include antibiotic resistance 
markers such as the E. coli neomycin gene (Franke et al., 1985) and xanthine-guanine 
phosphoribosyl transferase (gpt) gene (Falkner and Moss, 1988) and additional colour 
markers, green fluorescent protein (GFP) (Wu et al., 1995a) and E. coli (3-glucuronidase A 
gene {gus) (Carroll and Moss, 1995).
Where markers are not cross-reactive, it is possible to combine them for improved 
selection, as in the case of a gpt-gus fusion expressed under a single vaccinia promoter (Cao 
and Upton, 1997). Alternatively, they can be used simultaneously in the construction of 
recombinants containing multiple inserts. Another strategy for the isolation of 
recombinant vaccinia, developed using VACV, involves use of a modified parent strain with 
a deficiency restored by a gene included in the transfer vector (Blasco and Moss, 1995; 
Perkus et al., 1989).
When making rMVA products destined for clinical use, inclusion of a selection marker is not 
desirable. Several systems have been designed to allow for transient expression of marker 
genes, many employing a second recombination event for their removal (Falkner and Moss, 
1990; Scheiflinger et al., 1998; Wyatt et al., 2008b). Where recombinant protein is
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expressed on the surface of infected cells, selection markers may not be required at all if 
recombinant plaques can be immunostained and recombinant plaques visualised for 
isolation and further purification (Earl et al., 2001b). A popular approach in the 
development of rMVA based vaccines today is the use of transiently expressed fluorescent 
markers. A transfer plasmid vectoring transient GFP has been described (Wyatt et al., 
2008b) in which recombinant virus is plaque purified and then subjected to serial passage 
so that the GFP marker, located in between two direct repeat sequences, is eventually lost 
through a second recombination event.
1.2.4 Vaccinia promoter selection
As described above (Section 1.2.1), Vaccinia virus replication occurs in the host cell 
cytoplasm, using vaccinia-encoded proteins for genome replication and transcription. The 
role of the vaccinia promoter sequence is to bind one or more transcription factors in order 
to recruit RNA polymerase and initiate transcription. The expression of a foreign gene by a 
recombinant vaccinia virus (rVV) is, therefore, dependent upon insertion downstream of a 
vaccinia promoter.
An alternative promoter can be used, but the corresponding transcriptional machinery 
must be provided during viral replication. Such a system has been developed based on the 
bacteriophage T7 system. Briefly, cells are infected with a recombinant vaccinia virus 
expressing the bacteriophage T7 RNA polymerase and then co-transfected with a vector 
carrying the gene of interest flanked by T7 promoter and terminator sequences, thereby 
giving rise to T7-mediated gene expression (Fuerst etal., 1986). The same system has been 
implemented using attenuated vaccinia (Wyatt et al., 1995). The T7 system has been 
described as an optimised in vitro expression tool, but has yet to be widely reported as a 
means for driving vaccine antigen expression in vivo.
Vaccinia promoters, by virtue of the transcription initiation factors they bind (reviewed by 
(Broyles, 2003)), control the temporal regulation of gene expression and so can be classed
as early, intermediate or late (described in Section 1.2.1). They also affect the strength of 
gene expression. As described below, this is an important consideration in the design of a 
recombinant vaccine.
Vaccinia promoter structure
Vaccinia promoter studies employing a transgene encoding an enzyme, e.g. 
chloramphenicol acetyltransferase (CAT), have enabled promoters to be fully characterised. 
Following insertion, gene expression can be accurately measured via an assay for enzymatic 
activity (Mackett et al., 1984). The earliest promoter studies served to confirm the location 
of transcriptional regulatory regions within putative promoter sequences, and define their 
temporal category with regards to early or late expression (Weir and Moss, 1984). Among 
the first regulatory regions to be characterised was a 275 bp promoter sequence for a 
constitutively expressed protein of 7.5 kDa. This promoter (P7.5) was shown to contain 
tandem, independently-operating early and late promoter regions (Cochran etal., 1985).
Later, in depth mutagenesis studies identified in detail the promoter elements critical to 
expression activity for both early (Davison and Moss, 1989a), and late promoters (Davison 
and Moss, 1989b). Dissection of promoter sequences by individual base pair substitutions 
has revealed that early promotors comprise an A/T rich critical region of approximately 16 
bp, followed by a less critical region of 11-14 bp, beyond which is the initiation region 
(Figure 1.5A). Late promoters are also made up of 3 regions: a 20 bp A/T rich sequence, a 6 
bp spacer region and a highly conserved TAAAT sequence, within which transcription is 
initiated (Figure 1.5B). In the course of determining the significance of individual base pairs 
within the promoter, mutations capable of increasing transcriptional activity were 
identified, thus enabling the development of optimised promoters including the synthetic 
promoter (Psyn), which comprises optimised, overlapping early and late elements 
(Chakrabarti et al., 1997).
25
Historically, vaccinia virus genes have been categorised as either 'early' or 'la te / according 
to the timing of their expression relative to viral DNA replication. An intermediate category 
of genes has since been described in which gene expression occurs at the onset of DNA 
replication and via a promoter that does not utilise the complete TAAAT initiator (Vos and 
Stunnenberg, 1988). Intermediate promoters have been characterised via mutational 
studies (Baldick et al., 1992) and shown to comprise a 14 bp A/T rich core element, a 10 -11 
bp spacer and then a critical (initiator) region with the sequence TAAA (Figure 1.5C).
More recently, early vaccinia genes have been further categorised to include an immediate- 
early subset (Assarsson et al., 2008; Yang et al., 2010), for which there has been an initial 
report of a potential consensus promoter sequence (Di Pilato et al., 2013).
A. Early promoter elements
16 bp A/T rich 11 bp 7 bp
Core Spacer Initiator
B. Late promoter elements
20 bp A/T rich 6 bp TAAAT
Core Spacer Initiator
C. Intermediate promoter elements
14 bp A/T rich 10-11 bp TAAA
Core Spacer Initiator
Figure 1.5 Conserved elements of vaccinia promoter sequences. All three temporal 
classes of promoter comprise three regions - the core, spacer and initiation region. 
The core sequence is rich in adenine/thymine (A/T) bases. The initiation region is the 
site at which transcription starts. The core region binds transcription factors and so 
has sequence requirements, alterations to which will affect promoter activity.
Vaccinia promoter selection for optimal immunogenicity
Intuitively, rW-based vaccines must strive for high levels of transgene expression to
increase the immunological potency of the vectored antigen. The first examples of rW
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preceded elucidation of vaccinia promoter sequences and so regulatory regions were 
selected on the basis of their association with proteins that were abundant at both the 
early and late stages of the virus life cycle, e.g. a constitutively expressed protein of 7.5 
kDa. These viruses were capable of inducing antigen-specific antibodies in animal models 
and induced protective immunity. The first examples demonstrated immunogenicity of 
influenza virus haemagglutinin (Panicali et al., 1983) and immunogenicity and protective 
pre-clinical efficacy for hepatitis B antigen (Moss etal., 1984; Smith et al., 1983).
Following the characterisation of vaccinia promoters, optimisation of expression might 
have focused on late promoter elements which can give rise to higher protein levels; late 
promoters are active at a time when DNA template and transcription factors are relatively 
abundant. However, rVV studies have shown that promoter kinetics, and in particular late- 
stage expression, can be detrimental to transgene immunogenicity. Coupar et al. 
investigated the immunogenicity of rVV vectoring influenza haemagglutinin (HA) under the 
control of three different promoters: PF (early), P7.5 (early/late) and P l l  (late). All induced 
antibody responses in mice, but the P l l  construct produced limited T cell responses 
despite driving the highest levels of expression (Coupar et al., 1986).
Vaccinia virus late-stage gene expression is now understood to be blocked in professional 
antigen presenting cells (APC). APC are vital for the induction of cell-mediated immunity as 
they process and present antigens to T cells. That APC are able to support the early stages 
of the VV life cycle, but block late-stage replication has been demonstrated for rVV in 
macrophages (Broder et al., 1994) and in dendritic cells (DC) (Bronte et al., 1997). It has 
also been shown that entry into DC may be less efficient for Vaccinia virus (Drillien et al., 
2000). As discussed above (see Section 1.1.2), a potential application for viral vaccine 
vector technology is to induce both humoral and cell-mediated immune responses, to 
counter those infectious diseases for which antibody-responses alone have proved 
insufficient. Late-stage expression may have a role in generating recombinant antigen in
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non-APC cell types, but early-stage expression is vital for the quality of the immune 
response required.
As already stated, in the course of developing rVV based viral vectors, MVA was selected as 
a potential alternative with an improved safety profile. MVA is replication deficient, but in 
non-permissive cells gene expression, including the expression of recombinant genes, is 
able to occur (Sutter and Moss, 1992). That MVA is replication-deficient arguably increases 
the need to maximise transgene expression. The first rMVA-based vaccine sought to 
achieve this by selecting the optimised, synthetic early/late promoter Psyn; a rMVA virus 
was constructed to express influenza virus antigens and was successful in inducing 
protective immunity in mice (Sutter et al., 1994). However, when Psyn was selected to 
drive expression of parainfluenza virus 3 (PIV3) antigens, the resultant rMVA replicated 
poorly in vitro, with the high level of gene expression apparently detrimental to viral fitness 
(Wyatt et al., 1996). Powerful promoters, therefore, can result in cytotoxic effects where, 
dependent upon the gene being expressed, the recombinant may be unstable. With a view 
to using a promoter optimised for expression and stability, Wyatt et al. developed a novel 
promoter of intermediate strength to Psyn and the weaker P7.5. Informed by earlier 
mutagenesis studies, the naturally occurring early/late promoter for vaccinia gene H5 was 
altered via two nucleotide substitutions to create modified H5 (mH5). An important 
observation for the activity of this promoter, as characterised via expression of 15- 
galactosidase, was that, while it was of intermediate strength to Psyn and P7.5, it delivered 
three-fold higher early expression relative to Psyn. As described above, this may be an 
advantageous feature for transgene expression in APC and induction of cellular immunity. 
Thus, promoter mH5 is favourable for expression, stability and immunogenicity. Indeed, 
the mH5 promoter has been used as a comparator in more recent vaccinia promoter 
optimisation studies (Becker et al., 2014; Orubu et al., 2012).
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It is evident that vaccinia promoter selection is important to the efficacy of rMVA-based 
vaccines from ongoing efforts to optimise vaccinia promoter usage. As early-stage 
expression is advantageous for the promotion of T cell mediated immune responses, recent 
rMVA studies have investigated promoters driving immediate-early expression. As yet, no 
particular promoter features, in terms of the DNA sequence, have been associated with 
immediate-early expression. Preliminary attempts at driving immediate-early expression 
have shown that it may correlate with enhanced CD8+ T cell responses (Baur et al., 2010; Di 
Pilato etal., 2013).
1.2.5 Immunomodulatory molecules
The effectiveness of MVA based vaccines may also be improved through insertion of 
immune co-factors (ICF), especially where it is important to steer the immune system 
towards a particular type of T-helper response. A key advantage of MVA as a viral vector 
for vaccine antigen delivery, is its capacity for recombinant DNA; theoretically 30 kb. The 
first ICF to be co-expressed in rVACV was IL-2 which was shown to have an attenuating 
effect in nude mice (Flexner et al., 1987; Ramshaw et al., 1987). Subsequently, rVACV co­
expressing a range of immune enhancers have been constructed with a view to creating 
cytokine microenvironments in which favourable antigen-specific responses are activated. 
Many cytokines, e.g. IL-2 and IL-12, have anti-viral and anti-tumour activity, however, their 
toxic side effects can be severe when delivered systemically. Reports show that co­
expression of a model tumour-associated antigen (TAA) and IL-12 by a rVACV can obviate 
the requirement for systemic delivery of toxic levels of IL-12 (Carroll et al., 1998). Co­
expression of immune co-factors can offer a further dimension to safe and effective 
enhancement of rMVA based vaccines as has now been demonstrated in clinical studies 
(Dreicer et al., 2009; Liu et al., 2004; Ramlau et al., 2008), but for each construct, safety was 
required to be demonstrated.
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1.2.6 Antigen fusion strategies
Viral vaccine vectors and plasmid DNA vaccines carry antigens in the form of nucleic acid. 
To achieve effective delivery, the antigen must be expressed by the host cell, i.e. within the 
vaccine recipient. In order to achieve optimal secretion and presentation to immune cells, 
sorting signals or 'leader sequence' peptides can be expressed fused with the recombinant 
antigen, to direct them towards favourable intracellular trafficking pathways. Leader 
sequences that have been employed for this purpose include naturally occurring sorting 
signals taken from viral and bacterial genes. Eukaryotic genes have also provided a number 
of sequences and are more diverse, a product of their more complex protein trafficking 
which involves many intracellular compartments.
The first studies to investigate 'leader sequences' were principally aimed at investigating 
antigen processing and, in particular, the presentation of antigen peptides by major 
histocompatibility complex (MHC) class I and class II molecules (Bacik etal., 1994). In these 
studies, rVV provided a means of delivering leader sequence-antigen chimeras to 
investigate the role of the sorting signals themselves. However, the practical implications 
for virally vectored vaccine antigens were noted and explored. It was subsequently 
demonstrated that fusion of an endoplasmic reticulum targeting signal, derived from an 
adenovirus protein (E3/19k), could enhance CD8+ T cell responses to an influenza virus 
antigen (Restifo et al., 1995). Other examples of antigen fusions in rVV viral vaccine studies 
followed and, later, DNA provided a more efficient means of investigating antigen fusions. 
Established examples, the vectors they have been studied in, and their impact on transgene 
immunogenicity are listed in Table 1.4 and are summarised below.
Leader sequences reported to promote intracellular MHC II binding and, therefore, CD4+ 
responses, include the MHC ll-binding Invariant chain (li), the cytoplasmic tail sequence of 
CD1 antigen presentation molecule (CD1) and the lysosomal-associated membrane protein 
signal sequence (LAMP-1). These leaders direct proteins to intersect with the MHC II
pathway in the endoplasmic reticulum (ER), endosomes and late endosomes/lysosomes, 
respectively (Koch eta l., 2000; Niazi etal., 2007).
Table 1.4. Examples of leader usage in vaccine development studies. Established 
examples are listed in chronological order of their reporting.
Leader Vector Leader contribution Ref
LAMP- DNA ■ Rerouting to MHC II pathway, enhanced CD4+ (Wu et al.,
1 presentation 1995b)
rVV ■ HPV antigen retargeted to
endosomal/lysosomal compartments.
■ Improved immunogenicity
TPA DNA ■ Increased TB antigen expression in vitro. (Li et al.,
■ Increased Ab, Th-1 and Th-2 responses 1999)
■ Improved protective efficacy.
li DNA ■ Rerouting to MHC II pathway via endosomal (Koch et al.,
targeting 2000)
LAMP- DNA ■ Rerouting to MHC II pathway (Marques et
1 ■ Improved HIV antigen expression al., 2003)
■ Increased immunogenicity
TPA DNA ■ DNA vaccine design study showing higher (Wang et al.,
extracellular protein levels with TPA 2006)
BVP22 DNA ■ Both leaders used fused together (Mwangi et
al., 2007)
li ■ Enhanced priming and expansion to B and T
cell epitopes
CD1 DNA ■ Endosomal targeting - trafficking to MHC Class (Niazi et al.,
II pathway 2007)
Abbreviations: LAMP-1, lysosomal associated membrane protein -  1; rVV, recombinant
vaccinia virus; HPV, human papillomavirus; Ab, antibody; li, MHC Class II invariant chain,
BVP22, bovine herpesvirus 1 protein; CD1, cytoplasmic tail sequence of CD1 antigen
presentation molecule; TPA, human tissue plasminogen activator gene sorting signal.
The signal sequence of the human tissue plasminogen activator gene (TPA) targets protein 
to the ER for secretion. Use of TPA as a vaccine antigen fusion has been rationalised by 
studies demonstrating that it improves expression levels, immunogenicity and protective 
efficacy. It is commonly used in TB vaccines and is discussed further in Section 1.4.3.
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Ubiquitin (Ub) and M. tuberculosis heat shock protein 70 (HSP70) have been shown to 
promote presentation to the MHC I pathway and, therefore, promote CD8+ responses 
(Chen et al., 2000; Leifert et al., 2004). They achieve this by targeting antigen towards 
degradation pathways giving rise to peptides that are transported to the ER. There the 
peptides co-localise with MHC I molecules to which they can bind and be taken to the cell 
surface for presentation to CD8+ T cells.
Targeting antigen to the cell surface has proved effective as a means of enhancing antibody 
responses. This has been demonstrated using the transmembrane and cytoplasmic domain 
of Vesicular Stomatitis Virus glycoprotein (VSVg) fused to the C terminus of beta subunit of 
human chorionic gonadotropin (Srinivasan et al., 1995). Antibody responses, as well as 
CD8+ responses, have also been promoted by targeting antigen to the endosomal and 
lysosomal compartments using LAMP-1 (Wu etal., 1995b).
Another type of 'leader' sequence reported to influence the immunogenicity of 
recombinant vaccines is the BVP22 gene (bovine herpes virus 1 tegument protein). BVP22 is 
thought to promote intercellular trafficking, although the precise mechanism through 
which it achieves this is still under debate (Leifert et al., 2004; Mwangi et al., 2005).
A benefit of the antigen fusion approach is that findings are relevant to, and so can be 
exploited by, all vaccines based on in vivo expression. This includes viral vectors such as 
MVA and Ad as well as plasmid DNA vaccines.
1.2.7 Insertion site
Following the design of the recombinant antigen, the site of insertion into the MVA genome 
must be selected. In addition to the TK region described above, other sites targeted for 
exogenous DNA insertion are the haemagglutinin (HA) gene (Antoine et al., 1996), the more 
commonly used deletion (Del) sites formed during the course of MVA's attenuation (Sutter 
and Staib, 2003) and, most recently, intergenic regions (IGR) (Timm et al., 2006). Insertion
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into IGRs adjacent to essential MVA genes has been used as a strategy for generating stable 
rMVA where exogenous DNA has otherwise been observed to promote instability. In the 
event of a deletion or truncation, the essential genes are affected and the strain rendered 
unable to replicate; thus only full length recombinants are propagated (Manuel et al., 2010; 
Wyatt et al., 2009). A diagram of the MVA genome highlighting the positions of the 
Deletion sites commonly targeted for antigen insertion is shown in Figure 1.6.
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
MVA (177,923 bp) 
Hindlll restriction map
Figure 1.6 Hindlll restriction map of the MVA genome. Fragments forming after 
Hindlll restriction enzyme digest of the linear genome are labelled A -  0  in order of 
descending size. The positions of the six major genomic deletion sites arising during 
MVA's attenuation are indicated. The figure is adapted from a SeqBuilder (DNASTAR) 
file of the MVA DNA sequence (Accession number U94848).
1.3 Construction of recombinant MVA
Once the genetic configuration of a novel rMVA has been decided upon, the required 
sequence must be generated and inserted into the MVA genome. The first examples of 
recombinant vaccinia virus used homologous recombination as the mechanism for gene 
transfer (Mackett et al., 1982; Panicali and Paoletti, 1982) and this technique remains 
widely used (Kremer et al., 2012). However, bacterial artificial chromosome technology is 
another approach that is now in use and which has favourable attributes.
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1.3.1 Transfer plasmid methodology
As described above in Section 1.2.2, and in Figure 1.4, transfer plasmid methodology 
exploits the tendency for homologous DNA sequences to undergo recombination (Sigal and 
Alberts, 1972). Transfer plasmids contain the recombinant cassette destined for insertion 
in the MVA genome, flanked by sequences homologous to the intended site of insertion 
(Figure 1.7A). Recombination between the homologous sequences occurs when purified 
transfer plasmid DNA is transfected into MVA-infected cells.
The precise nature of the homologous flanks determines not only the site of insertion but 
also the orientation of the inserted sequence and the outcome of recombination in terms 
of any potential deletion of viral DNA (Figure 1.7B). The design of the intervening 
recombinant cassette determines the nature of the recombinant strain generated. Key 
features include the antigen to be inserted, the vaccinia promoter selected for control of its 
expression and a selection marker under the control of its own promoter; an example 
incorporating green fluorescent protein (GFP) is shown in Figure 1.7C. Where a markerless 
recombinant is required, transient expression can be achieved by inclusion of a direct 
repeat sequence that will lead to a further recombination event through which the marker 
will be removed (Figure 1.7D).
Transfer plasmids are based upon E. coli cloning vectors and so are readily propagated and 
isolated for repeat rounds of manipulation; they have an origin of replication (ori) enabling 
maintenance at high copy number and maintain selective pressure via an antibiotic 
resistance marker (Figure 1.7D). Using standard cloning methods (Green, 2012), any 
alteration can be made to the portion of the transfer plasmid representing the recombinant 
cassette, including introduction of N and/or C terminal fusions. These may be B cell 
epitopes to allow for immunodetection of expressed product, or leader sequences that will 
influence intracellular processing of the antigen upon its expression in MVA-infected cells.
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L e f t  F la n k p> GFP p> G O I R ig h t  F la n k
T r a n s f e r
p la s m id
D. GFP R ig h t  F la n kL e f t  F la n k DR G O I
T r a n s f e r
p la s m id
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Figure 1.7 Main features of the transfer plasmid. A) In the linear, double-stranded DNA 
(dsDNA) o f the MVA genome, sequences to the le ft (L) and right (R) o f the insertion site are 
repeated in the transfer plasmid either side o f the recombinant cassette. B) If L and R are 
not directly adjacent, the intervening sequenced (hatched area) w ill be deleted upon 
recombination. C) The cassette contains the gene o f interest (GOI), a vaccinia prom oter (P) 
to  drive its expression and a selection marker (GFP) under the control o f its own prom oter. 
D) If a markerless recombinant is required, a direct repeat (DR) o f a portion o f the 
preceding flank is included. The transfer plasmid has an origin o f replication (ori) fo r use as 
an E. coli cloning vector, and an antib iotic resistance gene, e.g. ampicillin (Ampr).
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The transfer plasmid may also incorporate Gateway® cloning (ThermoFisher Scientific, USA) 
for rapid insertion of the gene of interest (Hartley et al., 2000). The Gateway® system 
employs a recombination mechanism based on lambda phage attachment sites to allow for 
movement of genes between plasmids without traditional cloning methods, i.e. restriction 
digest and ligation. According to Gateway® terminology, the transfer plasmid is converted 
to a Destination vector (pDEST) so that the gene of interest (GOI) can be received, in frame 
with existing N/C terminal fusions, from another plasmid termed an Entry vector (pENTR). 
A combination of antibiotic resistance markers and a copy of the ccdB lethal gene ensure 
that the desired plasmid is readily isolated following GOI insertion. Using the Gateway® 
system, transfer plasmids can be generated that are ready for any GOI to be efficiently 
introduced.
1.3.2 Bacterial Artificial Chromosomes
Bacterial artificial chromosomes are also E. coli cloning vectors, but they are based on a 
naturally occurring collection of functional segments known as the fertility factor, 'F'. The 
initial description of F was related to the apparent ability or inability of bacteria to 
participate in genetic exchange (Lederberg et al., 1952). Since then, F has been 
characterised as a replicon on an episomal plasmid (Wollman and Jacob, 1958), the 
constitutive components of which enable maintenance at one or two copies per cell, with 
faithful allocation to daughter cells upon replication (Ogura and Hiraga, 1983).
Advances in the understanding of F, in particular the role of individual regulatory genes in 
the control of replication and copy number, has informed the development of F-based 
vectors for cloning of extrachromosomal DNA at low copy number (Hosoda et al., 1990; 
O'Connor et al., 1989; O'Connor et al., 1986). A driver for this area of cloning has been the 
need to propagate large segments of DNA, which in a high copy number system would be 
prone to recombination events. In an application related to human genome sequencing, an 
F-based vector was developed for the cloning and stable maintenance of fragments up to
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300 kb. It was in this work that the term bacterial artificial chromosome (BAC) was 
introduced (Shizuya et al., 1992).
The advent of BAC vectors provided a new means with which to manipulate viral genomes. 
Briefly, the defining features of the BAC plasmid are introduced to the viral genome using 
transfer plasmid methodology. Having inserted the regulatory genes of the F replicon, along 
with an antibiotic resistance marker, extracted viral genomic DNA can be electroporated 
into E. coli to be maintained and propagated as a BAC vector. This affords the opportunity 
to further manipulate the viral genome within the bacterial cloning vector. To produce 
recombinant virus, the BAC DNA is isolated and transfected into eurkaryotic cells for 
expression and repackaging to virions.
The generation of viral recombinants using the BAC system was first demonstrated with 
baculovirus (Luckow et al., 1993) and then herpesvirus (Messerle et al., 1997) and 
cytomegalovirus recombinants (Borst et al., 1999). Application of BAC methodology to the 
manipulation of Vaccinia virus necessitated two additional aspects to accommodate 
features of the vaccinia virus life cycle. Firstly, a means through which to circularise the 
linear dsDNA vaccinia genome; only circular DNA can be transferred to E. coli for further 
propagation, and secondly, use of a helper virus to yield infective virions from transfected 
eurkaryotic cells (Domi and Moss, 2002). The approach has since been applied to MVA 
(Cottingham et al., 2008).
The principal advantage of BAC technology for the generation of rMVA is that it negates the 
need to plaque purify; upon repackaging, the resultant virus should represent a 
homogenous recombinant strain. The main disadvantage is the lengthy set-up time 
required for creating a BAC based MVA vector and the risk of contamination of the cloned 
genome with bacterial insertion sequences (Cottingham, 2012).
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1.3.3 Preparation of recombinant MVA for clinical use
Regardless of the methodology selected for construction, rMVA can be generated and 
amplified under regulated (GMP) conditions for use in clinical trials. Retention of the 
selection marker at this stage is undesirable, but it can be removed via a recombination 
event using either methodology (Cottingham and Gilbert, 2010; Wyatt et al., 2008b). 
Evidence that rMVA are amenable to downstream development and large scale production 
is provided by the range of diseases they are being developed for use against, of which TB is 
one.
1.4 Recombinant MVA for the prevention of tuberculosis
Tuberculosis (TB) ranks alongside HIV/AIDS as the leading cause of death attributable to an 
infectious disease. In 2014, 9.6 million people fell ill with TB and 1.5 million people died, of 
which 0.4 million were co-infected with HIV (WHO, 2015). In addition, it is estimated that a 
third of the global population may be latently infected with TB and at risk of reactivation of 
disease.
A number of first and second-line drugs are available for the treatment of TB, but 
treatment schedules are challenging; they are dependent upon early diagnosis and lengthy 
treatment regimens which require directly observed therapy (DOT) and follow up support 
(Zumla et al., 2013). Drug resistance screening is also vital as there are an increasing 
number of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains of M. 
tuberculosis emerging.
As described earlier, a vaccine for TB was developed in the 1920's and remains in use. BCG 
is based on a live, attenuated form of M. bovis and is administered to infants as part of the 
Expanded Programme of Immunisation (EPI). BCG, however, has variable efficacy in 
different populations, ranging from 0 -  80% (Fine, 1995); it is considered ineffective at 
preventing pulmonary TB in adults, but provides some protection against the most serious
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forms of TB in children. Another disadvantage of the BCG vaccine is that it is live and 
replication competent and so is contraindicated for HIV positive patients. Thus, in areas of 
high HIV incidence, where TB is also commonly prevalent, BCG is unsuitable for use in a 
proportion of those requiring protection.
While the combination of improved diagnosis and treatment has done much to control TB, 
eradication of the disease is generally accepted to be dependent upon licensure of a 
vaccine superior to BCG (Raviglione et al., 1995). As with other diseases, the natural 
immune response to TB disease has been studied with a view to developing a vaccine that 
will emulate it.
1.4.1 Tuberculosis disease and immunity
The aetiological agent of TB is Mycobacterium tuberculosis (Mtb). The bacterium is spread 
by the aerosol route when an individual with active disease is coughing. Mtb is an 
intracellular pathogen which in the lung invades professional phagocytic cells such as 
macrophages and dendritic cells. A consequence of the immune response to Mtb infection 
is the formation of granulomatous lesions, with the loss of healthy lung tissue.
In the first stages of infection, innate immunity promotes phagocytosis of Mtb as well as 
the recruitment of further phagocytes, which in turn are also infected (Ernst, 2012). This is 
the beginning of granuloma formation. After a short delay, an adaptive immune response 
commences with the induction of IL-12 release. Phagocytosis of mycobacteria is a strong 
inducer of IL-12 and leads to initiation of a Th-1 type response, characterised by IFNy 
release (Ladel et al., 1997). In the adaptive immune response, professional APC migrate to 
the draining lymph nodes where they present MHC-bound antigen to T cells. Antigen- 
specific T cells subsequently expand and home to the site of infection to promote 
downstream antimicrobial pathways, e.g. phagolysosome fusion. At this stage, the 
adaptive immune response further contributes to granuloma formation. Whilst
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immunopathology might ultimately be of detriment to the host, it is essential if 
dissemination of Mtb is to be prevented.
As Mtb is an intracellular pathogen, presentation by MHC Class II molecules and recognition 
by CD4+ T cells is the dominant feature of the immune response. In particular, Th-1 
immunity is induced and Th-l-type cytokines, IFNy and TNFa, are essential for the control 
of bacterial growth (Flynn, 2004). Mtb infection has also been shown to induce CD8+ T cell 
responses and it has been proposed that the relatively weaker ability of BCG to do the same 
might be a reason for its ineffectiveness (Ryan et al., 2009). Another subset of CD4+ helper 
cells with an essential role in controlling early Mtb infection are Th-17 cells. They are 
stimulated by IL-23 and release IL-17, a proinflammatory cytokine which serves to further 
mediate inflammation (Khader and Cooper, 2008).
An effective adaptive immune response is sufficient to arrest the growth of Mtb, but is not 
sterilising. At this stage an individual is asymptomatic and considered to have latent TB 
infection (LTBI). This occurs in the majority of cases, but approximately 10% of those 
infected will go on to develop disease at a later date. Reactivation can be triggered by 
immunosuppression due to age, malnutrition, HIV infection or other factors.
1.4.2 Strategies for an improved TB vaccine
While the immune response to Mtb, and to BCG vaccination, has been studied in order to 
characterise protective immunity, a correlate of protection has not been found (Ottenhoff 
et al., 2012). Th-1 immunity and IFNy release are considered central to the control of Mtb 
infection and so induction of this type of immune response has been the key readout in TB 
vaccine development to date, and will likely remain so. However, a more balanced 
CD4+/CD8+ T cell response is being viewed with increasing importance, as is the induction 
of antibody responses for blocking initial infection (Andersen and Woodworth, 2014).
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As the current TB vaccine, BCG, confers sufficient benefit to  remain in use, there are tw o 
approaches under study fo r the development o f a novel TB vaccine. Most o f the novel TB 
vaccines under development aim to improve upon the immune response induced by BCG 
by serving as a booster inoculation. Others strive to  replace or supplement BCG as a 
prim ing agent, fo r which booster vaccines may still be required. There are 13 vaccines 
currently under clinical study and they comprise live attenuated whole cell vaccines 
(including Nontuberculous mycobacteria (NTM) strains), recombinant protein in adjuvant 
and viral vectored vaccines (Figure 1.8). Of the vaccines delivering sub-units, the number o f 
antigens they deliver ranges from  1 - 4 .
Phase I Phase lla
> 2
Phase lib Phase III >
M. obuense (NTM)
RUTI 
(fragmented Mtb)
VPM 1002 
(Recombinant BCG)
MTBVAC 
(attenuated M tb)
H I IC31 
(Ag85B, ESAT-6)
M72 + AS01E 
(MTB32A and MTB39A)
Ad
(AgSSA)
H56 IC31 
(Ag85B, ESAT-6, 
Rv2660c)
Ad -  MVA 
(Ag85A)
H4 in IC31 
(Ag85B, TB10.4)
MVA
(Ag85A)
1D93 + GLA-SE 
(Rv2608, Rv3619, 
Rv3620, and Rvl813)
M. vaccae (NTM)
Mycobacterial whole 
cell or Extract
Protein in adjuvant
(antigens)
Viral Vector
(antigens)
Figure 1.8 The Global Clinical Pipeline for TB Vaccine Candidates. Adapted from  
'The Global Plan to  End TB 2016 -  2020', (StopTBPartnership, 2015). Adjuvants: 
IC31, antibacterial peptide (KLKL(5)KLK) plus synthetic oligodeoxynucleotide (ODNla) 
(O lafsdottir et al., 2009); AS01E, Monophosphoryl Lipid A (MPL) and QS-21 (Quillaja 
saponaria purified extract) liposome form ulation (Penn-Nicholson et al., 2015); GLA- 
SE, glucopyranosyl lipid adjuvant -stable emulsion (Baldwin et al., 2013)
TB vaccine antigens
M tb antigens can be referred to  by the ir gene number (denoted Rv) or, if well 
characterized, by the name commonly applied to  the gene product. In 1993, the WHO
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declared TB a global emergency driving an increase in TB vaccine research. Early TB vaccine 
candidates were focused on antigens that would be abundant and expressed in the initial 
stages of TB infection. These included secreted proteins of the Ag85 complex: Ag85A, 
Ag85B and Ag85C (mycolyl transferases essential for maintaining Mtb cell wall integrity), 
and early secretory antigenic target of 6 kDa (ESAT-6; Rv3875). Other antigens were 
identified on the basis of their immunodominance, e.g. TB10.4 (Rv0288), Mtb32 (Rv0125) 
and Mtb39 (Rvll96). Immunogenicity and efficacy studies in animal models confirmed the 
validity of these vaccine candidates (Skeiky and Sadoff, 2006).
Overall, the goal for novel TB vaccines is to prevent primary infection, latent TB infection 
and reactivation of latent infection. As this will require protective efficacy against multiple 
stages of diseases, it is generally agreed that single subunit approaches will be improved 
upon by combining multiple antigens. Hence, efforts to identify further TB vaccine antigens 
are ongoing, particularly those that will target later stages of disease. A strategy for 
identifying such antigens has been to perform in vitro transcriptomic studies in which 
conditions of latent TB are replicated (Bacon and Marsh, 2007). Latency antigen Rv2660c 
(Figure 1.8) was discovered through a combination of in vitro and in vivo transcriptional 
analyses and was incorporated into a formulation containing earlier stage antigens to 
create a multi-stage vaccine (Aagaard et al., 2011). In the multi-subunit vaccine ID93 
(Aeras/IDRI, USA), antigen Rvl813 is upregulated in latency (Baldwin et al., 2013). Another 
late-stage vaccine candidate demonstrating protective efficacy pre-clinically is the acyl 
transferase R vO lll (Vipond et al., 2006a; Vipond et al., 2006b). Formulated as plasmid 
DNA vaccine, R vO lll is protective is guinea pig models of aerosol infection and has been 
shown to contain a number of T cell epitopes as determined by murine immunogenicity 
studies and in vitro assays for human T cell epitope mapping.
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TB vaccine delivery systems
With regards to the optimal delivery system for subunit candidates, plasmid DNA is a 
valuable tool for pre-clinical research, but in larger animals is reliant on additional 
strategies for improving its effectiveness, e.g. use in heterologous prime-boost regimens or 
gene-gun approaches. DNA-viral vector boosting strategies have been investigated for use 
against TB, but there are currently no clinical TB vaccine candidates based on plasmid DNA.
The feasibility of a protein in adjuvant approach is made more difficult by the absence of 
licensed adjuvants for potentiation of cell mediated immune responses. All of the clinical 
candidates based on recombinant protein are combined with proprietary adjuvants, which 
in themselves represent a novel area of research. The examples currently under clinical 
study have been shown to evoke cell mediated responses relevant to protection against 
Mtb infection and are listed under Figure 1.8.
Modified BCG can serve as a bacterial vector for the delivery of TB vaccine antigens. The M. 
bovis BCG strain was attenuated by serial passage, during which 38 open reading frames 
were deleted from the genome (Behr et al., 1999). BCG can be modified to express 
antigens that have been deleted, or to overexpress antigens that have been retained. 
Currently, the only recombinant BCG under clinical development is modified to enhance 
endosomal escape (Kaufmann et al., 2014). A key objective of this approach is that the 
safety and protective efficacy of the parent BCG is improved; a BCG strain overexpressing 
Ag85A, Ag85B and Rv3407 was recently assessed in Phase I clinical trials, but development 
ceased after adverse events (reactivation of shingles).
For delivery of vaccine antigens that are expressed by BCG, viral vectors exhibit many 
favourable characteristics for use as a boosting agent. This includes the capacity to deliver 
large bacterial proteins and the ability to induce potent humoral and cell mediated immune 
responses. Of the many viral vectors available for vaccine antigen delivery (reviewed in
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Section 1.1.3), Ad and MVA are to the date the most widely evaluated (Rollier et al., 2011), 
and their ability to boost responses to BCG has been confirmed.
1.4.3 Optimisation of MVA for delivery of TB antigens
The first studies to evaluate Vaccinia virus for the delivery of TB antigens compared 
replication competent and attenuated viruses Antigen-specific antibody, CD4+ and CD8+ 
responses were induced by both rVV and rMVA carrying MPT64, and were greater following 
a prime with plasmid DNA vectoring the same antigen (Feng et al., 2001). A heterologous 
prime-boost of DNA-MVA vectoring TB antigens ESAT-6 and MPT63 also induced CD4+ and 
CD8+ responses in mice and was shown to provide protection against Mtb challenge 
(McShane et al., 2001).
Immunisation protocol and rMVA formulation
Used as a heterologous boost following immunisation with BCG, MVA vectoring the TB 
antigen Ag85A (MVA85A) boosts CD4+ and CD8+ responses in mice (Goonetilleke et al., 
2003) and humans (McShane et al., 2004). Until recently, MVA85A was the most clinically 
advanced TB vaccine. It has been proven safe and immunogenic in several groups, 
including infants, and can induce Th-1 and Th-17 responses which are regarded as 
important for protection against TB. In 2011, MVA85A became the first TB vaccine to enter 
an efficacy trial since BCG studies performed over 40 years prior. In the study, infants that 
had been immunised with BCG at birth were boosted with MVA85A or given a placebo. 
While the vaccine was demonstrated to be safe, no improvement upon the placebo was 
seen (Tameris et al., 2013).
As described above (Section 1.1.4), optimisation of MVA can include investigation of 
heterologous prime-boost regimens. Any MVA vaccine for TB will be used in a 
heterologous prime-boost schedule with BCG serving as the priming agent, but this can be 
enhanced by further heterologous boosting, as with Ad-MVA which is being investigated in
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humans (Figure 1.8, Phase I). Alternative routes of immunisation can also be explored and 
recently the delivery of MVA85 by the aerosol route has been assessed (Satti et al., 2014).
Heterologous prime-boost regimens and route of delivery are a means of optimising rMVA 
beyond its construction. Prior to this it should be optimised at the genetic level for optimal 
expression and delivery of the recombinant antigen(s).
Optimisation of expression
In the limited number of studies reporting rMVA delivery of M. tuberculosis antigen(s), only 
two promoters have been used; these are the natural 7.5kDa early/late promoter (P7.5) 
and PsynE/L (summarised in Table 1.5). Immunogenicity and protective efficacy have been 
demonstrated, but no reference is made to whether promoter activity has been optimal. In 
contrast, other vaccine fields have undertaken thorough assessment of promoter usage. A 
model tumour-associated antigen delivered via native vaccinia was evaluated with 11 
different promoters to inform rMVA design; a positive correlation between in vitro 
expression levels and protective efficacy was apparent, but strong late expression with 
PsynE/L was shown to have a negative impact by inducing unfavourable antigen processing 
characteristics (Bronte et al., 1997). In a study relating to parainfluenza virus, PsynE/L was 
found to have another detrimental effect, this time on the ability to generate high titre 
stocks. As an alternative to both PsynE/L and the weaker early/late P7.5, a novel promoter 
of intermediate strength (mH5) was generated and proven to provide optimal expression of 
the transgene (Wyatt et al., 1996).
Similar studies are required for novel rMVA vectoring TB antigens. The impact on in vitro 
expression may be expected to be similar, but it is unknown how this will affect the T cell 
responses thought to protect against TB disease. Investigation is warranted and is the 
subject of this study.
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Table 1.5 Evaluation of rMVA for delivery M. tuberculosis antigens. All of the
studies listed were performed in mice. Dose refers to the amount of MVA delivered 
(PFU).
Antigen Route
Dose &  
Regimen
Immunogenicity findings Ref
Psyn (E/L)
ESAT-6 s.c 107 Antigens were expressed as a (Perera et
Ag85A MM fusion. al., 2009)
Ag85B Detectable immunogenicity
HSP65 against each, and protection
Mtb39A against Mtb challenge.
P7.5
MPT64 i.v 107 M M  gave measurable response, (Feng et
M M , DM DM response higher. al., 2001)
ESAT-6 i.d 106 No response from M M . DM (McShane
MPT63 M, MM gave a response and DDDM was et al.,
(fusion) DM,
DDDM
much improved (2 - 1 0  fold). 2001)
Ag85A i.v 106 As above. (McShane
As above et al.,
2002)
R v O lll i.d h-* o c
n
Only DDDM shown to be Rawkins
(generated by DM, effective. et al., (pers.
U.Oxf) DDDM comm)
Abbreviations: i.v, intravenous; s.c, sub-cutaneous; i.d, intradermal; D, DNA; M, MVA; 
U.Oxf, University of Oxford.
Optimised antigen processing
To date, published reports of rMVA delivering TB antigens have only described human 
tissue plasminogen activator (TPA) signal sequence as a leader and in one instance BVP22 
(Yao et al., 2009). The inclusion of TPA has been rationalized by studies demonstrating that 
it improves expression levels, immunogenicity and protective efficacy (Li et al., 1999; Malin 
et al., 2000). The exact mechanism by which TPA enhances the efficacy of TB vaccines is
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unknown, but it is speculated to involve enhanced secretion and uptake by antigen- 
presenting cells as a result of increased expression levels (Li et al., 1999). This subsequently 
leads to MHC Class II presentation and activation of CD4+ T cells, which is an essential 
component of TB protective immunity.
Protection against TB is now understood to require both CD4+ and CD8+ T-cell activation 
and for vaccines required to induce cellular immunity generally, phenotypically more 
diverse responses are evidently preferable; such as those achieved through heterologous 
prime boosting. Leader sequences promote stimulation of different immune responses 
and although they are not always discrete and consistent between antigens, leaders do 
appear to be a tool through which to diversify the response evoked to an antigen.
Not only should the effect of different leader sequences on the immunogenicity of TB 
antigens be investigated, but also the potential for different leader sequences to be 
combined in multiple-recombinant constructs, in order to traffic antigen to more than one 
route simultaneously. This could be evaluated in MVA, but the results would be of 
relevance to any recombinant vector, e.g. Adenovirus or plasmid DNA, both of which have 
been used in MVA heterologous prime-boost regimens. Investigation of this approach, 
using rMVA, is the subject of this study.
1.5 Hypotheses
MVA is an important vector in the field of TB vaccine development, but there have been 
few studies related to the optimisation of MVA-based vaccines for TB. To investigate the 
potential for MVA-based TB vaccines to be enhanced, independently of the vectored 
antigen or antigens, the following hypotheses were investigated:
>  Vaccinia promoter selection can influence the immunogenicity and protective efficacy 
of TB vaccine antigens vectored by MVA.
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>  The type of immune response evoked by an MVA-vectored antigen can be altered via 
the addition of leader sequences. Further, by targeting the antigen to multiple
pathways, the immune response can be made more diverse.
To test the above hypotheses, specific objectives for the study were to:
1. Design a panel of novel recombinant MVA viruses with which to test each hypothesis.
2. Create the required recombinant cassettes, ready for insertion into the MVA genome.
3. Generate purified stocks of each of the recombinant MVA viruses.
4. Evaluate the impact of vaccinia promoter selection on the immunogenicity and
protective efficacy of MVA based vaccines.
5. Investigate the potential for diversifying the immune responses to an antigen through 
the use of multiple leader sequences.
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Chapter 2 Materials and Methods
2.1 Construction of MVA Transfer plasmids
Transfer plasmids were created and purified using standard molecular cloning techniques 
(Green, 2012).
2.1.1 E. coli transformation
Chemically competent E. coli TOPIO (ThermoFisher Scientific) were transformed with 
plasmid DNA according to the manufacturer's instructions. Briefly, 1 pi of purified plasmid 
DNA or 5 pi of ligation reaction was added to a vial of competent cells. The E. coli were 
transformed via heat shock by incubating them at 42°C for 30 seconds and then transferring 
them to ice. Pre-warmed SOC medium (250 pi) was added and then the cells were 
incubated at 37°C, for 1 hour, with shaking at 225 rpm. Following transformation, £  coli 
were spread on agar and incubated at 37°C overnight.
2.1.2 E. coli culture
Transformed £  coli cells were cultured on Luria-Bertani (LB) agar or in LB broth 
(BioMerieux) and were selected for according to the antibiotic resistance conferred by 
plasmid uptake; the medium was supplemented with 100 pg/ml carbenicillin (a stable 
ampicillin analogue), 25 pg/ml chloramphenicol or 50 pg/ml Zeocin™.
£  coli clones were amplified in liquid culture by transferring a single colony from agar to 5 
ml LB broth. Cultures were incubated at 37°C with shaking at 300 rpm, for at least 7 hours 
and preferably overnight. Liquid cultures were inspected for advanced turbidity before 
separating £  coli from the medium. The bacteria were pelleted by centrifugation at 6000 x 
g for 10 minutes and the culture medium discarded.
2.1.3 Plasmid DNA purification
Plasmid DNA was extracted from transformed £  coli using QIAprep® plasmid Miniprep kits
(Qiagen) as per the manufacturer's instructions. Plasmid DNA was eluted in nuclease-free
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w ater and the concentration determ ined by spectrophotometry (Nanodrop 2000; 
ThermoFisher Scientific).
2.1.4 Gateway® cloning.
Gateway® cloning was used throughout the study and was carried out according to  the 
Gateway® Technology manual (ThermoFisher Scientific). A summary o f the process is 
presented in Figure 2.1.
a ttB J  g e n e  a ttB 2
D o n o r
V e c t o r
a ttP 2 C m R
a t tR l c c d B  a i(R 2
pDONRzeo
BP Clonase 
Reaction
g e n e
a t t L l
E n t r y
C lo n e
pENTR-gene
a ttL 2  a t t R l , a t t P l
I  E n t r y  1 I  D e s t i n a t i o n  1
1  C lo n e  1
+
1  V e c t o r  1
pTBD (empty)
LR Clonase 
Reaction
a ttP 2  a t tB i
D o n o r
V e c t o r
E x p r e s s io n
C lo n e
pTBD-Cene
Figure 2.1 Gateway® Cloning. The gene o f interest was introduced to the Gateway® 
system via the addition o f attB  sites to  e ither end o f the gene sequence. The gene 
was transferred to  an entry clone (pENTR) by mixing it w ith  pDONRzeo in a BP 
reaction so tha t attB  and attP  sites would recombine. Each o f the MVA transfer 
plasmids (pTBD) used in the study contained a Gateway® Destination cassette so tha t 
it would serve as a destination vector in an LR reaction; the gene o f interest was 
transferred from  the Entry clone to  the Destination vector via recombination of attL 
and attR  sites. Throughout, a combination o f the ccdB lethal gene and antib iotic 
resistance markers enabled selection o f the desired clones. The antib iotic resistance 
genes used by the system conferred resistance to  chloramphenicol (CmR), zeocin 
(ZeoR) and am picillin/carbenicillin (AmpR). (Figure adapted from 
www.therm ofisher.com ).
The addition of attB  sites to  the gene o f interest was achieved via PCR, i.e. inclusion o f the 
attB  sequence in gene-specific primers (examples are shown in Table 2.1).
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Table 2.1 Primers for offB-PCR. Each PCR reaction included a forward (F) and 
reverse (R) primer. The attB portion of each primer is shown in capital letters. The 
gene-specific sequence is shown in lower case.
Primer Name Primer Sequence (5" to 3')
attB PCR o fR v O lllT
MTB031 (F) GGGGACAAGTTTGTACAAAAAAGCAGGCTaacggccaacgtacgggctggtc 
MTB007 (R) GGGGACCACTTTGTACAAGAAAGCTGGGTcactggcgacccgcaccgaatc 
attB PCR of OVA
MTB115 (F) GGGGACAAGTTTGTACAAAAAAGCAGGCTggctccatcg 
MTB116 (R) GGGGACCACTTTGTACAAGAAAGCTGGGTaggggaaaca
As summarised in Figure 2.1, purified PCR products were transferred to the Entry clone and 
then to the pTBD vector by BP and LR reaction, respectively. Briefly, the PCR 
product/plasmids were mixed with BP or LR clonase in TE buffer (pH 8.0) and incubated at 
25°C for 1 hour. The reaction was stopped by incubation with proteinase K solution at 37°C 
for 10 minutes. After each BP or LR reaction, E. coli TOPIO bacteria were transformed with 
1 pi of reaction mix and the desired transformants selected for on LB agar containing 
antibiotic. The plasmids used during the course of the study are listed in Table 2.2.
Table 2.2 Plasmids propagated and manipulated during the course of the study.
Plasmid pLAS-2 was a kind gift from L. S. Wyatt, National Institute of Health (NIH).
Plasmids in the pTBD series (TB group Destination plasmids) were originally derived
from pLW-44, pLW-24 and pLAS-1 (also kindly donated by L. S. Wyatt, NIH).
Plasmid Antibiotic resistance marker(s) Source
pLAS-2 Ampicillin NIH
pDONRzeo Zeocin™
ThermoFisher
Scientific
Gateway® Destination vectors (prior to insertion of the gene of interest)
pTBDl Ampicillin and Chloramphenicol Laboratory stock
pTBD2 t i / /
pTBD3- 4 tt it
pTBD5-1 4 a This study
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2.1.5 Site directed mutagenesis
Site directed mutagenesis was carried out on plasmids pTBD3 and pTBD4 using QuikChange 
Lightening Site-Directed Mutagenesis kits (Agilent Technologies) as per the manufacturer's 
instructions. Primers (Table 2.3) were designed using the manufacturer's online primer 
design tool. They were required to be 25-45 base pairs in length with base pair changes at 
or near the centre of the sequence. Mutated DNA was transformed into E. coli XL10 Gold 
ultracompetent cells after digestion of the parent DNA template by Dpn I enzyme.
Table 2.3 Primers designed for site-directed mutagenesis. Base pair changes were 
made to the indicated plasmids in order to introduce novel unique restriction 
enzyme sites. Mutations are shown in bold capital letters.
Primer Name Primer Sequence (5' to 3')
Introduction of Age! to pTBD3
QM01 (F) gcgagaaataatcataaataagAccggtgccaccatgga
QM02 (R) tccatggtggcaccggTcttatttatgattatttctcgc
Introduction ofAgel to pTBD4
QM03 (F) gaagtagaatcataaagaacagtAccggtgccacca
QM04 (R) tggtggcaccggTactgttctttatgattctacttc
Introduction of EcoRV to pTBD3 and pTBD4
QM05 (F) ccgattcagaagaggagccagatctGATatcaaacaagtttgtacaaaaaagc
QM06 (R) gcttttttgtacaaacttgtttgatATCagatctggctcctcttctgaatcgg
2.1.6 Restriction enzyme digest
Restriction enzymes (New England Biosciences) were used according to the manufacturer's
instructions. Briefly, 1 unit of enzyme (1 pi) was added to 1 pg DNA (plasmid or PCR
product). Each reaction included the appropriate NEB buffer, with or without bovine serum
albumin (BSA) as prescribed and was made up to the required volume with nuclease-free
water. The reaction was incubated at 37°C for at least 1 hour. For digestion with two
enzymes, a double-digest was performed provided enzyme conditions were compatible.
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Where they were not, a sequential digest was performed. To prevent re-ligation of 
digested plasmid, 5' phosphate groups were removed using Antarctic phosphatase (New 
England Biosciences) as per the manufacturer's instructions.
2.1.7 Separation of DNA fragments by agarose gel electrophoresis
Horizontal gels were prepared by dissolving agarose (1%) in Tris-acetate 
ethylenediaminetetraacetic acid (TAE) buffer. Sybr® Safe DNA gel stain (ThermoFisher 
Scientific) was added so that DNA fragments were visible under ultra-violet light for image 
capture (UVIdoc) or blue-light transillumination for band excision (ThermoFisher Scientific). 
Samples of DNA were loaded into each gel using gel loading dye and were run in parallel 
with 1 kb DNA ladder (ThermoFisher Scientific). Electrophoresis was performed at 100 V 
for up to 1 hour. Fragments requiring excision were extracted using QIAquick® Gel 
extraction kits (Qiagen) as per the manufacturer's instructions.
2.1.8 Polymerase chain reaction (PCR)
High-fidelity PCR was performed using KAPA HiFi Hotstart readymix (Kapa Biosystems) as 
per the manufacturer's instructions. Briefly, forward and reverse primers were added at a 
final concentration of 0.3 pM. Template DNA was present at less than 100 ng (genomic 
DNA), or between 0.1 and 10 ng (less complex DNA, e.g. fragments). The reaction volume 
was made up using nuclease-free water. Initial denaturation was performed at 95°C for 2-5 
minutes. Cycling conditions were 35 cycles of 98°C for 20 seconds, 65°C for 15 seconds and 
72°C for 15 seconds per kilobase (kb). A final extension step of 72°C for 1 minute per kb 
was performed before cooling the reaction to 4°C. PCR products were cleaned up for use in 
ligation reactions by gel extraction (Section 2.1.7) or by performing QIAquick PCR 
purification (Qiagen) as per the manufacturer's instructions.
High-fidelity PCR was applied to generate fragments for transfer plasmid construction. The 
primers used to create DNA fragments homologous to Deletion site II are listed in Table 2.4. 
Where possible, primers were 20 -  30 nucleotides long, had a guanidine/cytosine (GC)
content of 40 -  60% and a melting temperature (Tm) between 60 and 70°C. Four 
nucleotides were added 5' to restriction enzyme recognition sites to promote efficient 
cutting. Secondary structure was examined using an online tool 
(http://biotools.nubic.northwestern.edu/OligoCalc.htmn.
Table 2.4 Primers for creating Del II fragments by high-fidelity PCR. Forward (F) and 
reverse (R) primers were designed to add unique restriction enzyme recognition sites 
(underlined). Where the PCR product might have otherwise contained a unique site 
of value to the cloning process, a two-step PCR reaction (Section 2.1.9) was applied 
to introduce a mutation (bold, lower case) that would remove it. The template DNA 
was plasmid pl_AS-2 (Table 2.2).
Primer Name Primer Sequence (5' to 3')
Del II Direct repeat: adding EcolRCI (F) andXhol (R)
MTB95 (F) TAATGAGCTCGCTTTCTCTCTAGCAAAGATG
MTB96 (R) T AAT CT CG AG G AAT CAT CCAGT CCACT G AATAG
Del II Left Flank: 2 step PCR removing Agel, adding Sbfl (F) and Hindlll (R)
MTB97 (F) TAATCCTGCAGGGGATGCGATCATGACGTCC
MTB105 (R) CGT ACAG G ACGTAACTATAAACCG cTT
MTB106 (F) CTT G AACA AATATA AAgCG G
MTB98 (R) TAATAAGCTTGGTTTGATCGTTGTCATTTCTCC
Del II Right Flank: Two-step PCR removing Hindlll, adding Narl (F) and AscI (R)
MTB109 (F) GAAGTCTAAGCAGCTGAAAtGCTTTC
MTB110 (R) GCA TCT TTG CTA GAG AGA AAG CaT TTC
MTB107 (F) TAATGGCGCCCTCCTGAAAAACTGG
MTB108 (R) TAAT G G CG CG CCG AAT CAT CC AGTCC ACTG
2.1.9 Overlap extension (OE) PCR
OE-PCR was applied to generate DNA fragments incorporating multiple PCR products, 
and/or oligonucleotides. The fragments were combined in a PCR reaction with Kapa HiFi 
polymerase and subjected to cycling conditions as described in Section 2.1.8. After 15
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cycles, the reaction was stopped and primers homologous to the ends of the combined
product were added. A further round of 20 cycles was then carried out.
2.1.10 DNA annealing
Custom synthesised oligonucleotides (Table 2.5) were mixed at equimolar concentration in 
Ligase buffer (New England Biosciences) and incubated at 85°C for 10 minutes. Stepwise 
cooling was performed in 5°C increments down to 25°C. Each temperature was held for 5 
minutes.
Table 2.5 Oligonucleotides for plasmid modification. Custom synthesised DNA 
fragments (Integrated DNA Technologies) were prepared ready for annealing and 
ligation; they were designed to have ends compatible with restriction enzyme- 
digested vector and were 5' phosphorylated.
Oligo
Name
Oligo Sequence (5' to 3')
pTBD5/6 to pTBD9/10: Kozak sequence, no leader
MTB111 CCG GTG CCACCAT G G AT
(F)
M T B lllr ATCCATGGTGGCA
(R)
pTBD7/8 to pTB D ll/12 /13 /14: N terminal V5 tag
MTB112 CCGGTGCCACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCT
(F) ACGGATCTAGAGGG
CCCGCGGTTCGAAGAT
MTB112r ATCTTCGAACCGCGGGCCCTCTAGATCCGTAGAATCGAGACCGAGGAGAGG
(R) GT TAGGGATAGGCT TACCCATGGTGGCA
pTBD7/8 to pTB D ll/12: C terminal VSVg
MTB113 GGCCCGAGCAGCATCGCCAGCTTCTTCTTCATCATCGGCCTGATCATCGGCC
(F) TGTTCCTGGTGCTGCGCGTGGGCATCCACCTGTGCATCAAGCTGAAGCACAC
CAAG AAG CGCCAG AT CTACACCG ACAT CG AG ATG AACCG CCT GGG CAAGTA
ACTCGACCTGCA
MTB113r GGTCGAGTTACTTGCCCAGGCGGTTCATCTCGATGTCGGTGTAGATCTGGC
(R) GCTTCTTGGTGTGCTTCAGCTTGATGCACAGGTGGATGCCCACGCGCAGCAC
CAGGAACAGGCCGATGA
pTBD7/8 to PTBD13/14: C terminal stop
MTB114 GGCCCGTAACTCGACCTGCA
(F)
MTB114r GGTCGAGTTACG
(R)
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2.1.11 DNA ligation
Fragments of DNA were ligated together using the Quick-Ligation™ kit (New England 
Biosciences) as per the manufacturer's instructions. Briefly, the reaction was set up to 
include 50 ng of vector with a three-fold molar excess of insert. Quick-Ligation reaction 
buffer and Quick T4 DNA ligase were added at the required concentrations and the reaction 
incubated at room temperature for 5 minutes. The reaction mix was chilled on ice prior to 
transformation of E. coli TOPIO (Section 2.1.1). The inserts used in each ligation were 
derived from high-fidelity PCR (Sections 2.1.8 and 2.1.9) or were otherwise purchased as 
oligonucleotides and annealed (Section 2.1.10).
2.1.12 DNA sequencing
Sanger sequencing of DNA samples was performed using an external sequencing service 
(Beckman Coulter Genomics, Takeley, UK). Plasmid DNA or purified PCR products were 
sent at, or above, the minimum concentration and volume required. Where universal 
primers were not available, sequences for custom synthesised primers were provided. 
Primers were designed to bind to the template sequence at approximately 700 base pair 
intervals, were typically 20-30 nucleotides long and had a GC content between 40 and 60%. 
Sequences with secondary structure (examined as described in Section 2.1.8) were avoided.
2.1.13 Conversion of pTBD5 to pTBD9
A combination of oligonucleotide custom synthesis, PCR and OE-PCR was applied to the 
preparation of inserts for the conversion of pTBD5 to pTBD9. A summary of the inserts 
prepared and their means of preparation is described in Figure 2.2.
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Fragments and their means o f preparation:
A 17 bp (Not shown in the above diagram)
Annealed oligonucleotides; M T B l l l / M T B l l l r  (see Table 2.5)
Age I/EcoRV
B 252 bp Custom synthesised by IDT.
Xhol/N otl
C 1899 bp 1. TPA to V5 was amplified from  pTBD5 by PCR.
2. TPA was removed from  the PCR product by restriction enzyme digest 
with EcoRV.
3. OE-PCR w ith fragm ent B was performed.
Xhol/PspOMI
D 2849 bp 1. GFP to TPA was amplified from  pTBD5 by PCR.
2. TPA was removed from  the PCR product by restriction enzyme digest 
with Age I.
3. OE-PCR with fragm ent B was perform ed fo llow ed  by OE-PCR with  
fragm ent C.
Eco53KI (EcolCRI isoschizomerj/PsoOMI
Figure 2.2 Fragments for the conversion of pTBD5 to pTBD9. Plasmid maps fo r 
sections o f pTBD5 and pTBD9 are shown. Plasmid conversion using fragm ent A was 
unsuccessful. Larger fragments (B-D) were prepared and are illustrated, below which 
the ir means o f construction is described. Restriction enzymes used fo r vector/insert 
digestion are shown underlined.
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2.1.14 Construction of the Ovalbumin (OVA) gene
The OVA gene (Gollus gallus ovalbumin; NCBI Accession number NM_205152.1), minus the 
native start, was custom synthesised as three overlapping gBIock fragments (Integrated 
DNA Technologies) as shown in Figure 2.3. The fragments were joined by OE-PCR and 
incorporated attB  sites fo r recombination into pDONRzeo (see 2.1.4 Gateway® cloning). 
Am plification was achieved using primers binding to  the end o f the product (the sequences 
fo r primers MTB115 and MTB116 are shown in Table 2.2). As w ith  the other antigens used 
in this study, the OVA gene was screened fo r the vaccinia transcription term ination 
sequence I I 11 I NT in silico, prior to  cloning (none were found to be present).
attB-OVA Linear Map vjith  scale (bp), SeqBuilder DNA Lasergene 11
attB 1 attB2
| 1200 I <00 1600 1800 I 1003 I
E|  Ovalbumin ^ > H
gBIock YH3
<  _________gBIock VH2______________j
g Block YH1
Forward MTB115 Reverse MTB116
Figure 2.3 Construction of the OVA gene by OE-PCR. In the firs t step o f the reaction, 
three overlapping gBIock fragments were combined. In the second step o f the 
reaction, the product was amplified by the addition o f primers MTB115 and MTB116 
(Table 2.2). AttB  sites were added to the sequence so tha t it could be used in 
Gateway® cloning.
2.2 Generation of Recombinant MVA (rMVA)
Recombinant MVA were generated using establish protocols fo r transfer plasmid mediated 
construction (Earl et al., 2001a; Earl and Moss, 2001; Earl et al., 2001b; Kremer et al., 2012). 
Aseptic technique was applied throughout.
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2.2.1 Cell culture
Cell line BHK-21 (ATCC CCL-10) was maintained in Minimal Essential Medium (MEM) 
supplemented with 10% fetal bovine serum (FBS), 5 mM L-glutamine, 100 units/ml 
penicillin and 100 pg/ml streptomycin (all reagents -  Sigma Aldrich). Cells were maintained 
in static tissue culture flasks, incubated at 37°C, 5% C02 and 95% humidity. The cell culture 
medium was changed twice a week and cells were passaged every 7 - 1 0  days. No more 
than a total of 10 passages were performed as BHK-21 cells are susceptible to phenotypic 
drift.
Primary chick embryo fibroblast (CEF) cells were obtained from The Pirbright Institute, UK. 
Cells were seeded into tissue culture flasks at approximately 2 x 107 cells per 175 cm2 in 
supplemented MEM, as described above. Flasks were incubated at 37°C, 5% C02 and 95% 
humidity for 24 hours before reducing the incubating temperature to 30°C. Cells were 
passaged at least once prior to use and from there on were incubated at 37°C.
Throughout, BHK-21 or CEF cells were cultured in multi-well tissue culture plates or in 
tissue culture flasks with a surface area of 25 cm2 (T25), 75 cm2 (T75) or 175 cm2 (T175). 
Cells were infected with MVA diluted in supplemented MEM containing 0 or 2% FBS -  
referred to as '0% MEM' or '2% MEM', respectively. Incubations were performed at 37°C, 
5% C02 and 95% humidity. Infected cell monolayers were examined by inverted light 
and/or fluorescence microscopy to monitor the development of cytopathic effects (CPE) 
and where rMVA was present, the expression of the selection marker - GFP.
2.2.2 Preparation of wild-type MVA stock
A working stock of MVA (ATCC-VR-1508) was prepared by two sequential rounds of
amplification on CEF cells. The virus was diluted in 2% MEM and applied to a T75 flask at a
multiplicity of infection (MOI) of approximately 0.1. The cells were incubated for 3 days
and then harvested by scraping and centrifugation at 1200 x g for 10 minutes. The cell
pellet was resuspended in 1-2 ml 2% MEM supernatant and stored at -80°C. Cells were
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lysed by three repeat rounds of freeze-thawing and were vortexed and sonicated on each 
round to promote dissociation of the viral particles. The working stock was created after a 
second round of amplification performed on eight T175 flasks. The harvested material was 
diluted down to a working concentration, aliquoted and stored at -80°C for future use. 
Viral titre was determined as described below.
2.2.3 Determination of MVA titre by immunostaining
CEF cells were seeded into 6 well plates so that they were nearing confluency at the time of 
use. Viral samples were vortexed and sonicated immediately prior to performing 10-fold 
serial dilutions in 0% MEM. CEF were infected with a range of dilutions, in duplicate wells, 
0.5 ml per well and then incubated for 90 minutes with rocking at 15 minute intervals. 
After 90 minutes, 0% MEM was removed and replaced with 2% MEM containing 1% low 
gelling temperature agarose (2-hydroxyethylagarose Type VII; Sigma Aldrich). The pre- 
molten overlay was allowed to solidify before incubation of the plate(s) for 2-3 days.
The solid overlay was removed from each well immediately prior to immunostaining. Care 
was taken not to damage the cell monolayer. Anti-vaccinia polyclonal antibody raised in 
rabbit (AbD Serotec) was added to each well and then detected using VECTASTAIN® ABC-AP 
Rabbit IgG kit (Vector Laboratories). The kit was used as per the manufacturer's 
instructions. Briefly, biotinylated anti-rabbit secondary antibody was applied followed by 
combined avidin/biotinylated-alkaline phosphatase (AP) reagents. Viral plaques were made 
visible by the addition of Vector Red AP substrate. Plaques were counted under an inverted 
light microscope (x4) and the number arising from duplicate wells multiplied by the dilution 
factor to determine the viral titre (PFU/ml) of the original sample.
2.2.4 Generation of rMVA by infection/transfection (l/T) reaction
BHK-21 were grown to 85-90% confluence in a T25 culture flask and then infected with
MVA in 0% MEM at an MOI of 0.05. After 90 minutes, the MVA was removed and 5.6 pg of
transfer plasmid DNA transfected into the cells using Lipofectamine®, as per the
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manufacturer's instructions (ThermoFisher Scientific). After 5 hours, the transfecting 
medium was removed and replaced with 2% MEM. Two - three days later, BHK-21 were 
viewed using an inverted light microscope to monitor CPE and GFP expression before 
harvesting the cell layer into 1 ml of supernatant. The harvested sample was subjected to 
three rounds of freeze-thawing, with vortexing and sonication before being progressed to 
plaque purification.
2.2.5 Isolation of rMVA by plaque purification
CEF were seeded into multi-well tissue culture plates and were infected as described for 
immunostaining (Section 2.2.3). Briefly, material from the l/T step was serially diluted and 
plated at dilutions of 1:100,1:1000 and 1:10000. After 90 minutes incubation, the infecting 
material was removed and replaced with solid overlay. After 2-3 days incubation, viral 
plaques expressing GFP were visualised using inverted fluorescence microscopy and were 
picked from the cell layer using a Gilson pipette. Each viral pick was transferred to 0.5 ml 
0% MEM for freeze-thawing with vortexing and sonication.
Subsequent rounds of plating were performed as above, but by plating dilutions of 1:10, 
1:100 and 1:1000. At each stage, plaques were picked from the highest possible dilution so 
as to carry over the least amount of parent MVA.
Plaque samples were numbered according to the round of plaque purification and their 
number, which took into account their lineage e.g. P I (1.3.2). Where helpful, this was 
presented schematically, as per the mock example shown in Figure 2.4.
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P I
P2
(1.2)
P2
(1.3)
P2
(1.1)
P3
(1-3.3)
P I
Figure 2.4 A family-tree for rMVA isolation. A mock example is depicted. Following 
the infection and transfection step (l/T), 3 plaques are isolated - P I (1), P I (2) and P I 
(3). Plaque sample P I (1) is propagated and a further 3 plaques are picked. Two of 
these samples are propagated to yield a further 4 plaques. Samples are labelled 
according to the round of plaque purification and their number, which takes into 
account the lineage of the sample.
2.2.6 Generation of markerless rMVA
Following successful isolation of rMVA, viruses generated to express GFP transiently were 
further passaged to promote removal of the selection marker by an internal recombination 
event (described in Section 1.3.1). The viral population comprising GFP positive and GFP 
negative rMVA was propagated on CEF until CPE, but no GFP was visible.
In some instances, GFP expression was observed to persist. This was overcome by infection 
of CEF in a multi-well plate followed by incubation under a solid 2% MEM overlay (as 
described in Section 2.2.3). After 2-3 days, areas of the monolayer exhibiting CPE, but no 
GFP expression, were picked into 0.5 ml 2% MEM for further propagation, thereby 
expediting GFP removal.
2.2.7 Purification of rMVA by sucrose cushion density centrifugation
Samples of purified rMVA were amplified on CEF cells by serial propagation in culture
vessels of increasing size. Large scale amplification was performed using 10 or more T175
flasks. Amplified virus was separated from the cell lysate by density centrifugation. Briefly,
the cell pellet was harvested in 10 ml of 10 mM Tris-HCI. The cells were lysed by freeze-
thaw cycles, homogenised using a Dounce homogeniser (50 strokes) and sonicated. The
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homogenate was layered onto a 36% sucrose solution prepared in 10 mM Tris-HCI and 
centrifugation performed at 33000 x g, 4°C for 90 minutes. The viral pellet was 
resusepnded in PBS for aliquoting and titration. All viral material was stored at -80°C.
2.3 In vitro characterization of rMVA
2.3.1 Extraction of viral genomic DNA
Viral samples were amplified on CEF in multi-well plates for 2-3 days. Viral genomic DNA 
(gDNA) was extracted using a Wizard SV Genomic DNA Purification Kit (Promega) as per the 
manufacturer's instructions. Briefly, the cell culture medium was removed from each 
infected well and the contents transferred to a mini-column in lysis buffer. Each 
purification column was subjected to repeat washes before eluting gDNA in nuclease-free 
water.
2.3.2 Analytical PCR
PCR was performed using KAPA 2G Fast Hotstart readymix (Kapa Biosystems) as per the 
manufacturer's instructions. Briefly, forward and reverse primers were added at a final 
concentration of 0.5 pM. Template DNA (viral gDNA) was present at less than 100 ng. 
Initial denaturation was performed at 95°C for 1 minute. Cycling conditions were 35 cycles 
of 95°C for 15 seconds, 60°C for 15 seconds and 72°C for 60 seconds. A final extension step 
of 72°C for 5 minutes was performed before cooling the reaction to 4°C. In each reaction, 
transfer plasmid DNA was used as a positive control and nuclease-free water in place of 
DNA as the negative control. The primer pairs used to examine insertion sites and/or the 
presence of a recombinant cassette are listed in Table 2.6.
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Table 2.6 Primers for rMVA analytical PCR. Each primer pair bound to the flanking 
region of a particular insertion site (Del II or Del III) and/or the recombinant cassette. 
Primers were obtained from existing stocks or from those created above, i.e. during 
transfer plasmid construction (Table 2.1 and Table 2.4).
Primer Name Primer Sequence (5' to 3')
Del III Leftflank(F) to Del III Right flank (R)
MTB93 (F) CGGCACCTCTCTTAAGAAGT
MTB21 (R) GTGTAGCGTATACTAATGATATTAG
N-terminal TPA (F) to C-terminal V5 (R)
MTB01 (F) GCCACCAT GG ATG CAAT G AAG AG A
MTB34 (R) TTACGTAGAATCGAGACCGAGGAG
GFP (F) to Del III Right Flank (R)
MTB92 (F) CGTAAACGGCCACAAGTTCAGCG
MTB21 (R) GTGTAGCGTATACTAATGATATTAG
Del II Right flank (F) to Del II Left flank (R)
MTB109 (F) GAAGTCTAAGCAGCTGAAATGCTTTC
MTB105 (R) CGTACAG G ACGTA ACTATAAACCG CTT
OVA gene start (F) to OVA gene end (R)
MTB115 (F) GGGGACAAGTTTGTACAAAAAAGCAGGCTGGCTCCATCG
MTB116 (R) GGGGACCACTTTGTACAAGAAAGCTGGGTAGGGGAAACA
GFP (F) to Del II Left Flank (R)
MTB92 (F) CGTAAACGGCCACAAGTTCAGCG
MTB105 (R) CGTACAG G ACGTAACTATAAACCG CTT
2.3.3 Detection of recombinant antigen expression by Western Blotting
Viral samples were amplified on CEF in multi-well plates for 2-3 days. After removal of the 
cell culture medium, CEF and viral proteins were harvested in lithium dodecyl sulphate 
(LDS) buffer containing 10% denaturing reagent (ThermoFisher Scientific). Each sample was 
further denatured by heating to 90°C for 10 minutes.
Proteins were separated by polyacrylamide gel electrophoresis using NuPage 4-12% Bis-Tris 
gradient gels (ThermoFisher Scientific). SeeBlue Plus2 pre-stained protein ladder and Magic
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Mark XP Western protein standard (both ThermoFisher Scientific) were included in each 
run and electrophoresis performed at 200 V for up to 1 hour.
Following electrophoresis, protein was transferred to Hybond ECL nitrocellulose membrane 
(GE Healthcare Life Sciences) by Western Blotting; an XCell II™ Blot module and NuPage 
Transfer buffer (ThermoFisher Scientific) were used as per the manufacturer's instructions. 
Blotting was performed at 40 V for 1 hour and successful protein migration was monitored 
according to movement of the SeeBlue Plus2 ladder from the gel to the membrane.
Immunodetection was performed after blocking with 3% milk powder (Sigma Aldrich) 
diluted in PBS/Tween 20 (0.05%). The membrane was incubated with anti-V5 monoclonal 
antibody (AbD Sertotec) and chemiluminescent detection of anti-V5 reactive bands 
achieved via incubation with anti-mouse HRP conjugate. The application of ECL Plus 
chemiluminescent reagent and exposure to Hyperfilm ECL (GE Healthcare Life Sciences) was 
performed as per the manufacturer's instructions.
2.3.4 Semi-quantitative measurement of expression by dot blotting
Viral samples were amplified on CEF and the cells lysed as described above. Material was 
applied directly to nitrocellulose in 5 pi spots prior to blocking and immunodetection with 
anti-V5 (as described for Western blotting). Hyperfilm was scanned using a BioRad GS-800 
densitometer (BioRad) and optical density measured by ImageQuant TL image analysis 
software (GE Healthcare) or Quantity One ID  analysis software (BioRad).
2.4 In vivo characterization of rMVA
Mouse studies were conducted according to UK Home Office legislation for animal 
experimentation and were approved by the local ethical committee.
Mouse immunisation, M. tuberculosis aerosol challenge and post-terminal sampling were 
performed by the Biological Investigations Group and the Small Animal Vaccine Evaluation 
team.
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2.4.1 Mouse strain and immunisation
Groups of female C57BI/6 or CB6F1 mice (8 -10 weeks of age) were immunised with MVA 
diluted in PBS. A dose of 106 or 107 PFU was given in 100 pi, intramuscularly (50 pi per hind 
leg), twice at two week intervals.
BCG Danish (Staten Serum Institut, Denmark) was diluted in Sautons medium as per the 
vaccine supplier's instructions. Mice were administered a dose of 1 x 105 CFU in 100 pi, 
subcutaneously in the nape of the neck.
Unvaccinated mice were matched for age and sex and received no immunisation. 
Post-terminal sampling was performed to obtain whole blood and spleens.
2.4.2 Measurement of cytokine release by ELISpot assay
Splenocytes were harvested and assessed for antigen specific recall responses two weeks 
after the final immunisation. Cells were isolated via mechanical dissociation of the spleen 
followed by centrifugation at 500 x g for 7 minutes at 18°C. Red blood cells were lysed 
with ammonium-chloride-potassium (ACK) buffer (ThermoFisher Scientific). Processing and 
cell culture was performed aseptically in RPMI medium supplemented with 10% FBS, 5 mM  
L-glutamine, 100 units/ml penicillin, 100 pg/ml streptomycin, 0.5 pM 3-mercaptoethanol 
and 12.5 mM HEPES buffer (all reagents Sigma Aldrich, except 3-mercaptoethanol - 
ThermoFisher Scientific).
Murine ELISpot assays for IFNy, IL-4 and IL-17 (MAbtech) were performed as per the
manufacturer's instructions. PVDF plates (Merck Millipore) were coated with IFNy capture
antibody. Splenocytes were added at 5 x 104 or 2 x 105 cells per well. Cells were cultured
with restimulating peptides (described below), each present at a final concentration of 2
pg/ml. A mixture of 0.1 pg/ml Phorbol 12-myristate 13-acetate (Sigma Aldrich) and 1 pg/ml
lonomycin (Merck Millipore) was added to positive-control wells. Background IFNy release
was measured in wells containing splenocytes and cell culture medium only. Plates were
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incubated at 37°C, 5% C02 and 95% humidity for 18 hours priors to removal of the cells for 
spot detection.
Bound IFNy was detected via the addition of biotinylated anti-IFNy followed by streptavidin- 
AP conjugate. Spots were developed following incubation with AP substrate - BCIP/NBT 
(MAbtech). Spots were counted using an AID ELISpot reader and results expressed as spot 
forming units (SFU) per million cells (SFU/106) after subtraction of background (media only) 
responses. Responses greater than background plus two standard deviations were deemed 
to be positive. Statistical comparison between two groups was performed using unpaired 
T-tests (Microsoft Excel 2010). Comparison between multiple groups was achieved using 
one-way ANOVA (GraphPad Prism 6).
Cryopreservation of splenocytes was performed by freezing cells in FBS containing 10% 
DMSO. Cells were frozen at -80°C in a storage container designed to control the cooling 
rate (-1°C per minute). Cells were then transferred to the vapour phase of liquid nitrogen 
storage tanks.
2.4.3 Restimulating peptides and protein
Lyophilised peptides (Mimotopes) representing M. tuberculosis strain FI37Rv genes R v O lll 
and Ag85A (Rv3804c) and were prepared as 15 amino acid oligomers (15 mers) offset by 
5/overlapping by 10. Vaccinia peptides (Mimotopes) were based on immunogenic 
determinants (8-10 mers) for genes B8R, A19L, A47L, A42R and K3L, as described by 
Tscharke et al. (Tscharke et al., 2005). Ovalbumin peptides (Mimotopes) were based on 
MFIC Class I and MHC Class II epitopes; OVA257-264 'SIINFEKL' and OVA323.339 
'ISQAVHAAHAEINEAGR', respectively.
All peptides were resuspended in 10% DMSO to a concentration of 8 mg/ml and diluted to 
a final concentration of 2 pg/ml for cell stimulation. Peptide pools were created by the 
addition of equal volumes of each peptide.
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Whole OVA protein was obtained in the form of purified albumin from chicken egg white 
(Sigma Aldrich) and was used at the concentration specified. Tuberculin purified protein 
derivative (PPD) was obtained from the Staten Serum Institute and used at a final 
concentration of 10 pg/ml.
2.4.4 Measurement of OVA-specific IgG isoforms by ELISA
An in-house enzyme-linked immunosorbent assay (ELISA) was developed for the detection 
of murine anti-OVA IgG. Reagents were sourced from Sigma Aldrich unless otherwise 
stated. Serum was separated from whole blood via centrifugation in serum separator tubes 
(Becton Dickinson) as per the manufacturer's instructions.
Immuno MaxiSorb microtitre plates (ThermoFisher Scientific) were coated with IgG or 
ovalbumin diluted in 0.05 M carbonate-bicarbonate buffer, pH 9.6. Plates were incubated 
overnight (16+ hours) at 4°C and then blocked with 1% BSA in PBS for at least 2 hours at 
room temperature. Anti-ovalbumin IgGl or mouse serum, diluted in PBS, was added at 50 
pi per well and incubated for 2 hours at room temperature.
Indirect detection of bound IgG was achieved using biotinylated isotype-specific anti-mouse 
IgG, followed by ultrasensitive streptavidin-HRP conjugate, both added for 1 hour at room 
temperature. Measurement of bound IgG was achieved via addition of the chromogenic 
HRP substrate tetramethylbenzidine (TMB). TMB was incubated for 2 minutes before 1M 
H2S04was added to stop the reaction. The plates were read at 450 nm and 690 nm and 
results for the latter subtracted from the first. Non-specific binding (NSB) was subtracted 
from all of the results, i.e. the OD measured in the absence of primary antibody (coating IgG 
or mouse serum) and was determined for a minimum of three wells.
2.4.5 Evaluation of vaccine efficacy after M. tuberculosis aerosol challenge
Groups of C57BI/6 mice (Section 2.4.1) were infected with an aerosolised dose of M. 
tuberculosis strain Erdman. The challenge apparatus and methodology were as previously
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described (Clark et al., 2011). Briefly, a suspension of Mtb Erdman was aerosolised in a 
contained Henderson unit to infect the mice via nose-only exposure. The concentration of 
the bacteria in the Collison nebuliser was sufficient to provide an inhaled retained dose of 
approximately 100 CFU. After infection, animals were housed under Advisory Committee 
on Dangerous Pathogens (ACDP) Hazard Group 3 containment measures and monitored 
daily for outward signs of ill-health. At four weeks post-infection, post-terminal sampling of 
the lung and spleen was performed. Whole lung and spleen were homogenised in sterile 
water and plated on 7H11 OADC selective solid medium (bioMerieux) for enumeration of 
bacterial load. Groups were compared by unpaired, non-parametric Mann-Whitney test 
(GraphPad Prism 6).
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Chapter 3 Design and construction of novel transfer plasmids
3.1 Introduction
In order to test the study hypotheses (see Section 1.5), several novel rMVA viruses needed 
to be created. As discussed in Chapter 1.3, there are two principal approaches for 
generating recombinant MVA: transfer plasmid methodology and BAC technology. Transfer 
plasmid methodology was selected for the current study on the basis that an existing panel 
of transfer plasmids was available for use and/or modification. As described in Section
1.3.2, BAC technology confers the principal advantage of negating the need for plaque 
purification, but is technically demanding to establish (Cottingham, 2012).
The transfer plasmids available at the outset of the study were Gateway® cloning vectors. 
They are listed in Section 2.1.4, Table 2.2. It was proposed that alteration of this plasmid 
set via standard cloning techniques would be the most expedient route to obtaining the 
novel recombinant cassettes required. Before the transfer plasmids could be selected 
and/or modified, the precise nature of the rMVA viruses needed for the study had to be 
decided upon. (Generation of the rMVA viruses is described in Chapter 4).
3.1.1 Transfer plasmids for the Vaccinia promoter study
To investigate the impact of vaccinia promoter selection on the immunogenicity and 
protective efficacy of rMVA vectoring M. tuberculosis antigens, it was essential to have 
viruses identical in every regard except for the vaccinia promoter driving antigen 
expression. The rationale for the vaccinia promoters and M. tuberculosis antigens selected 
for this aspect of the study is described in more detail in Chapter 5. Briefly, two vaccinia 
promoters, P7.5 and mH5, and two M. tuberculosis antigens (R vO lll and Ag85A) were 
chosen. The complete panel of rMVA viruses is listed in Table 3.1. One of the viruses 
(MVA-mH5-Ag85A) and all of the transfer plasmids were available and so no further cloning 
work was needed.
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Table 3.1 rMVA viruses for the vaccinia promoter study. Existing transfer plasmids 
were available for the purpose of generating the expression products shown.
Recombinant MVA  
virus
Expression product Common Features
M VA-m H5-Ag85 A 
MVA-P7.5-Ag85A
TPA-Ag85A-V5 Insertion site: Del III 
Selection marker: stable
MVA-mH5-Rv0111
MVA-P7.5-Rv0111
TPA-Rv0111-V5 GFP
Other features conferred by the existing transfer plasmids were in-frame expression of a 
TPA leader (see Section 1.2.6) at the start (N-terminus) of the polypeptide sequence and in­
frame expression of V5 at the end (C-terminus) of the protein. Both fusions are discussed 
in more detail in Chapter 5. The V5 protein tag, also known as Pk, is a B cell epitope 
sequence. It is 14 amino acids long and is derived from the P and V proteins of the 
paramyxovirus of simian virus 5 (Southern et al., 1991). Expression of V5 as an antigen- 
fusion enables immunodetection of the expression product using anti-V5 IgG, thus, 
circumventing the need for antigen-specific antibodies.
3.1.2 Transfer plasmids for the Leader Sequences study
To investigate the impact of leader sequences on transgene immunogenicity, including the 
impact of targeting a recombinant antigen to multiple pathways, two leader sequences 
were selected for use in two, separate insertion sites: TPA - Del III and VSVg - Del II. The 
antigen selected for comparison of antigen-fusion effects was the model antigen ovalbumin 
(OVA). The rationale for the antigen selected, and further explanation for the specific 
design of the constructs is discussed in Chapter 6. Briefly, the TPA and VSVg fusions were 
expressed at the N and C terminus of OVA, respectively. At the other terminus, a V5 tag 
was inserted. For each of the leader sequences under investigation, a corresponding 'no- 
leader' plasmid was created to enable provision of a no-leader control virus. The viruses 
required and their expression products, relative to the insertion site, are listed in Table 3.2.
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Table 3.2 rMVA viruses required for the leader sequences study. The panel of rMVA 
comprised single and double-recombinant viruses. For each virus expressing OVA 
fused to a leader sequence, there was a corresponding 'no-leader7 control.
Recombinant MVA virus
Expression product 
Del II
Expression product 
Del III
MVA-OVAtra - TPA-OVA-V5
MVA-OVA - OVA-V5
MVA-OVAVsvg V5-OVA-VSVg -
MVA-OVA V5-OVA -
M VA-OVAtpa/ OVAvsvg V5-OVA-VSVg TPA-OVA-V5
MVA-OVA/OVA V5-OVA OVA-V5
To create the transfer plasmids required, Destination vectors pTBD3 and pTBD4 (Section 
2.1.4, Table 2.2) were selected for modification. Plasmids pTBD3 and pTBD4 incorporate 
mH5 and P7.5 for antigen expression, respectively. A summary of their main features is 
shown in Table 3.3. Also listed are the transfer plasmids that would need to be generated 
from them in order to create the rMVA listed in Table 3.2. An Entry clone was also needed 
for insertion of OVA via Gateway® cloning.
Plasmids pTBD3 and pTBD4 carry the GFP selection marker flanked by a direct repeat 
sequence. Thus, upon transfer to the MVA genome, the marker is excised via a 
recombination event. All of the transfer plasmids listed in Table 3.3 were required to 
contain transiently expressed GFP so that single recombinant viruses could be used to 
generate multiple recombinant viruses, i.e. become markerless for monitoring of insertion 
of a second recombinant cassette.
72
Table 3.3 Novel plasmids for the leader sequences study. Each of the transfer 
plasmids was a Gateway® Destination vector and could receive antigen via 
recombination with an Entry clone (pENTR). In all of the vectors GFP was flanked by 
a direct repeat sequence, for transient expression upon transfer to the MVA genome, 
as described in Section 1.3.
Plasmid
Insertion N- c-
Promoter
terminal
Source
site terminal
Destination vectors (contain a Gateway'* cloning site for antigen insertion)
pTBD3/4 Del III mH5/P7.5 TPA V5 Laboratory stock
pTBD5/6 Del III mH5/P7.5 *TPA* V5 This study
pTBD7/8 Del II mH5/P7.5 *TPA* V5 This study
pTBD9/10 Del III mH5/P7.5 none V5 This study
pTBD ll/12 Del II mH5/P7.5 V5 VSVg This study
PTBD13/14 Del II mH5/P7.5 V5 None This study
Entry vector 
pENTR-OVA n/a n/a n/a n/a This Study
*Unique restriction enzyme sites
Another objective set for the development of the novel transfer plasmids was that they 
remain suitable for the study of alternative antigens. For each of the recombinant 
cassettes required, a pair of plasmids was generated, one incorporating mH5 for transgene 
expression, the other P7.5, so as to retain each as an option for use in the current and 
future studies. The B cell epitope tag, V5, was included throughout for immunodetection of 
the expression product; anti-OVA IgG is available (various commercial sources), but future 
studies may involve antigens for which antigen-specific IgG is less readily obtainable. It was 
also considered important that the transfer plasmids be as amenable to further alteration 
as possible, for example by retaining unique restriction enzyme sites at useful positions. 
Accordingly, aims for transfer plasmid construction were as described below.
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3.2 Chapter aims
>  Plan and implement a series of sequential alterations through which to obtain the 
required plasmids, each derived from pTBD3 or pTBD4.
>  Introduce ovalbumin (OVA) to the Gateway® system by creating pENTR-OVA.
>  Finalise transfer plasmid construction by transfer of OVA via Gateway® cloning.
3.3 Results
3.3.1 An efficient cloning strategy for construction of the required transfer plasmids
To generate a panel of novel transfer plasmids derived from parent vectors pTBD3 and 
pTBD4, a series of manipulations (summarised in Figure 3.2) were identified through which 
to obtain the required constructs as efficiently as possible. In the first instance, pTBD3 and 
pTBD4 were examined for unique restriction sites allowing for alteration of each flank (L 
and R), the direct repeat sequence (DR), and N and C terminal fusions (Figure 3.2 A). 
Interrogation of unique restriction sites revealed all of the above to be excisable, with the 
exception of the N-terminal fusion (TPA), therefore, the first modification sought to address 
this limitation by introducing unique restriction enzyme sites.
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Figure 3.2 Cloning steps for construction of required transfer plasmids. 1. Unique 
restriction sites fo r removal o f TPA sequence were introduced by site mutagenesis. 2. 
Flanking sequences (L and R) and direct repeat (DR) fo r Del III (blue) were removed and 
replaced fo r sequences targeting Del II (green). 3. TPA was removed. 4. TPA and V5 were 
removed and replaced w ith  V5+linker and VSVg, respectively. 5. TPA and V5 were 
removed, and replaced w ith  V5+linkerand stop, respectively.
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Conversion of pTBD3/4 to pTBD5/6
Unique restriction enzyme sites were introduced via site mutagenesis to enable excision 
and replacement of the existing N-terminal fusion (TPA). The mutations required were 
selected by examining the existing sequence against sequences for absent sites. In pTBD3 
and pTBD4, the sequence prior to TPA was CCCGGT (A). The sequence after TPA was 
CCCATCAA (B). Of 39 possible unique recognition sites, 20 were immediately discounted on 
the grounds of being degenerate, i.e. more than one nucleotide possible at one or more 
positions (Table 3.4). For the remaining 19 sites, the number of base pair changes needed 
to convert the existing sequence to the restriction enzyme site was noted.
Introduction of only 1 base pair change permitted the sequence preceding the TPA leader 
to become the recognition site for restriction enzyme Agel; site mutagenesis primers were 
designed accordingly (Section 2.1.5, Table 2.3).
A minimum of 3 base pairs were required to introduce a unique site downstream of TPA. 
Of 7 possible options, EcoRV was selected on the grounds that the base pairs required to be 
changed were adjacent. It was also noted that concomitant with the change, one and not 
two coding changes would be introduced; proline (CCC) to aspartic acid (GAT). Whilst the 
intervening sequence located between TPA and the gene of interest is not considered 
biologically significant, it is within the open reading frame. Here, the change of one amino 
acid is presumed not to have an impact on presentation of the encoded antigen. Site 
mutagenesis primers were designed accordingly and the required mutations introduced 
(Section 2.1.5, Table 2.3).
The mutations required to provide Agel and EcoRV restriction sites were introduced
sequentially. Clones were investigated for introduction of the required mutation via
analytical restriction digest (Section 2.1.6) with the corresponding enzyme. Plasmid DNA
isolated from putative clones was subjected to sequencing across the manipulated area to
confirm that pTBD5 and pTBD6 had been successfully generated.
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Table 3.4 Restriction enzyme sites absent from pTBD3 and pTBD4. Sequences for absent 
sites were compared to the DNA sequence before (A) and after (B) the TPA leader. N 
denotes any base. The number of base pair changes required to introduce the site was 
recorded. The individual base pairs required to be mutated are shown in bold in square 
brackets. Some of the changes introduced one* or two**coding changes.
Absent
sites
Sequence
Conversion of (A) 
CCCGGT
Conversion of (B) 
CCCATCAA
Aarl CACCTGCNNNN/NNNN - -
Afel AGC/GCT 3 >3
Agel A/CCGGT 1 [CCCGGT] >3
Ajul NNNNNNNNNNNNGAANNNNNNNTTGG - -
Ajul' GAANNNNNNNTTGGNNNNNNNNNNN - -
Alol NNNNNNNNNNNNGAACNNNNNNTCC - -
AsiSI GCGAT/CGC >3 > 3
Avrll C/CTAGG 3 > 3
Blpl GC/TNAGC - -
Bmtl GCTAG/C >3 3 [CCCATCAA]**
Bpll NNNNNNNNNNNNNGAGNNNNNCTC - -
Bpll' GAGNNNNNCTCNNNNNNNNNNNNN - -
BsiWI C/GTACG >3 > 3
BstEII GGTNACC - -
Bsu36l CCTNAGG - -
CspCI NNNNNNNNNNNNNCAANNNNNGTGG - -
CspCI' CAANNNNNGTGGNNNNNNNNNNNN - -
Dralll CACNNNGTG - -
EcoRV GAT/ATC >3 3 [CCCATC]*
Fsel GGCCGG/CC >3 >3
Hpal GTT/AAC >3 >3
Nael GCC/GGC 2 3 [CCCATCAA]**
NgoMIV G/CCGGC 2 3 [CCCATCAA]**
Nhel G/CTAGC >3 3 [CCCATCAA]**
Nrul TCG/CGA >3 >3
Pad TTAAT/TAA >3 >3
Pmel GTTT/AAAC >3 >3
Pmll CACGTG 3 3 [CCCATCAA}**
PpuMI RGGWCCY - -
PshAl GACNNNNGTC - -
Psil TTA/TAA >3 3 [CCCATCAA]*
Rsrll CG/GWCCG - -
SanDI GG/GWCCC - -
SexAl A/CCWGGT - -
Sfil GGCCNNNN/NGGCC - -
SgrAI CR/CCGGYG - -
Stul AGG/CCT >3 >3
Swal ATTT/AAAT >3 >3
T th l l l l GACN/NNGTC - -
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Conversion of pTBD5/6 to pTBD7/8
A panel of transfer plasmids targeting an alternative site was constructed with a view to 
introducing inserts at two sites in the MVA genome. The MVA homologous sequences for 
Del III, L, DR and then R, were replaced sequentially via restriction digest and ligation. 
Fragments homologous to Del II were obtained by PCR using primers designed to 
incorporate restriction sites (Section 2.1.8, Table 2.4). During in silico preparation of 
plasmid maps, sequences for Del II L and Del II R were observed to contain Agel and Hindlll, 
respectively. In order to preserve the uniqueness of these sites within the system, for use 
in this or future studies, they were removed by overlap extension (OE) PCR (Section 2.1.9) 
prior to ligation.
For transfer plasmids targeting insertion site Del II, left and right homologous flanks were 
introduced in the reverse orientation to those targeting Del III (Figure 3.2, Step 2). This was 
to ensure that the recombinant cassette would be inserted into the MVA genome in the 
opposite orientation and thereby the same orientation as adjacent open reading frames; a 
factor potentially linked to the efficiency of transcription (Panicali and Paoletti, 1982). The 
design, i.e. length of the Del II homologous DNA fragments, matched that of an existing 
plasmid (pLAS-2), with proven history for insertion of recombinant cassettes at this site in 
the MVA genome (Earl et al., 2009).
As transfer plasmids pTBD5 and 6 were modified to become pTBD7 and 8, clones were 
assessed via analytical restriction digest at each stage. Following restriction digest, DNA 
fragments were separated by agarose gel electrophoresis (Section 2.1.7) to determine the 
number of fragments and their sizes. An example representing the final manipulation for 
construction of pTBD7 is shown in Figure 3.3. Sequence data complete for the modified 
regions confirmed that correct clones were progressed.
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Figure 3.3 Analytical digest of pTBD7 with Sbfl and Hindlll. Purified plasmid DNA 
was subject to  restriction enzyme digest fo llow ing insertion o f the final Del II 
homologous sequence: Del II L in place o f Del III R. The plasmid, prior to  
modification, was digested as a control (C) and yielded the expected fragments: 6.3 
kb and 522 bp (arrow head). Of 8 clones assessed, 5 appeared to  be correct yielding 
fragments o f 6.3 kb and 695 bp: # 2, 4, 5, 7 and 8. Plasmid #2 was selected fo r 
sequencing and was progressed to the next stage.
Conversion ofpTBD5/6 to pTBD9/10
Transfer plasmids containing antigen w ith  no N-terminal fusion were required fo r the 
purpose o f creating rMVA 'no-leader' control strains. Plasmids pTBD9 and 10 were created 
from  parent plasmids pTBD5 and 6, respectively, by removal o f the existing N-term inal 
Kozak-TPA sequence, via Agel/EcoRV digest, fo llowed by ligation o f annealed 
oligonucleotide containing the Kozak sequence only (Figure 3.2 Step 3). Forward and 
reverse oligonucleotides were designed fo r ligation directly after annealing, i.e. w ith  ends 
complementary to  the digested plasmid (Section 2.1.10, Table 2.5). Putative clones fo r 
pTBDIO were identified by analytical restriction digest; one was selected fo r sequencing 
across the modified region and confirmed to be correct. Conversely, putative clones o f 
pTBD9 failed to  be identified; the plasmids were variable in size and all were smaller than 
expected (Figure 3.4).
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Figure 3.4 Analytical digest of putative pTBD9 and 10 clones with Xhol and Notl.
Purified plasmid DNA was subject to  restriction enzyme digest. Parent plasmid was 
digested as a control (C) and in each case yielded the expected fragments: 6.9 kb and 
350 bp (pTBD5) or 6.9 kb and 528 bp (pTBD6). Following removal o f the TPA 
sequence, a reduction o f 100 bp in the smaller fragm ent was expected fo r each 
plasmid. Putative pTBDIO clone #1 was sent fo r sequencing and confirmed to  be 
correct.
Repeat attempts to  generate pTBD9 produced similar results to those shown in Figure 3.4; 
a ttempts to  resolve the issue by re-cutting pTBD5, and/or by varying the vector:insert ratio 
in the ligation reaction (Section 2.1.11), were unsuccessful. Throughout, cut pTBD5 was 
examined by gel electrophoresis to  ensure tha t the digest was complete and yielding tw o 
fragments of the expected size. Annealed oligonucleotides were not re-prepared on 
account o f successful ligation into cut pTBD6 to generate pTBDIO.
The characteristics o f plasmids pTBD5 and pTBD6 were re-assessed in silico and found to be
identical in every regard except fo r the vaccinia prom oter included fo r transgene
expression. Thus, successful conversion of pTBD6 to pTBDIO provided evidence fo r no
intrinsic flaw  in the design o f the cloning step, i.e. Agel/EcoRV vector digest followed by
ligation o f M T B l l l / l l l r  annealed oligonucleotides was proven to work efficiently. To
fu rthe r investigate the reduction in plasmid size observed fo r pTBD5, one clone (Figure 3.4,
#6) was selected fo r analysis via sequencing (Section 2.1.12). Results revealed tha t the
Kozak-only oligonucleotide had been inserted, but was inserted twice, in tw o orientations
(back-to-back) and tha t 1.7 kb o f the Gateway® cassette was missing: the N-terminal
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attachm ent site (o ffR l), the chloramphenicol resistance gene (CmR) and a portion o f the 
second Gateway® selection marker (ccdB). A schematic o f the Gateway® cassette and of 
the deleted region is shown in Figure 3.5.
pTBD9 Linear Map with scale (bp) 
SeqBuilder DNA Lasergene 11
Age! 
EcoRV 
Notl
EcolCRI Xhol Eagl PspOMI
I <05 I«00 [ 800 I 1000 I ’ 230 I 1400 I 1500 I 1800 [ToOO f a * 2*30 12903 2800 1 3000
R1 CmR ccdB R2 ►
mH5 V5
. Deleted
Figure 3.5. Schematic of a portion of plasmid pTBD9. The TPA sequence in pTBD5 
was excised by Agel/EcoRv digest, which would be reinstated upon ligation o f a 17 bp 
oligonucleotide (A). Ligation o f fragment A led to  a section o f the Gateway® cassette 
(yellow features) being deleted (red bar). Increasingly larger inserts were generated: 
B (252 bp), C (1900 bp) and D (2850 bp), fo r insertion into the vector employing 
restriction enzyme sites: Xhol/Not, Xhol/PspOMI and Eco53KI*/PspOMI, respectively. 
The features o f pTBD9 shown are: selection marker (GFP); direct repeat sequence 
(DR); mH5 prom oter (pink triangle), Gateway cassette recombination sites (R l, R2); 
chloramphenicol resistance gene (CmR); lethal gene (ccdB); B cell epitope tag V5 
(blue triangle); right MVA homologous flank (R). *EcolCRI isoschizomer
It was speculated that other clones, fo r reasons unknown, may have undergone sim ilar or 
more extensive deletions. To circumvent the problem, repeat d igest/ligations were 
performed using increasingly longer inserts. In the firs t a ttem pt, the original 
oligonucleotide (Figure 3.5, A) was replaced w ith a longer, custom-synthesised fragm ent 
incorporating mFI5 and o ftR l (Figure 3.5, B) w ith  restriction sites Xhol and Notl replacing 
Agel and EcoRV, respectively. Following transform ation o f E. coli w ith  ligated DNA, putative 
clones were screened via analytical digest. The results appeared to  confirm successful 
removal o f TPA and ligation o f insert B. However, the plasmids had again undergone a
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deletion, this tim e incurring a greater reduction in size: approximately 3 kb (Figure 3.6). An 
a ttem pt to  interrogate the nature o f the deletion by sequencing (clone #2) was 
unsuccessful, presumably on account o f primer binding sites no longer being present in the 
template.
Figure 3.6 Analytical digest of putative pTBD9 clones with Xhol and Notl. Purified 
plasmid DNA was subject to  restriction enzyme digest. Parent plasmid (pTBD5) was 
digested as a control (C) and yielded the expected fragments: 6.9 kb and 350 bp. 
Removal o f TPA appeared successful fo r clones 2 - 4 and 7 -  12; a reduction o f 100 bp 
in the smaller fragm ent was observed. However, the plasmid backbone, which was 
expected to  be the size same as C (6.9 kb), was much reduced.
Two larger inserts were subsequently created. As described in Section 2.1.13 (Figure 2.2), 
inserts C and D were generated by overlap extension PCR and then insert and parent vector 
(pTBD5) subjected to  the same double or sequential restriction digest. The unique 
restriction sites employed fo r inserts C and D were Xhol/PspOMI and Eco53kl/PspOMI, 
respectively. Both inserts were made w ith  existing primers and so were longer than 
required; both incurred a reduction in size upon restriction enzyme digestion. Ligation of 
cut vector w ith  fragments C and D again resulted in a deletion. The apparent reduction in 
plasmid size was approximately 1 kb, which was less than had been observed w ith insert B.
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Upon sequencing, data were obtained and alignment revealed tha t a portion o f the 
Gateway® cassette had again been lost.
Until this point, propagation o f the Gateway® destination vectors had been in medium 
supplemented w ith  carbenicillin, as the addition of chloramphenicol had been observed to 
impede growth. In order to  preserve selection pressure on the Gateway® cassette, E. coli 
(TOPIO) were transformed w ith  ligation reaction containing inserts A, B C or D and plated 
on LB supplemented w ith  both antibiotics. A fter 18 hours incubation, no colonies were 
observed fo r A, B and C and only three colonies fo r D. Each was picked and propagated in 
LB medium containing carbenicillin and chloramphenicol. Plasmid DNA was subsequently 
extracted and subjected to  tw o analytical restriction digest reactions: BamHI fo r excision o f 
CmR to  ensure it was present and Xhol/Eagl fo r interrogation o f the N-term inal a lteration 
(Figure 3.7). Two putative clones were identified and, on sequencing across the modified 
region, one was correct and suitable fo r fu rthe r use.
BamHI
Figure 3.7 Analytical digest of putative pTBD9 clones. Parent plasmid (pTBD5) was 
included as a control (C). Following restriction enzyme digest w ith  BamHI, fragments 
o f the expected size (6.5 kb (C)/6.4 kb and 702 bp) were observed fo r all digests w ith  
the possible exception o f #3, the backbone o f which was potentia lly reduced. 
Interrogation o f the N-terminal m odification, fo r successful removal o f the TPA 
leader showed the expected result fo r the parent plasmid (6.9 kb and 350 bp) and fo r 
clones 1 and 2 (6.9 kb and 245 bp), but not #3.
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Conversion ofpTBD7/8 to p TB ll/12  and pTBD13/14
As summarised in Figure 3.2 (steps 4 and 5), plasmids pTBD7 and 8 were digested with 
PspOMI and Sbfl to remove the existing V5 C-terminal tag. Oligonucleotides providing the 
required C-terminal modification (MTB113/133r and MTB114/144r, Section 2.1.10, Table 
2.5) were annealed and ligated to create pTBD ll/12 and pTBD13/14 intermediates, 
respectively. Conversion to pTB D ll/12 and pTBD13/14 was completed by excision of the 
existing TPA leader via digestion with Agel and EcoRV, and ligation of annealed 
oligonucleotides MTB112/112r for introduction of an N-terminal V5 B-cell epitope tag. 
This identical N-terminal modification, which might have been performed on pTBD7/8 in 
the first instance, was required to be performed after C-terminal changes and not before on 
account of deliberate re-introduction of PspOMI -  a restriction site exploited for the C- 
terminal modification. Regardless of the vaccinia promoter present, none of the issues 
observed with pTBD5 were seen to manifest themselves when modifying the Kozak region: 
all four plasmids were successfully altered on the first attempt. As above, analytical digest 
was used to identify putative clones at each step, with sequencing across the modified 
regions used to confirm that the required changes had been made.
3.3.2 Completion of transfer plasmid construction with insertion of the gene of interest
The ovalbumin gene (OVA) was created by splice overlap extension PCR (Section 2.1.14) 
and amplified with attB primers. A clean band of the expected size was observed upon 
separation by gel electrophoresis. Purified PCR product was transferred to pDONRzeo by 
BP reaction to create pENTR-OVA (Section 2.1.4). All four clones investigated following 
transformation, carried pENTR-OVA. Sequencing data revealed three out of four clones to 
contain point mutations within the open reading frame and the fourth to be suitable for 
progression to LR reaction. Following LR recombination of OVA into each pTBD vector, 
putative clones were identified by analytical digest and verified by sequencing. In each 
case, sequence alignment for OVA and the entire open reading frame, inclusive of N and C
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terminal fusions was obtained. Plasmid maps, annotated to show the sequenced region, 
are presented in Appendix I.
3.4 Discussion
In this Chapter, novel transfer plasmids had to be constructed. Specifically, a panel of 
transfer plasmids with which to generate rMVA expressing OVA for an investigation into the 
impact of leader sequences on immunological potency. The approach selected was one of 
modifying existing transfer plasmids that were Gateway® Destination vectors. An 
additional objective, to be achieved in parallel, was to create a panel of transfer vectors 
that would be amenable to further alteration, including insertion of alternative antigens.
3.4.1 Alteration of existing vectors via conventional cloning techniques
Conventional cloning techniques such as PCR, restriction enzyme digest and enzyme- 
mediated ligation were applied to modify the existing transfer plasmids. In the first 
instance, a plan for making the desired alterations was devised in silico. The primary 
objective for the cloning strategy was to construct the required plasmids as efficiently as 
possible. Secondly, they were to remain suitable for further alteration, in case additional 
modification should be required within the scope of this study or in future work.
As described in Section 3.3.1, it was possible to devise and implement such a plan by 
making use of existing unique restriction enzyme sites, introducing new unique sites where 
necessary, and preserving them where they might otherwise be removed. This endeavour 
was assisted by the pre-existence of unique sites around the majority of the regions of 
interest, e.g. the homologous flanks and direct repeat sequences. This was presumably as a 
consequence of the provenance of the plasmids; pTBD3 and pTBD4 were derived from 
pLAS-1, which was originally constructed using restriction digest and ligation techniques 
(Wyatt et a!., 2008b).
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Generally, the application of conventional cloning techniques proved an efficient means of 
completing the desired alterations; the majority of restriction digest and ligation steps were 
completed successfully, within one attempt and the screening of 8 - 10 putative clones. 
However, this was not the case in one instance - the conversion of pTBD5 to pTBD9. For 
this alteration, many repeat attempts and ultimately a change in cloning strategy were 
necessary to generate the desired vector.
The reason for the difficulty experienced with pTBD9 was not immediately obvious. The 
planned modification involved removal of the N-terminal TPA leader via Agel/EcoRV 
restriction digest followed by ligation of annealed oligonucleotides MTB111/MTB111R. 
Evidence for the reliability of this step was provided by pTBDIO, which was generated from 
pTBD6 by exactly the same means and in parallel with pTBD5/9 which failed. Furthermore, 
four other plasmids (pTBDll-14) were successfully modified in the same region by the 
same restriction digest, albeit followed by ligation with different oligonucleotides (Figure
3.2, steps 4 and 5).
At each repeat attempt of the ligation, cut pTBD5 was examined by agarose gel 
electrophoresis to ensure that the digest was complete and yielding fragments of the 
expected size. No abnormalities were found and so no explanation for the truncated 
products observed after ligation was provided. Scrutiny was applied to the pTBD5 vector. 
All of the available sequence data relating to the plasmid (laboratory files and sequencing 
performed in this project) were re-aligned against the in silico map to ensure that it was as 
expected. Indeed, there was alignment with no mismatched base pairs, thus, confirming 
that the restriction enzyme sites employed were rightly expected to be unique.
The characteristics of plasmid pTBD5 were compared with those of the plasmids which had 
been successfully modified. Plasmid pTBD5 contains the vaccinia promoter mH5 for 
expression of the transgene upstream of the region incurring a deletion, whereas plasmid 
pTBD6 contains the P7.5 promoter. Like pTBD5, plasmids pTBDll and 13 contain the mH5
promoter for transgene expression; however, they both differ by having an adjacent direct 
repeat sequence homologous to MVA insertion site Del II. Thought was given to whether 
the combination of the Del III direct repeat combined with the mH5 sequence might be 
making the pTBD5 plasmid unique in an unfavourable way; there is evidence for some DNA 
sequences being prone to adverse rearrangements, through homology-dependent and 
independent mechanisms (Bzymek and Lovett, 2001; Conley et al., 1986). Further work, 
beyond the scope of this study, would have been required to determine if something of this 
nature was the root cause. To circumvent the difficulties encountered, inserts of increasing 
size were generated which served to move an increasing number of features from the 
vector to the insert (Figure 3.5, fragment D). This approach was successful, although the 
number of putative clones remained low.
3.4.2 Alteration of Gateway® Destination Vectors and insertion of OVA
A contributing factor to the difficulty observed in converting pTBD5 to pTBD9 may have 
been failure to maintain selection pressure for both of the antibiotic resistance markers 
present; ampicillin resistance on the plasmid backbone and chloramphenicol resistance in 
the Gateway® cassette. Ultimately, a correct clone was obtained using both antibiotics, i.e. 
carbenicillin (ampicillin analogue) and chloramphenicol. Of note, the use of carbenicillin 
alone did not impact upon the success of any of the other cloning steps. Further, use of 
carbenicillin alone was deemed preferable; inclusion of both antibiotics was observed to 
impede cell growth (reduced turbidity after overnight culture) and, therefore, the ability to 
progress the cloning steps expediently.
After insertion of the ovalbumin gene into a Gateway® Entry vector, the antigen was 
transferred to each of the Destination vectors. The plasmids were then sequenced to 
confirm integrity of the entire open reading frame (ORF). This was considered an essential 
prerequisite to the use of the plasmids in the generation of rMVA. Transfer of the 
recombinant cassette would be monitored by GFP expression, and also via PCR of the MVA
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genome across the insertion site, but expression of OVA was dependent upon insertion of 
the correct sequence in the correct reading frame. In addition, to the ORF sequence data, 
many other regions of each plasmid were sequenced in the course of confirming that 
modification has been made successfully. Long term stocks of transformed E. coli were 
deposited for each plasmid, both before and after OVA insertion. The extent of the 
sequenced regions for the OVA panel of plasmids is shown in Appendix I.
3.4.3 Suitability of the transfer plasmid panel for future work
The transfer plasmids generated are Gateway® Destination vectors and so can be used for 
the insertion of alternative antigens. The panel offers the ability to append a TPA or VSVg 
leader sequence, or no leader at all. For each type of plasmid, there is the opportunity to 
alter the level of antigen expression by employing either P7.5 or mH5 for transgene 
transcription. All of the plasmids contain a V5 tag in the expression cassette for 
immunodetection of antigens for which antibody is currently unavailable. If no leader 
sequence and no V5 tag were required, inclusion of an in-frame stop at the end of the 
antigen sequence would terminate translation so that no tag was expressed. In addition, 
unique restriction enzyme sites were retained around regions of interest so that each 
plasmid would lend itself favourably to further alteration. The position of these unique 
sites is illustrated in Appendix I.
3.4.4 Alternative approaches to the selected cloning strategy
Gateway® cloning is expedient by virtue of its selection mechanism (Section 2.1.4, Figure 
2.1). Conventional cloning, meanwhile, can be time consuming as was the case for the 
conversion of pTBD5 to pTBD9. An alternative approach might have been to employ 
custom synthesis of DNA fragments. The current study utilised custom oligonucleotides 
from 20 -  40 bp (primers) up to 500 bp (for the construction of OVA). During the course of 
the study, the maximum length of custom-made DNA fragments increased from 500 bp to 2
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kb (Integrated DNA Technologies). In future work, greater advantage could be made of the 
longer oligonucleotides now available.
Custom plasmid synthesis was also a possible alternative, but as with DNA fragments of 
increasing size, was proportionally more expensive. Ultimately, the majority of the cloning 
steps progressed efficiently, without delay and at relatively low cost. Thus, the value of 
being able to alter plasmid features via conventional methods was demonstrated. Another 
attribute of custom synthesis would have been the ability to generate sequences exactly as 
desired with no extraneous material or coding changes (applicable where alterations fall 
within the open reading frame). For the work undertaken in the current study this was not 
anticipated to have been a compromising factor. However, future work involving multiple 
changes to a plasmid should use custom synthesis as far as is economically possible.
3.5 Conclusions
Conventional cloning was successfully applied to generate the transfer plasmids required. 
Subsequently, they were used to generate novel rMVA viruses.
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Chapter 4 Generation of novel recombinant MVA viruses
4.1 Introduction
Two panels of rMVA viruses were needed to test the study hypotheses (described in 
Section 1.5); one for an investigation into the impact of vaccinia promoter selection, the 
other for an investigation into the influence of leader sequences on transgene 
immunogenicity. The rMVA virus-panels designed to test each hypothesis and the transfer 
plasmids required to make them are summarised in Table 4.1. As shown, one virus was 
already available.
Table 4.1 Summary of the rMVA viruses employed to test each hypothesis. Some 
of the transfer plasmids (*) were already available. The remainder were constructed 
within the current study (described in Chapter 3). For the leader sequences study, 
the set of transfer plasmids incorporating mH5 was selected for creating rMVA. This 
and the precise design of the inserts used to test each hypothesis are discussed 
further in Chapters 5 and 6, as indicated.
Recombinant MVA  
virus
Transfer Plasmid rMVA source
Vaccinia promoter study (Chapter 5)
MVA-mH5-Ag85A *pTBDl-Ag85A Laboratory stock
MVA-P7.5-Ag85A *pTBD2-Ag85A This study
MVA-mH5-Rv0111 *pTBDl-Rv0111 This study
MVA-P7.5-Rv0111 *pTBD2-Rv0111 This study
Leader sequences study (Chapter 6)
MVA-OVAtpa PTBD5-OVA This study
MVA-OVA pTBD9-OVA This study
MVA-OVAVsVg pTBDll-OVA This study
MVA-OVA pTBD 13-OVA This study
M VA-OVAjpa/  OVAvsvg pTBD5-OVA & pTBDll-OVA This study
MVA-OVA/OVA pTBD9-OVA & pTBD13-OVA This study
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4.1.1 Transfer plasmid methodology and plaque purification
Transfer plasmid methodology was selected as the approach for inserting recombinant 
cassettes into the MVA genome (see Section 3.1). All of the recombinant cassettes 
contained the GFP gene for use as a selection marker to identify and isolate rMVA plaques. 
Plaque purification is an established methodology for isolating recombinant viral progeny 
away from the parent virus (Earl et al., 2001b; Kremer et al., 2012). Following infection of 
BHK-21 cells with the parent MVA strain and transfection with the appropriate transfer 
plasmid, cells are incubated for 2-3 days and then the cells and viruses harvested. Virus 
particles are released from the infected cells by freeze-thaw cycles, and dissociated from 
the cellular material by vortexing and sonication. Sequential rounds of plaque purification 
are then performed on CEF (or BHK-21) monolayers. At each round, the cells are cultured 
under a semi-solid overlay to promote the development of discrete plaques. Recombinant 
viral progeny are made distinguishable from the parent virus via the use of a selection 
marker, e.g. GFP, so that they can be physically picked away from the cell monolayer. 
Where possible, this is done at a distance from areas observed to exhibit cytopathic effects 
(CPE), but no selection marker expression, so as to reduce the likelihood of co-isolating the 
parent strain, although, in the earlier rounds of plaque purification this is difficult to 
achieve.
4.1.2 Generation of markerless rMVA
Recombinant MVA can be generated for stable or transient expression of the selection 
marker (see Section 1.3.1). Transient expression is achieved by inclusion of an identical 
DNA sequence either side of the selection marker in the recombinant cassette, the 
presence of which leads to an internal recombination event through which the marker is 
'self-excised' (Wyatt et al., 2008b). To generate a stock of markerless rMVA, plaque 
purification is carried out in the same way as it is for stable marker expression, i.e. until no 
parent virus remains, at which point the viral population comprises both marker-positive
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and marker-negative lineages. Further passages are then performed until only the 
markerless population remains.
In the current study, stable GFP expression was selected for the viruses needed to 
investigate vaccinia promoter selection. For the leader sequences study, transient GFP 
expression was selected to facilitate the creation of double-recombinant viruses.
4.1.3 Characterisation of novel rMVA and preparation of viral vaccine stocks
Comprehensive methods for preparing and characterising rMVA are available (Earl et al., 
2001a; Earl and Moss, 2001; Earl et al., 2001b; Kremer et al., 2012) and relevant aspects are 
summarised here.
Stocks of rMVA must be characterised to ensure purity of the viral population and stability 
of the intended insert. This is routinely achieved using analytical PCR; MVA genomic DNA 
(gDNA) is extracted and amplified across the insertion site, using primers binding to the 
flanking regions. A single amplicon of the expected size for the recombinant cassette 
serves to confirm a homogenous population of rMVA. Smaller products, dependent upon 
their exact size, are indicative of truncated inserts and/or the presence of native MVA.
Faithful expression of the transgene can be confirmed by immunostaining of the cell 
monolayer with transgene-specific antibodies. An alternative means of confirming 
transgene expression is to subject infected cell lysate to Western blotting (separation of 
protein by SDS PAGE followed by transfer to protein-blotting membrane for 
immunodetection).
Prior to immunisation studies, amplified stocks of rMVA must be separated from the host 
cell lysate because an unpurified preparation will contain recombinant antigen generated in 
the course of viral replication. Combination-administration of virally vectored antigen with 
recombinant antigen enhances antigen-specific immune responses (Hutchings et al., 2007). 
This is a valid strategy for enhancing the immunological potency of rMVA-based vaccines,
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but to make an interpretable assessment of rMVA immunogenicity alone, extraneous 
recombinant antigen must be removed by density centrifugation. There are established 
protocols for purifying vaccinia stocks by pelleting through a layer of sucrose solution.
Before a purified stock of rMVA can be evaluated at a specified concentration, the stock 
must be titrated to enumerate the number of plaque forming units per millilitre (PFU/ml): 
serial dilutions of the stock are plated on permissive cells, under a solid overlay in multi­
well plates. After 2-3 days incubation, plaques are counted and PFU/ml calculated 
according to the dilution factor. An alternative method for quantifying MVA viral particles 
is to titrate for determination of tissue culture infectious dose 50 (TCID50). This is the 
concentration of virus required to kill 50% of cells. This method is more labour intensive as 
a greater number of counts must be performed to accurately determine the proportion of 
cells infected over several dilutions. With either method, plaques must first be made visible 
for counting as MVA does not form lytic plaques. This may be achieved by virtue of the 
selection marker, or can otherwise be accomplished by immunostaining of the cell 
monolayer using anti-vaccinia, or anti-transgene antibodies.
It is only following satisfactory preparation and characterisation of rMVA viruses that their 
relative attributes can be fairly evaluated and compared. Accordingly, aims for this Chapter 
were as follows.
93
4.2 Chapter Aims
To assess the impact of vaccinia promoter strength on the immunogenicity and protective 
efficacy of rMVA vectoring M. tuberculosis antigens (described in Chapter 5):
>  Create and amplify stocks of the rMVA viruses listed in Table 4.1, each derived from 
wild-type MVA and stably expressing GFP.
>  Characterise stability and purity via PCR.
>  Confirm antigen expression via Western blot.
>  Generate purified stocks of known titre.
To assess the influence of leader sequences on transgene immunogenicity; including their 
combined effect in a multiple recombinant (described in Chapter6):
>  Create and amplify markerless stocks of the rMVA viruses listed in Table 4.1, each 
derived from wild-type MVA or from a single rMVA virus expressing OVA.
>  Characterise stability and purity via PCR for one (single rMVA) or both (double rMVA)
inserts.
>  Confirm antigen expression via Western blot.
>  Generate purified stocks of known titre.
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4.3 Results
Not all of the rMVA required for the study were amenable to plaque purification. The 
outcome for each virus is summarised in Table 4.2.
Table 4.2 Generation of rMVA viruses for the current study. For those that were
insufficiently stable, a purified viral stock could not be prepared.
Recombinant MVA  
virus
Transfer Plasmid Outcome
Vaccinia promoter study
MVA-mH5-Ag85A pTBDl-Ag85A Laboratory stock
MVA-P7.5-Ag85A pTBD2-Ag85A Purified
MVA-mH5-Rv0111 pTBDl-RvOlll Unstable
MVA-P7.5-Rv0111 pTBD2-Rv0111 Purified
Leader sequences study
MVA-OVATpA PTBD5-OVA Purified
MVA-OVA pTBD9-OVA Purified
MVA-OVAvsvg pTBDll-OVA Purified
MVA-OVA PTBD13-OVA Purified
MVA-OVAjpa/ OVAvsvg pTBD5-OVA & pTBD 11-OVA Unstable
MVA-OVA/OVA pTBD9-OVA & pTBD13-OVA Unstable
For those rMVA that did appear to be stable, scrutiny was applied to the integrity of the 
recombinant insert and the ability of the rMVA to express the transgene. Where viruses 
could not be purified this was further examined, as far as practicable, to understand the 
root cause and to determine next steps.
4.3.1 Generation of novel rMVA expressing either Ag85A or R v O lll
The novel rMVA viruses required for the vaccinia promoter study (Table 4.1) were created 
using transfer plasmids as described in Section 2.2. To characterise the viruses generated, 
virus samples were amplified and examined via PCR and Western blot, as described in 
Section 2.3.
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Recombinant MVA expressing antigen under the contro l o f  P7.5
Recombinant MVA viruses expressing Ag85A or R v O lll under the control o f the weaker, 
P7.5 prom oter were both readily purified: both MVA-P7.5-Ag85A and MVA-P7.5-Rv0111 
were isolated away from  w ild-type MVA after three rounds of plaque purification. 
Representative results fo r analytical PCR and Western b lot are shown in Figure 4.1.
A
B
MVA-P7.5-Rv0111
mH5-
Ag85A
P7.5-
Ag85A
Figure 4.1 In v itro  characterisation of novel recombinant MVA. A) W ild-type MVA 
(WT) and MVA-P7.5-Rv0111 virus samples were amplified on CEF cells and gDNA 
extracted fo r analytical PCR o f the insertion site. PCR products were subsequently 
separated by gel electrophoresis. Transfer plasmid DNA was used as template in the 
positive control (+) reaction and yielded a product o f the expected size. W ater was 
used in place o f DNA in the negative control (-) reaction and did not produce an 
amplicon. B) Infected CEF cell lysate was separated by SDS PAGE and then 
transferred via Western Blot to  nitrocellulose fo r immunodetection w ith  anti-V5.
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The amplicons generated after PCR of the insertion site provided evidence for the presence 
of either wild-type MVA (549 bp) or rMVA (MVA-P7.5-Rv0111; 3901 bp). Results for MVA- 
P7.5-Ag85A are not shown. The failure of the PCR to yield two products, indicative of a 
mixed population, was speculated not to occur, or to occur rarely, because of preferential, 
more efficient amplification of the smaller target. Each rMVA virus was considered to be 
pure when wild-type MVA was no longer detectable.
For both MVA-P7.5-Ag85A and MVA-P7.5-Rv0111, evidence for antigen expression was 
provided by Western blot; the presence of anti-V5 immunoreactive bands demonstrated 
that the C-terminal V5 tag had been expressed (Figure 4.1B). In the case of MVA-P7.5- 
R vO lll, the expected size of the product was 86.3 kDa. Within the cell lysate, a number of 
breakdown products were detected. The expected size of the V5-tagged expression 
product for MVA-P7.5-Ag85A was 44.5 kDa. A band of this size and a smaller product were 
seen. In both cases, the presence of anti-V5 immunoreactive bands confirmed that the 
recombinant antigen was being expressed as translation had occurred through to the C- 
terminus. No V5-immmunoreactive product was seen in CEF infected with wild-type MVA 
(Figure 4.1A). However, a non-specific band of approximately 70 kDa was observed if the 
ECL hyperfilm was exposed to the blot for longer time periods.
Having been successfully purified, MVA-P7.5-Ag85A and MVA-P7.5-Rv0111 were available 
for further amplification and titration (discussed below).
Recombinant MVA expressing antigen under the control of mH5
When rMVA viruses expressing Ag85A or R vO lll under the control of the stronger mH5 
promoter were generated, only the Ag85A construct was amenable to plaque purification: 
MVA-mH5-Ag85A was isolated from wild-type MVA after four passages (this information 
was obtained from laboratory records). Meanwhile, the MVA-mH5-Rv0111 virus remained 
unpurified after three attempts to perform the infection/transfection and subsequent 
plaque purification.
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The apparent instability of MVA-mH5-Rv0111 was investigated further by amplifying all of 
the available infection/transfection harvests and plaque picks on CEF monolayers. After 
two days incubation, cell layers were examined for CPE and GFP expression and then 
harvested for characterisation by PCR and Western blot. A sample of wild-type MVA (WT- 
MVA) and samples relating to MVA-P7.5-Rv0111 (which had been successfully purified), 
were included in the experiment for comparison.
For each sample, the presence of CPE and GFP was arbitrarily scored to reflect the relative 
levels visible within the cell layer. After processing of cell lysate for determination of 
antigen expression, Western blots were scored similarly with results ranging from no V5- 
immunoreactive bands visible (-) to a strong V5-positive product (+++). In some cases a 
faint band may have been visible, but was difficult to discern above background (-/+). After 
extraction of MVA gDNA, two PCR reactions were performed and their products visualised 
after separation by gel electrophoresis. Primers for the 'L/R' PCR reaction bound to the left 
and right flanks of the Del III insertion site. The reaction was observed to yield either a 
small product, interpreted to confirm the presence of wild-type MVA (WT), or a large 
product observed to correspond to the size of the intended recombinant insert (Rec). As 
described above, the L/R PCR reaction did not yield two products, as might be expected for 
a mixed population of wild-type and recombinant virus. This was speculated to be because 
of preferential, more efficient amplification of the smaller wild-type target whenever it was 
present. Therefore, in order to investigate the presence of rMVA by PCR, a reaction 
employing primers annealing within the recombinant cassette was implemented; the 
forward primer annealed within the TPA leader sequence (N-terminal antigen fusion) and 
the reverse primer annealed within the V5 tag (C-terminal antigen fusion) (for a full 
description of the oligonucleotides, see Section 2.3.2, Table 2.6). All of the results obtained 
for WT-MVA, MVA-P7.5-Rv0111 and MVA-mH5-Rv0111 are summarised in Table 4.3.
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Table 4.3 Characterisation of viral samples arising in failed attempts to generate 
MVA-mH5-Rv0111. After two days amplification on CEF cells, the relative levels of 
CPE and GFP expression were recorded. Cell lysates were harvested and processed 
for interrogation by PCR and Western blot. Samples relating to wild-type (WT) MVA 
(the parent strain) and MVA-P7.5-Rv0111 (P7.5) were analysed in parallel.
Sample Promoter Description CPE GFP V5 WB PCR
L/R
PCR
TPA/V5
1 N/A WT-MVA +++ - - WT -
2 P7.5 l/T +++ - + WT +
3 P I +++ + + WT +
4 P2 + ++ ++ WT +
5 P3 + +++ ++ Rec -
6 A l ++ ++++ +++ Rec ++
7 A2 +++ ++++ +++ Rec ++
8 A3 +++ ++++ +++ Rec +
9 mH5 l/T +++ - + WT +'
10 (attempt 1) P I +++ + - WT -
11 mH5 l/T +++ - + WT +
12 (attempt 2) P I ++ + - WT -
13 P2 +++ ++ - WT -
14 P3 ++ +++ - WT -
15 mH5 l/T +++ - + WT +
16 (attempt 3) PI +++ + -/+ WT -/+
17 P2 ++ - - WT -/+
18 P3 ++ - - WT -
Abbreviations: CPE, cytopathic effects; GFP, green fluorescent protein, V5 WB, anti-V5 
Western blot; PCR, polymerase chain reaction; L/R, forward and reverse primers 
binding within the Left (L) and Right (R) flank; TPA/V5, forward and reverse primers 
binding within the TPA leader and V5 tag; l/T, infection/transfection sample, PI, 
'plaque pick' sample & round of purification; A l, 'amplification' sample & round of 
amplification; WT, wild-type; Rec, recombinant.
The results observed for WT-MVA and MVA-P7.5-Rv0111 were as predicted. WT-MVA  
induced CPE, gave no GFP expression, was detectable as wild-type (WT) when the insertion 
site was amplified (L/R PCR) and gave a negative result when an attempt to amplify a
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section o f the recombinant insert was made (TPA/V5 PCR). MVA-P7.5-Rv0111 induced CPE 
to  a level consistent w ith  the amount o f MVA expected to  be present; a decreasing amount 
as the recombinant was isolated away from  the parent strain and then an increasing 
amount as the purified recombinant was amplified. The level o f GFP expression increased 
as the recombinant was isolated and amplified, as did V5 expression. Native MVA was 
detectable until the strain was purified, which took three rounds o f plaque purification. 
There was evidence fo r the recombinant insert (TPA-V5) being present at all times except 
fo r the sample derived from  the th ird  plaque pick (P3). This is presumed to  be an 
anomalous result; an alternative explanation m ight be lack o f gDNA template, but sufficient 
virus, measurable by the number o f GFP expressing plaques, had been present.
Given tha t many o f the MVA-mH5-Rv0111 amplified samples expressed GFP, but gave little  
(-/+) or no (-) evidence fo r the TPA to V5 section of the recombinant cassette, another PCR 
reaction was performed using a forward primer binding near the start o f the GFP gene and 
a reverse prim er binding in the right flank (GFP/R, Section 2.3.1, Table 2.6). Results 
revealed a product fo r all samples except fo r the negative control, sample No. 1 and sample 
No. 18 (Figure 4.2).
Figure 4.2 Interrogation of the insertion site following failed attempts to 
generate MVA-mH5-Rv0111. Products o f the GFP/R PCR reaction were separated 
by gel electrophoresis (see table 4.3 fo r a description o f the samples; 1-18). 
Transfer plasmid DNA was used in the positive control (+) reaction and gave a 
product o f the expected size (3190 bp). W ater was used in place o f DNA template 
to  provide a negative control (-). Only one product was observed fo r each 
reaction. NB. Sample 14 appears tw ice because lane-to-lane leakage was 
observed when loading the gel. The positive control band was very bright, but on 
close inspection was not considered to be tw o bands merging.
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The absence of a product for the WT-MVA control (sample No. 1) was expected and 
confirmed that without a recombinant cassette, specifically the GFP gene, the forward 
primer would not be complementary to the viral gDNA template and no amplicon would be 
generated. A product of 3190 bp was expected for all of the samples related to MVA-P7.5- 
R vO lll and this was observed, matching the product in the positive control for which the 
template had been the MVA-P7.5-Rv0111 transfer plasmid.
For the MVA-mH5-Rv0111 samples where GFP expression had been observed, but there 
was no evidence for the recombinant cassette upon TPA/V5 PCR, it was speculated that a 
truncated product might arise. Instead, all of the MVA-mH5-Rv0111 samples gave yield to a 
PCR product the same size as that in the positive control. This was investigated further by 
having these PCR products sequenced (Section 2.1.12).
Sequence files returned for the GFP-R PCR products were analysed against sequence maps 
for the corresponding transfer plasmid (pTBDl-RvO lll or pTBD2-Rv0111). The results are 
summarised in Table 4.4 where samples are confirmed as having the expected sequence 
('correct7) or an unexpected sequence ('wrong'). It was not deemed necessary to send all 
of the samples relating to MVA-P7.5-Rv0111 for sequencing (-).
MVA-P7.5-Rv0111 was successfully purified with no anomalous PCR results and so 
sequence data relating to the amplicon derived from this construct were expected to be 
correct. Indeed, they aligned with no mismatched base pairs.
Sequence data for the MVA-mH5-Rv0111 3rd attempt (Samples 15-17) were also correct 
and this strain had shown a weak TPA-V5 product suggesting that perhaps the required 
rMVA virus was present, but at low titre, eventually becoming undetectable by the third 
round of plaque purification (P3, Sample No. 18).
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Table 4.4 Sequence analysis for GFP-R PCR products. Purified PCR products were 
sequenced and compared to the expected sequence, to determine which were correct.
Sample Promoter Description Sequence Data
1 N/A WT-MVA No product
2 P7.5 l/T Correct
3 P I Correct
4 P2 -
5 P3 -
6 A l -
7 A2 -
8 A3 Correct
9 mH5 (attempt 1) l/T Correct
10 P I Correct
11 mH5 (attempt 2) l/T Correct
12 P I Wrong
13 P2 Wrong
14 P3 Wrong
15 mH5 (attempt 3) l/T Correct
16 PI Correct
17 P2 Correct
18 P3 No product
Evidence for the intended recombinant virus having been present, but again at low titre, 
was also observed for the MVA-mH5-Rv0111 1st attempt (Samples 9-10), which gave the 
correct sequence despite a TPA-V5 PCR product and V5 expression not being detectable.
Sequence data for the MVA-mH5-Rv0111 2nd attempt showed that an aberrant 
recombinant had been generated. Transfer plasmid backbone had been incorporated 
which replaced the majority of the R vO lll antigen, but which gave, coincidentally, a GFP-R 
PCR product of the expected size. Evidently, this recombinant was stable in nature, 
explaining why GFP expression was observed to increase with successive plaque 
purification rounds, just as it did for MVA-P7.5-Rv0111.
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Overall, an assessment of the 3 attempts to generate MVA-mH5-Rv0111 concluded that it 
may have been made successfully, but was only ever present at very low levels and was 
unable to propagate such that it could be isolated away from wild-type MVA. 
Characteristics of the R v O lll transgene were reviewed to investigate why MVA-mH5- 
R vO lll could not be purified.
Truncation of R vO lll to enable generation of stable MVA-mH5-Rv0111 virus
R vO lll is predicted to contain 10 transmembrane domains (Figure 4.3) and so this was 
considered a likely cause for its instability (Krogh et al., 2001). It was speculated that a 
truncated version of the gene, eliminating the majority of the predicted transmembrane 
helices, may enable a stable MVA-mH5-Rv0111 virus to be generated. Accordingly, a 
truncated R vO lll sequence, Rv011136i -685 (RvO lllT), was amplified from M. tuberculosis 
strain H37Rv gDNA. The rationale for the length of R vO lllT  was to eliminate as many 
predicted transmembrane helices as possible while retaining immunogenic epitopes 
(murine and human T cell epitopes have been identified, as discussed in Section 1.4.2).
R vO lllT  was amplified from the M. tuberculosis genome using primers incorporating attB 
sequences, so that the gene could be rapidly transferred to the required MVA transfer 
plasmid via Gateway® cloning (Section 2.1.4). Upon completion, the transfer plasmid was 
sequenced to ensure that there were no mutations in the open reading frame. A transfer 
plasmid map annotated to show the sequenced regions is presented in Appendix II. Once 
the transfer plasmid was confirmed to be correct, the infection/transfection reaction in 
BHK-21 was repeated. In the subsequent attempt to isolate recombinant virus, MVA-mH5- 
R vO lllT  was successfully isolated and native MVA confirmed to be absent (by PCR) after 
three rounds of plaque purification. Evidence for recombinant antigen expression was also 
obtained via Western blot (not shown).
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TMHMM posterior probabilities for WEBSEQUENCE
1.2
RvOlllT
0 100 200 300 400 500 600
transmembrane ------  ins ide---------- outside --------
Source: T M H M M  Server v2.0, CBS, Denmark
Figure 4.3 R v O lll transmembrane helices The R v O lll amino acid sequence (685 
residues) was entered into a server fo r transmembrane helices prediction 
(TMHMM Server 2.0, Centre fo r Biological Sequence Analysis, Denmark). Arrows 
show the length o f R v O lll before (2-685) and after (361 -  685) truncation.
Amplification of MVA-Ag85A and M VA -R vO lll virus stocks
Each o f the recombinant viruses successfully isolated away from  w ild-type MVA were 
subsequently amplified by propagation through culture vessels o f increasing size, 
culm inating in a large-scale amplification involving m ultiple tissue culture flasks. Cell lysate 
was harvested and viral particles separated from  host cell and vaccinia-derived protein by 
sucrose-cushion density centrifugation (Section 2.2.7).
T itration on CEF monolayers was performed in order to  determ ine the titre  (PFU/ml) o f the 
purified stocks (Section 2.2.3). In parallel, purified material was amplified and harvested for 
a fu rthe r round o f PCR and Western blot characterisation, to  ensure tha t it was o f suitable 
quality fo r subsequent studies (Section 2.3). A summary is provided in Table 4.5.
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Table 4.5 Purified stocks for an investigation into vaccinia promoter selection
Summary for sucrose 
cushion purified material
MVA-P7.5-
Ag85A
MVA-mH5-
Ag85A
MVA-P7.5-
R v O lll
MVA-mH5-
R vO lllT
No. of passages taken to 
isolate recombinant MVA
3 3 3 3
Total no. of passages
(plaque purification & 
amplification)
7 8 7 8
Stability of insert 
confirmed by PCR
✓
Expression product 
detected via Western blot
4.3.2 Generation of markerless rMVA expressing ovalbumin (OVA)
The novel rMVA viruses required for the leader sequences study (Chapter 6) were created 
and characterised as described above, with the addition that after isolation of recombinant 
virus further passages were performed to remove transiently expressed ('self-excising') GFP 
(Section 2.2.6). In light of the findings for MVA-mH5-Rv0111, where an erroneous 
recombinant had been purified, a panel of analytical PCR reactions was devised for robust 
analysis of the recombinant insert at each round of plaque purification. Expression was 
investigated as before, using anti-V5 for immunodetection of the recombinant antigen 
following Western blot of infected CEF cell lysate.
An expanded PCR panel for virus characterisation
Using the transfer plasmids created in Chapter 3, four recombinant MVA viruses expressing 
OVA were constructed. Between them, recombinant cassettes were introduced at two 
sites in the MVA genome, Deletion site II (Del II) and Deletion site III (Del III). For all, the 
selection marker was transiently expressed by virtue of homologous sequences flanking the 
GFP gene. The PCR reactions that were implemented are summarised in Figure 4.4. 
Existing primer pairs (previously applied to the characterisation of M VA -R vO lll) were 
employed for Del III specific reactions - L/R and GFP/R. For the remainder, it was possible
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to  establish primer pairs using oligonucleotides originally synthesised fo r construction o f 
the transfer plasmids (sequences are listed in Section 2.3.2, Table 2.6).
Del III
OVAGFP DR rr»H5
(OVA)
MTB115 MTB116
(GFP/R)MTB92 MTB21
(L/R)MTB93 MTB21
Del II
mH5 DR GFPOVA
(OVA)
MTB115MTB116
(GFP/L) MTB92MTB105
(L/R) MTB109MTB105
Figure 4.4 Primer pairs for characterisation of recombinant MVA expressing OVA
For each insert site, analytical PCR was employed to detect w ild-type vs recombinant 
virus (L/R) and to  detect GFP in the context o f the insertion site (GFP/R and L/GFP). A 
PCR test targeting OVA, w ith in the recombinant cassette, was also implemented. As 
described in Chapter 3, the recombinant cassette fo r Del II is introduced in the 
opposite orientation. (Abbreviations: L, le ft flank; R, right flank; DR, direct repeat; 
GFP, green fluorescent protein; OVA, ovalbumin; mH5, modified vaccinia promoter 
H5).
The transient GFP system leads to the generation of antigen-free rMVA
Following the infection/transfection process, samples were plated fo r isolation o f GFP- 
positive plaques. A fter the firs t round o f plaque picking, harvested plaques were amplified 
fo r extraction o f MVA gDNA and characterisation by PCR. Results pertaining to  each o f the 
four viruses provided evidence fo r a mixed population comprising recombinant and w ild- 
type virus. In addition, a th ird  population was identified; it was observed tha t some o f the 
virus was recombinant, contained GFP, but had an insert smaller than was expected fo r the 
intended recombinant cassette. The size o f the insert was consistent w ith  a recombinant
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virus containing the GFP gene only (MVA-GFP). It was reasoned tha t this would occur on 
account o f an undesired homologous recombination event involving the d irect repeat 
sequence (Figure 4.5B). Further, it was speculated that a fourth  population could arise in 
which OVA, but not GFP would be transferred to  the MVA genome (Figure 4.5C).
A
MVA gDNA
DRGFP mH5 OVA
Transfer plasm id
B
MVA gDNA
mH5
Transfer plasm id
OVAGFP DR
C
MVA gDNA
GFP DR mH5 OVA
Transfer plasmid
Figure 4.5 Putative homologous recombination events between MVA gDNA and a 
transient-marker transfer plasmid. A) The desired recombination event involves the 
regions flanking the insertion site. B) The presence o f a direct repeat (DR) sequence, 
homologous to  the end o f the preceding flank (L) makes possible an alternative 
recombination event in which only the GFP gene is transferred. C) It may also be 
possible fo r the antigen, but not GFP, to  recombine into the MVA genome. For each 
scenario, features o f the transfer plasmid transferring to  MVA gDNA are shown w ith  
a bold outline.
For each o f the viral populations tha t could emanate from  the infection/transfection 
process (Figure 4.5) the length of the amplicon expected to  arise in each PCR reaction was 
determ ined (Table 4.6).
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Table 4.6 PCR reactions for virus characterisation and expected products (bp). Viral 
populations and the transfer plasmid(s) from which they could arise are shown. For 
some virus-PCR combinations, no product was expected (-). For viruses in which GFP 
was transiently expressed, a reduction in PCR product size upon GFP loss was 
anticipated (shown in parentheses).
Target and primer pairs
Virus
OVA
MTB115
MTB116
Del III
L/R GFP/R
MTB93 MTB92 
MTB21 MTB21
Del II
R/L GFP/L
MTB109 MTB92 
MTB105 MTB105
Wild-type MVA - 549 - 750 -
pTBD5 or pTBD9-OVA (Del III), pTB D ll or pTBD13-OVA (Del II) 
MVA-GFP - 1599 1071 1739 1622
pTBD5 orpTBD9-OVA (Del III), pTB D ll or pTBD13-OVA (Del II) 
MVA-Ag only 1205 2069 2274 -
PTBD5-OVA 
MVA-OVAtpa(Del III)
(without GFP)
1205 3119
(2069)
2591
(-)
750 -
pTBD9-OVA
MVA-OVA (Del III)
(without GFP)
1205 3014
(1964)
2486
(-)
750
(n/a)
pTBDll-OVA
MVA-OVAVsvg (Del II)
(without GFP)
1205 549 “ 3262
(2274)
3159
(-)
pTBD13-OVA
MVA-OVA (Del II)
(without GFP)
1205 549 - 3115
(2127)
3012
(-)
For all four MVA-OVA viruses, the decrease in amplicon size expected to occur following 
loss of transiently expressed GFP gene was also calculated. In some instances, no PCR 
product was expected, because the homologous sequence for one or both primers would 
be absent from the template, or because primers would bind, but at separate insertion
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sites (Del II and Del III are separated by 130 kb of genomic DNA, the PCR reaction is 
optimised for an amplicon of approximately 3 kb). It was noted that, should antigen-only 
recombinant MVA arise directly from the infection/transfection process (Figure 4.5C), it 
would be genetically identical to the intended construct following GFP loss and so 
indistinguishable upon PCR. In each PCR test, transfer plasmid DNA was included as a 
positive control and water used in place of DNA to provide a negative control.
Isolation of markerless rMVA expressing OVA
MVA-OVATPA(Del III) and MVA-OVA (Del III) were both purified after two rounds of plaque 
purification. A schematic summarising the viral samples harvested for each virus and their 
status with regards to recombinant cassette insertion and transgene expression, as 
determined by PCR and Western blotting, is shown in Figure 4.6. Viral sample 
nomenclature is described in Section 2.2.5.
MVA-OVAvsvg (Del H) and M V A -O V A  (Del II) were both purified after 3 and 4 rounds of 
plaque purification, respectively. A  schematic summarising the viral samples harvested for 
each virus and their status with regards to recombinant cassette insertion and transgene 
expression is shown in Figure 4.7.
Representative PCR and Western blot data for the four MVA-OVA viruses are shown below. 
For ease of reference throughout, the viruses are referred to by a single digit, 
corresponding to the transfer plasmid used to create them.
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Key to PCR and Western Blot Results
PI
PI
(1)
Round of plaque purification and 
plaque number. No fill: no PCR data.
PI
(1)
Green/Red fill:
OVA detected/not detected.
PI Light green:
(1) faint OVA product.
Green writing:
MVA-GFP population detected.
Green border- OVA expression 
detected via Western Blot
Green 'glow' -  no native MVA 
detected.
5: MVA-OVAtpa (Del III}
P4
( l . l . l . l )
P4
(1.1.1,2)
P4 
(1.1.1.3)
(1.1-5)
P3
(1-1-6)
Figure 4.6 Plaque purification of MVA-OVAtpa (Del III) and MVA-OVA (Del III). Plaque-pick 
samples, the ir propagation and the results o f in vitro  characterisation (PCR and Western 
blot) are summarised. Numbers adjacent to  the virus name indicate the pTBD plasmid used 
to  generate the virus e.g. pTBD5-OVA fo r MVA-OVAtpa (Del III). Not all picks were analysed 
by Western blot and only positive results fo r expression are shown. Abbreviations: l/T, 
infection/transfection reaction; P I (1), Plaque pick, round of plaque purification and plaque 
sample number(s) (the latter shown in parentheses).
110
Key to PCR and Western Blot Results
PI
(1)_
PI
{1}
Round of plaque purification and 
plaque number. No fill: no PCR data.
PI
(1)
Green/Red fill:
OVA detected/not detected.
PI Light green:
(1) faint OVA product.
Green writing:
MVA-GFP population detected.
Green border- OVA expression 
detected via Western Blot
Green 'glow' -  no native MVA 
detected.
11: MVA-OVAVSVg(Del II)
P3
(1-3.6)
(1 ,3 .1 .
P I P I P IP I P I P I
P2
(1.2)(1.1
P3
(1.1.1)
P4
(1.1.2.1)
P4 
(1.1.2.3)
P3
(1-1-3)
P3
(1-1-2)
13: MVA-OVA (Del II)
P3
(1.1.4)
P3
(1-1-5)
P3
(1.1.6)
Figure 4.7 Plaque purification of MVA-OVAVSvg (Del II) and MVA-OVA (Del II). Plaque-pick 
samples, the ir propagation and the results o f in vitro  characterisation (PCR and Western 
blot) are summarised. Numbers adjacent to  the virus name indicate the pTBD plasmid used 
to  generate the virus e.g. pTBD5-OVA fo r MVA-OVAtpa (Del III). Not all picks were analysed 
by Western blot and only positive results fo r expression are shown. Abbreviations: l/T, 
infection/transfection reaction; PI (1), Plaque pick, round o f plaque purification and plaque 
sample number(s) (the latter shown in parentheses).
I l l
Rationalised processing o f genomic DNA samples for PCR
For all four MVA-OVA viruses, all plaque picks were amplified and viral genomic DNA 
(gDNA) harvested, but to  accommodate the extended panel o f PCR reactions, stepwise 
analysis o f the samples was implemented. A fter the firs t round o f plaque purification (PI), 
one plaque sample fo r each virus was initia lly analysed using the primer pairs described in 
Figure 4.4 and Table 4.6. The PCR products arising from  reactions 'OVA', 'L/R' and 'GFP/R' 
are shown in Figure 4.8.
Figure 4.8 Analytical PCR of MVA-OVA samples collected in the first round of 
plaque purification. Virus from  plaque-pick samples was amplified fo r extraction of 
gDNA and characterisation o f the insert site and recombinant cassette via PCR. For 
each virus, DNA from  the corresponding transfer plasmid was used as template in the 
positive control reaction (+). W ater was included in place o f DNA in the negative 
control (-). For ease o f reference, the plaque samples were referred to  by a single 
digit, corresponding to  the transfer plasmid used to  create them (shown in Table 
4.4).
Across the PCR reactions, negative controls produced no amplicon. The products observed 
fo r each o f the positive controls fo llow ing the 'OVA' reaction were close to  the expected 
size and appeared to  have migrated fu rther on account o f having been run at high 
concentration. For both '5 ' (MVA-OVAtpa Del III) and '9 ' (MVA-OVA Del III), the OVA 
reaction confirmed tha t a viral population carrying the ovalbumin gene (1205 bp) was 
present; a fa in t band was visible fo r virus derived from  pTBD5. Plaque samples fo r '11'
(MVA-OVAvsvg Del II) and '13' (MVA-OVA Del II) also contained ovalbumin-positive gDNA.
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Following reaction 'L/R', the positive control (transfer plasmid) DNA yielded bands 
consistent with each plasmid having undergone a recombination event, excising the 
selection marker in the same manner anticipated for the recombinant viral gDNA. Thus, 
they provided an indication of the expected products, both with and without GFP. As 
expected, amplification across the insertion site revealed the presence of wild-type MVA 
(549 bp) and this product was amplified in preference to larger amplicons derived from the 
recombinant gDNA, known to be present in the sample because of the 'OVA' result. The 
'L/R' reaction targets insertion site Del III and so plaque samples for '11' and '13' yielded 
bands consistent with a native genotype and this would have been expected even had they 
been purified recombinant virus.
Amplification of the GFP gene in the context of insertion site Del III (reaction 'GFP/R') 
preferentially highlighted a recombinant population containing GFP only (MVA-GFP) for 
both '5' (MVA-OVAtpa Del III) and '9' (MVA-OVA Del III). There was also evidence for a non­
specific band (~850 bp) faintly visible in each of the positive controls.
It was noted that in both the 'L/R' and the 'GFP/R' reactions, the positive control template 
also revealed a non-specific product larger than the recombinant cassette (> 4kb), likely to 
be plasmid DNA carried over from the PCR reaction on account of the template being 
insufficiently dilute. This was remedied in future reactions by further dilution of the 
plasmid DNA.
Overall, for both of the Del III constructs, investigation by PCR revealed the presence of at 
least three virus populations - wild-type MVA, MVA-GFP and MVA carrying the ovalbumin 
gene. The latter was potentially present with and without the GFP gene. As summarised in 
Figure 4.7, the results for '11' (MVA-OVAVsvg Del II) and '13' (MVA-OVA Del II), some of 
which can be seen in Figure 4.8, revealed the presence of wild-type MVA and MVA-OVA  
(with and without GFP). There was no evidence for a MVA-GFP population.
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The P I plaque samples characterised by PCR were also investigated for evidence of antigen 
expression via Western blot of infected cell lysate. The results did not reveal an anti-V5 
reactive band for any of the viruses (not shown). Whilst the ovalbumin gene had been 
detected upon PCR, this was considered a plausible outcome on account of the potentially 
very low amount of recombinant virus present. Material from each of the 
infection/transfection steps did provide evidence for V5 immunoreactivity.
Plaque samples from the first round of plaque isolation were subsequently diluted and 
plated for further plaque isolation. In subsequent rounds of PCR analysis, more plaques 
were analysed, but the PCR reactions were performed in stages to down-select those 
worthy of further investigation, e.g. those containing the ovalbumin gene.
Purification of MVA-OVA (Del III)
At the second round of purification (P2), PCR was performed as above and revealed that 
MVA-OVA (Del III), derived from pTBD9, had been isolated efficiently. Of seven P2 plaque 
samples harvested and characterised, four were confirmed by PCR to contain virus carrying 
the ovalbumin gene (not shown): P2 (1.1), P2 (1.2), P2 (1.5) and P2 (1.6). Reaction 'L/R' and 
'GFP/R' were subsequently performed on these four samples. Results are shown in Figure 
4.9A.
In three of the pTBD9-derived P2 samples (1, 5 and 6), amplification across the insertion 
site ('L/R') was able to demonstrate a mixed population - wild-type MVA (549 bp), MVA- 
GFP (1599 bp) and GFP-free MVA-OVA (1964 bp). The ability of the reaction to detect 
larger inserts in addition to the native product, which might have otherwise been 
preferentially amplified, was attributed to an increase in the proportion of recombinant 
viral populations. The relative intensity of each band was not interpreted beyond that as 
the amplification efficiency for PCR products of different size is not anticipated to be equal. 
For P2 (1.2), the 'L/R' reaction provided evidence for GFP-free MVA-OVA and possibly a
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very faint band for the recombinant cassette with the GFP gene. Wild-type MVA was not
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Figure 4.9 Characterisation of MVA-OVA samples collected in the second round of 
plaque purification (P2). A) Viral samples relating to  '9 ' (MVA-OVA Del III) were 
amplified fo r extraction o f gDNA and characterisation o f the insert site and 
recombinant cassette via PCR. DNA from  the corresponding transfer plasmid was 
used as tem plate in the positive control reaction (+9). W ater was included in place of 
DNA in the negative control (-). B) All 4 o f the samples relating to  those investigated 
by PCR were observed to express recombinant antigen on Western blot (expected 
product size, 47.8 kDa). All contain a non-specific product o f approximately 70 kDa 
(arrow head) observed to be a feature o f MVA-infected CEF cell lysate (negative 
control not shown).
In support o f the 'L/R' PCR result, reaction 'GFP/R' confirmed the presence o f MVA-GFP in 
the P2 (1.1), P2 (1.5) and P2 (1.6) samples. For sample P2 (1.2), it provided evidence fo r the 
desired recombinant only, inclusive o f the GFP gene. Hence, between the 2 reactions it was
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apparent that both a GFP-positive and GFP-negative population of MVA-OVA (Del III) was 
present. This was expected as visual inspection of the cell layer prior to extraction of gDNA 
had shown GFP-positive plaques.
At the second round of plaque purification, those samples in which the ovalbumin gene was 
detectable by PCR also demonstrated expression by Western blot (Figure 4.9B). At this 
stage, plaque sample P2 (1.2) was selected for further passaging for removal of the GFP 
gene.
Purification of MVA-OVAtpa (Dei III)
As summarised in Figure 4.6, further plaque purification of sample P I (1) was carried out, 
but at the fourth round of purification (P4) the MVA-GFP (no OVA) population was shown 
to persist. Ultimately, further plaque samples from round 1 were investigated to select an 
alternative for progression, specifically, a plaque sample in which MVA-GFP was not 
apparent. As described above for MVA-OVA (Del III), the required recombinant was then 
isolated and, again, by the second round. Sample P2 (5.1) was selected for further passage 
for removal of the GFP gene.
Purification of MVA-OVAVSVg (Del II) and MVA-OVA (Del II)
As described above, one plaque sample for each virus was analysed at the first round of 
plaque isolation (Figure 4.8). Both of the recombinant MVA viruses went on to be purified 
from these samples after three and four rounds of plaque purification, respectively. The 
PCR reactions applied throughout were 'OVA' (as used for the Del III constructs), and 'R/L' 
and 'GFP/L' which were Del II specific. An example of the results obtained at the fourth 
round of plaque purification (P4) for MVA-OVA (Del II), derived from pTBD13, are shown in 
Figure 4.10. Sample P4 (1.1.2.2) was selected for further passage to remove the GFP gene, 
while for MVA-OVAVSvg (Del II), derived from pTBDll, sample P3 (1.3.2) was selected (as 
shown in Figure 4.7).
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Figure 4.10 Analytical PCR of MVA-OVA samples collected in the fourth round of 
plaque purification. Viral samples relating to  MVA-OVA (Del II), derived from  
pTBD13, were amplified fo r extraction o f gDNA and characterisation o f the insert site 
by PCR. A fter amplification across the Del II insertion site (R/L), tw o  o f the three 
pTBD13-derived MVA-OVA plaques were observed to  contain a m ixture o f the 
required recombinant, w ith  and w ithou t the GFP gene. No w ild-type MVA was 
detected. Amplification o f the insertion site using a primer binding w ith in  the GFP 
gene (GFP/L) revealed the required rMVA only and no MVA-GFP, i.e. rMVA w ith  no 
OVA antigen. All o f the samples were observed to contain the ovalbumin gene 
(results not shown).
Removal o f transiently expressed GFP and amplification o f virus stocks
After isolation o f each o f the MVA-OVA viruses away from  w ild-type MVA, the purified 
samples were subjected to  serial passage to  remove the GFP gene. As described in Section 
2.2.6, the removal o f GFP by serial passage was assisted by culturing CEF under a solid 
overlay so tha t discrete plaques expressing GFP could be physically removed p rior to  
harvesting the cell layer. Where a GFP-positive population o f MVA-OVA was found to  
persist, the approach o f picking discrete foci o f GFP-free cells was taken to  maximise the 
likelihood o f amplifying GFP-free recombinant virus only. The number o f passages required 
before each virus no longer exhibited GFP expression is summarised in Table 4.7. A t each 
subsequent round o f amplification cell monolayers were screened to ensure tha t no GFP 
positive cells were visible. Upon PCR analyses o f the final, purified rMVA stock, no GFP- 
positive PCR products were observed.
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Table 4.7 Purified stocks for an investigation into leader sequences. Purified, 
titrated stocks were subjected to PCR of the insertion site to reveal products of the 
expected size for pure, GFP-free recombinant MVA-OVA. Expression was also 
confirmed via Western blot.
Sucrose cushion (SC) 
purified stocks:
MVA-OVAtpa 
(Del III)
MVA-OVA 
(Del III)
MVA-OVAvsvg 
(Del II)
MVA-OVA 
(Del II)
No. of passages taken to 
isolate MVA-OVA (+GFP)
2 2 3 4
No. of additional
passages taken to isolate 
MVA-OVA (- GFP)
2 5 4 2
Total no. of passages
(purification, GFP 
removal and 
amplification)
9 11 11 11
Stability of insert 
confirmed by PCR
✓ ✓
Expression product 
detected via Western blot
Following isolation of GFP-free MVA-OVA, each of the viruses was amplified through culture 
vessels of increasing size and then purified by sucrose cushion purification (Section 2.2.7). 
The concentration of the purified stocks (PFU/ml) was determined by titration on CEF in 
multi-well plates (Section 2.2.3). All of the titrated stocks were subjected to a final, further 
round of characterisation by PCR and Western blot to ensure that the material was of 
suitable quality for subsequent studies (summarised in Table 4.7). The results for the 
Western blot are shown in Figure 4.11. Each virus produced a V5 reactive band of the 
expected size. MVA-OVAtpa (Del III) ('5') also produced a larger band, possibly a dimer of 
the expected product. Overall, the results confirmed that all four MVA-OVA viruses were 
suitable for further use, to create double recombinants (below) or for comparison of their 
relative immunogenicity (Chapter 6).
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Figure 4.11. Expression of Ovalbumin by four MVA-OVA viruses. Infected CEF cell 
lysate was separated by SDS PAGE and transferred to  nitrocellulose fo r 
imm unodetection w ith  anti-V5. Viruses are referred to by the number o f the pTBD 
plasmid used to  create them (see Table 4.6). From left to  right, the expected size fo r 
the product was 51.6, 47.8, 53.9 and 48.3 kDa. All contain a non-specific product o f 
approximately 70 kDa observed to  be a feature o f MVA-infected CEF cell lysate 
(arrow head). The presence o f OVA as a doublet is expected due to  the form ation o f 
d ifferent glycosylated forms.
4.3.3 Instability of double recombinant MVA-OVA
The MVA-OVA viruses above were generated to be markerless so that, as single 
recombinants, all would have the potential to  be transformed into a double recombinant 
virus via insertion o f a second, separate recombinant cassette. The infection/transfection 
reactions carried out are listed in Table 4.8. MVA-OVAtpa (Del III) and MVA-OVA (Del II) 
were selected to  serve as the parent strains (because they had been available first). The 
viruses were diluted fo r infection o f BHK-21 at the required MOI (see section 2.2.4). 
Subsequently, the infected cells were transfected w ith  transfer plasmid to  create double 
recombinant MVA viruses (summarised in rows 1 and 2 o f Table 4.8).
Table 4.8 Creation of double recombinant MVA-OVA viruses. The names given to  
the double recombinant viruses reflect the order in which the antigens w ith  leader 
sequences have been inserted.
l/T
Infecting MVA parent 
strain
Transfected transfer 
plasmid
Resultant double 
recombinant
1 MVA-OVATpA (Del III) pTBDll-OVAVSvg(Del II) MVA-OVATPA/OVAVsvg
2 MVA-OVAvsvg (Del II) pTBD5-OVATPA(Del III) MVA-OVAvsvg/OVAtpa
3 MVA-OVA (Del II) pTBD9-OVA (Del III) MVA-OVA/OVA
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A modified PCR panel for characterisation of double recombinant MVA-OVA
Due to pre-existence of the recombinant cassette in the first insertion site, new primer 
pairs were incorporated into the analytical PCR protocol to detect OVA in the context of the 
flanking regions (Table 4.9). As before, amplification across the insertion site was 
performed to detect the presence of multiple populations: wild-type MVA, MVA-GFP and 
MVA-OVA (with and without GFP). Throughout, both insertion sites were analysed to 
ensure stability of the first insert.
Table 4.9 PCR characterisation of double recombinant MVA and expected products 
(bp) Amplification from the OVA gene to each of the flanks means that one amplicon 
will include the GFP gene and reduce in size upon its loss (shown in parentheses).
Target and primer pairs
Del III
Viral inserts 0 V A /R L/OVA
MTB115 MTB93 
MTB21 MTB116
Del II
OVA/L R/OVA
MTB116 MTB105 
MTB109 MTB115
Existing insert (from pTBD5):
MVA-OVATpA (Del III) 1417 1859 - -
Second insert (from pTB D ll)
MVA-OVAvsvg (Del II)
(without GFP)
- 2590
(1602)
1852 
(no change)
Existing insert (from pTBD13):
MVA-OVA (Del II) 1627 1705
Second insert (from pTBD9))
MVA-OVA (Del III) 1417 
(without GFP) (no change)
2802
(1754)
- -
Isolation of MVA-OVATPA/OVAV5vg
Two attempts were made to generate a double recombinant virus expressing OVA fused to
two different leader sequences. Following the first infection/transfection reaction (Table
4.8, l/T No.l) propagation of the harvested l/T sample gave rise to only two plaques, on two
separate occasions (Figure 4.12A). A promising isolate was identified at the second round
120
of plaque purification, (P2) 2.2, but was found to be devoid of the required virus in the 
subsequent round (P3). Throughout, the recombinant cassette in the first insertion site 
(Del III) was present and of the expected size and so appeared to be stable. The inability to 
isolate MVA-OVATPA/O VAVsvg on this occasion was considered likely to stem from the 
inadequate number of plaques arising from the l/T-step; the number of BHK-21 cells visibly 
expressing GFP prior to collection of the sample had been less than expected.
To obtain the required double recombinant MVA, two alternative strategies were 
attempted in parallel: the same infection/transfection was reattempted using increasing 
concentrations of the infecting virus. The infection/transfection was also repeated using 
the alternative single-recombinant MVA as the recipient strain (Table 4.8, l/T No. 2).
Of the two approaches, the latter appeared to yield more putative plaques, but by the 
second round of plaque purification the ovalbumin gene at the first insertion site (Del II) 
was no longer detectable via PCR. Indeed, there was no product at all for PCR reactions 
incorporating primers binding to the Del II region. This result was confirmed at the third 
round of purification (P3), where six out of six plaque samples were shown to be purely 
recombinant gDNA with regards to Deletion site III (Figure 4.12B).
Isolation of MVA-OVA/OVA
As outlined in Table 4.8 (l/T No. 3), MVA-OVA/OVA was created by introducing a second 
recombinant cassette into the MVA genome at Deletion site III. After four rounds of plaque 
purification, no more virus of native genotype remained for the second, Del III insertion site 
(P4 (5.1.1.1), Figure 4,12C), but by this round of plaque purification the insert at Deletion 
site II had been lost. Again, no PCR products were observed for reactions incorporating 
primers binding to the Del II region. This was confirmed in further passages which would 
have otherwise served to amplify the virus.
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A) l/T  N o .l
S /ll: MVA-OVA^/OVA^ 
(Del Ill/Del II)
P3
(2,1.6)
P3 P3
12,2.5) (2,2,6)
B) l/T  No.2
11/5: MVA-OV/Vsvg/OVA^ 
(Del ll/D el III)
P3
(4-2.1)
N o
p la q u e s
N o
p la q u e s
C) l/T  No. 3
13/9: MVA-OVA/OVA 
(Del ll/Del III)
Figure 4.12 Plaque purification and propagation to create MVA-OVA double recombinant 
viruses. Plaque-pick samples, the ir propagation and the results of PCR characterisation for 
the second insertion site are summarised. Numbers adjacent to  the virus name indicate the 
firs t and second pTBD plasmid used to  create the virus e.g. pTBD5-OVA and pTBDll-O VA 
fo r MVA-OVATpA/OVAVSvg (Del Ill/Del II)). Abbreviation and Key: as shown in Figure 4.6 and 
Figure 4.7. Red outline: no PCR product fo r firs t (Del II) insert.
122
In summary, while the single recombinant MVA viruses expressing OVA were successfully 
purified, neither of the double-recombinant viruses was successfully isolated within the 
time available. In both cases, the insert at Deletion site II was lost during the additional 
passages needed to insert the second recombinant cassette.
4.4 Discussion
As discussed in Section 3.1, transfer plasmid methodology is one of two approaches 
available to generate rMVA; the other alternative is to apply BAC technology. The transfer 
plasmid system was selected for the current study because of the advantages conferred by 
its ease of set-up and implementation. The main disadvantage of the transfer plasmid 
system is the need to plaque-purify recombinant viral progeny.
4.4.1 Plaque purification of rMVA
After each infection/transfection (l/T) reaction the BHK-21 cell layer was harvested and 
subjected to sequential rounds of plaque isolation on CEF cells. It was possible to monitor 
the success of each l/T step by inspecting the BHK-21 cell layer for cells expressing GFP. 
The detection of adequate GFP expression proved an important prerequisite to undertake 
successful plaque purification.
Plaque purification was very efficient for MVA-P7.5-Ag85A and MVA-P7.5-Rv0111, taking 
only three rounds to complete. In contrast, the process was more challenging for MVA- 
mH5-Rv0111; the insert was unstable at the higher expression level, thus providing a 
growth advantage to non-expressors. Analytical PCR reactions were fundamental to 
determining what had occurred in this instance and demonstrated the importance of 
applying PCR tests at every round of plaque purification to ensure that only appropriate 
isolates were progressed.
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Characterisation of rMVA by PCR
For each novel rMVA, amplification of gDNA at the site of antigen insertion was vital to 
ensure that the recombinant cassette was present, had not been truncated and to identify 
the point at which native MVA was no longer contaminating the recombinant viral stock. 
The use of primers that bound either side of the insertion site might have had the potential 
to simultaneously detect multiple populations, e.g. wild-type and recombinant viral DNA. 
This occurred in some instances, but more often the reaction was observed to demonstrate 
a bias towards smaller products. Rather than presenting a significant limitation, this 
feature worked in favour of the overall objective which was to ensure that no WT-MVA 
remained. However, it did mean that other reactions had to be implemented in order to 
more fully examine each recombinant cassette.
For samples pertaining to MVA-mH5-Rv0111, additional PCR reactions specific for the 
recombinant antigen were able to demonstrate that it was absent beyond the early 
purification rounds, despite continued presence of the GFP gene on one occasion. These 
analyses were essential to being able to conclude that the virus was insufficiently stable to 
be purified.
Improved stability was observed for the single rMVA viruses expressing OVA; following 
antigen insertion, viral replication was able to occur and the rMVA viruses were readily 
isolated. However, each of these viruses was generated to express GFP transiently and the 
ability for an unwanted rMVA population to arise was revealed to be an inherent 
complication for this system; the transient-marker recombinant cassette was able to 
mediate transfer of the GFP gene alone.
Additional PCR tests were able to clarify which viral populations were present within a
given sample but, in terms of expedient rMVA preparation, the application of an extended
panel of reactions was time consuming. The apparent propagation of plaque samples that
were either unsuitable according to PCR data, or not required (as shown in Figures 4.6, 4.7
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and 4.12), was a reflection of the need to continue propagation whilst waiting for PCR 
results to become available. For double recombinant MVA the number of required PCR 
tests was again increased, but was vital in demonstrating the instability of recombinant 
viruses at their first insertion site (discussed further below).
In summary, the difficulties presented by plaque purification were arguably off-set by the 
relative ease with which they could be interrogated by analytical PCR, but more time was 
required for transient marker expression and/or the creation of double recombinants. 
Ultimately, some rMVA were readily isolated and PCR was an expedient means of 
confirming purity and stability of the recombinant insert.
Characterisation of rMVA by Western Blot
In addition to characterisation by PCR, transgene expression was investigated using anti-V5 
antibodies. During plaque purification, detection of an expression product lent support to 
PCR findings in some instances. However, in the earlier rounds of plaque purification 
transgene expression might not have always been detectable on account of the low level of 
rMVA present. Thus, the main benefit of characterisation by Western blot was not to 
support the selection of appropriate plaque isolates, but to verify faithful transfer of the 
recombinant antigen for effective transcription and translation. This appeared to be 
particularly pertinent at certain stages of rMVA preparation. Accordingly, material arising 
from each l/T step was analysed for early assurance of successful antigen insertion and, 
later, expression from the amplified stocks was checked as a precursor to performing 
further rMVA studies.
The manner in which the expressed recombinant products manifested was varied. MVA
expressing R vO lll produced V5-positive proteins that were a range of sizes, including a
dominant band of approximately 30 kDa. The R v O lll gene encodes a membrane-bound
acyltransferase with 10 transmembrane domains; thus, it is hydrophobic and insoluble.
This was considered a likely cause for the range of anti-V5 immunoreactive products
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observed. In support of this conclusion it was calculated in silico that a C-terminal fragment 
of R vO lll, devoid of transmembrane domains, would give rise to a V5-positive protein of 
approximately 30 kDa.
Both Ag85A and OVA are soluble, and MVA expressing each of these proteins both 
produced two - three discrete V5-positive products upon Western blot. Eukaryotic 
expression of Ag85A has been reported to culminate in glycosylated and non-glycosylated 
forms, thus, the protein appears as two products when separated according to size (Huygen 
et a i,  1996). Ovalbumin is also reported to appear as a doublet because of the existence of 
mono and di-glycosylated products (Suzuki et al., 1997).
Immunodetection with anti-V5 antibodies was applied throughout despite the availability 
of transgene-specific antibodies in some instances, e.g. anti-OVA. This was in order to 
demonstrate the flexibility of the system for investigating alternative recombinant antigens, 
as had to happen with R vO lll which was truncated to promote stability under higher 
transcriptional regulation. It was noted that in the presence of degraded antigen, as seen 
for R vO lll, greater assurance of successful translation was provided by the inclusion of a C- 
terminal V5 tag, i.e. to confirm translation of the entire open reading frame. For those 
rMVA expressing an N-terminal V5 tag, e.g. MVA-OVA (Del II), it was reassuring to see V5- 
reactive products of the expected size.
With regards to the use of rMVA as viral vaccine vector, the appearance of the expression 
product after separation by SDS PAGE may be less relevant than the ability to detect it at 
all. This is because novel vaccines for use against TB (and other important diseases) are 
primarily being developed to induce cell-mediated immunity, i.e. T cell responses to 
processed antigen peptides and not B cell responses to conformational epitopes.
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4.4.2 rMVA viruses for an investigation into Vaccinia promoter selection
Of the four rMVA viruses required for this aspect of the study, only three were successfully 
purified. The fourth, MVA-mH5-Rv0111, was apparently unstable and could not be 
isolated. MVA expressing R vO lll under the control of the weaker, P7.5 promoter was 
readily purified and so instability of MVA-mH5-Rv0111 was attributed to heightened levels 
of R vO lll expression. An rMVA virus expressing a truncated R vO lll gene was generated 
(MVA-mH5-Rv0111T) and was readily isolated. As this version of the recombinant antigen 
excluded the majority of the protein's putative transmembrane domains, evidence for their 
being the cause of, or a contributing factor to, the instability was provided. A link between 
transmembrane regions and rMVA instability has been reported previously (Wyatt et a i, 
2009). The validity of undertaking a comparison of promoter effects for a full length 
antigen versus a truncated version is discussed in Chapter 5.
4.4.3 rMVA viruses for an investigation into the use of Leader sequences
Six rMVA expressing OVA needed to be created, two of which would contain recombinant 
cassettes at two insertion sites. To facilitate insertion of a second recombinant cassette, all 
of the viruses were created to express GFP transiently so that markerless rMVA could be 
obtained. The single-recombinant viruses were apparently stable and were successfully 
purified, while the double-recombinant viruses were not. As discussed above, the transient 
marker system led to less efficient rMVA purification, but this would not appear to have 
contributed to the instability observed for the double-recombinants. There was some 
evidence to suggest that this may have been associated with the maintenance of a 
recombinant cassette in Deletion site II.
Deletion site II confers inferior stability
The single recombinant MVA expressing OVA comprised two strains employing Deletion 
site III for insertion of the recombinant cassette and two strains utilising Deletion site II. All 
were readily purified within 2-4 rounds of plaque purification. Prior to the amplification of
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the viruses, further passages were performed to remove the transiently expressed, 'self- 
excising' GFP gene. By the time that viral purification was undertaken, all of the rMVA had 
undergone between 9 - 1 1  passages. Purified viral stocks were plated to determine their 
titre and at the same time, all were satisfactorily examined by PCR to confirm purity and 
stability of the recombinant inserts. Subsequently, some of the viruses were used to create 
double recombinant MVA-OVA, none of which were successfully isolated.
MVA-OVATpA (Del III) was used for insertion of a second recombinant cassette in Deletion 
site II. By the time of abandoning the attempt, the parent virus had been passaged 14 
times in total and the recombinant cassette in Deletion site III was still present.
MVA-OVAvsvg (Del II) and MVA-OVA (Del II) were both used for insertion of a second 
recombinant cassette in Deletion site III. By the time of their 14th and 16th total passage, 
respectively, the insert in Del II had been lost. The PCR tests employing primers binding to 
the Del II region gave no product at all.
The six major genomic deletion sites of MVA have been used routinely as regions for 
insertion of exogenous DNA. There is some evidence in the literature to suggest that 
Deletion site II may confer inferior stability for HIV antigens (Wyatt et al., 2009) and in this 
example the use of intergenic regions was favoured, i.e. insertion between essential regions 
so that spontaneous deletions would be lethal. Many rMVA studies have employed OVA as 
a model antigen and this gene was not anticipated to induce spontaneous loss in the Del II 
region. There was insufficient time within the course of the current study to confirm 
conclusively if one or both insertion sites would incur stability issues over a protracted 
number of passages. There was also insufficient time to rectify this issue. The impact on 
the overall objectives and the value in assessing those rMVA-OVA that were successfully 
purified is discussed in Chapter 6, as are alternative approaches to successfully generating 
the double-recombinant MVA.
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4.5 Conclusions
Transfer plasmid methodology was an efficient means of generating novel rMVA, including 
markerless rMVA, provided it was supported by a suitable and sufficient number of PCR 
tests to characterise viral progeny.
The model antigen ovalbumin was inserted in two sites of the MVA genome and may have 
had a greater tendency to induce spontaneous deletions when inserted into Deletion site II, 
as opposed to Deletion site III. Further work would be needed to determine whether this 
was the case.
Characterisation by PCR identified those rMVA that were sufficiently stable and pure to be 
used in further studies, while Western blot was applied to confirm each was able to express 
the recombinant antigen. The viruses available for future work are listed in Table 4.10.
Table 4.10 rMVA available for further study. All of the rMVA listed are single 
recombinant viruses expressing a product from either Del II or Del III.
Recombinant MVA virus
Expression product 
Del II
Expression product 
Del III
Vaccinia Promoter Study
MVA-P7.5-Ag85A - TPA-Ag85A-V5
MVA-mH5-Ag85A - TPA-Ag85A-V5
MVA-P7.5-Rv0111 - TPA-Rv0111-V5
MVA-mH5-Rv0111T - TPA-Rv0111T-V5
Leader Sequences Study
MVA-OVATpA - TPA-OVA-V5
MVA-OVA - OVA-V5
MVA-OVAvsvg V5-OVA-VSVg -
MVA-OVA V5-OVA -
The rMVA listed in Table 4.10 were subsequently used to test the hypotheses of the study 
(described in Section 1.5). Thus, the impact of vaccinia promoter selection on the 
immunogenicity and protective efficacy of TB vaccine antigens vectored by MVA was 
investigated and is described in Chapter 5, while the potential for leader sequences to
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diversify the quality of the immune response evoked to antigens vectored by rMVA was 
studied and is described in Chapter 6.
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Chapter 5 Does vaccinia promoter selection have the potential to alter 
the efficacy of rMVA TB vaccines?
5.1 Introduction
Vaccine antigen expression in rMVA based vaccines is achieved via insertion of the 
transgene downstream of a vaccinia promoter. The vaccinia promoter sequence contains 
binding sites for transcription initiation factors and determines both the strength and 
timing of transcriptional activity. To achieve high levels of transgene expression, promoters 
combining early and late (E/L) regulatory elements are routinely used. Optimised, synthetic 
promoters combining early and late elements are available (PsynE/L), but as discussed in 
Section 1.2.4, they may compromise virus stability.
One of the first vaccinia promoters to be employed for the expression of foreign genes was 
the naturally occurring early/late promoter P7.5. This promoter is still widely used, but 
alternatives offering greater levels of transgene expression are available for selection, 
provided they do not compromise stability. In an attempt to create a promoter of 
intermediate strength to PsynE/L and the weaker P7.5, the naturally occurring H5 promoter 
was modified (mH5) to provide optimised expression and stability (Wyatt et al., 1996). 
Recombinant Vaccinia virus studies have shown that the timing and magnitude of 
transgene expression also influences the nature of transgene-specific immune responses; 
early expression is critical for the induction of cell mediated immunity (discussed in Section 
1.2.4). In this regard, the attributes of mH5 are highly desirable as early expression in 
particular is increased relative to H5.
5.1.1 Promoter effects on antigen expression, immunogenicity and protective efficacy
There have been at least three reports describing head-to-head comparison of vaccinia 
promoters P7.5 and mH5, using rMVA expressing the same antigen. In a study involving the 
luciferase gene fused with a T-cell epitope sequence, promoters P7.5 and mH5 gave rise to
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similar levels of expression over 24 hours, but the mH5 construct was able to induce a 
higher frequency of CD8+ antigen-responding T cells (Orubu et al., 2012). In a pair of rMVA 
viruses expressing the model antigen ovalbumin, mH5 drove higher levels of expression 
than P7.5, but there was little change in the induction of CD8+ T cell responses to the 
immunodominant ovalbumin epitope. Meanwhile, responses to subdominant CD8+ 
epitopes were increased suggesting that mH5 may alter immunodominance hierarchy 
(Becker et al., 2014). Of more relevance to the TB field, a dual rMVA expressing an HIV 
antigen (HIVA) and Ag85A was described in which mH5 and PsynE/L were compared to 
P7.5. There was evidence for increased expression by mH5 as compared to P7.5, 
established in vitro for a single infecting dose only, and increased expression did appear to 
correlate with increased immunogenicity. However, the results were complicated by 
simultaneous delivery of two separate antigens and investigation of some of the responses 
in the context of boosting a previously administered recombinant BCG strain. Further, the 
impact of increased immunological potency on protective efficacy was not assessed 
(Hopkins et al., 2011). Overall, these studies did not define the relationship between 
transgene expression and the immunological potency and efficacy of the rMVA under test.
5.1.2 Optimisation of vaccinia promoter selection for TB antigen delivery
MVA85A is the only vaccinia-based TB vaccine candidate to have entered human trials and 
until recently, was the most advanced TB vaccine candidate under clinical development 
(see Section 1.4.3). Unfortunately, results for a Phase lib efficacy study in infants were 
unable to demonstrate improved protection relative to the placebo control (Tameris et al., 
2013). Research efforts for MVA85A have since focused on alternative delivery routes and 
immunisation regimens. Aerosol delivery has been investigated in rhesus macaques and 
was proven to induce equivalent antigen-specific responses to intradermal delivery, with 
the added benefit that anti-vector immune responses were reduced (White et al., 2013). 
Similar findings were subsequently reported for humans (Satti et al., 2014) and most
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recently, another Phase I clinical study of MVA85A was conducted to assess its ability to 
boost Adenovirus vectoring TB vaccine antigens (Sheehan et al., 2015).
MVA85A delivers a single M. tuberculosis antigen (Ag85A) fused to a TPA leader sequence 
and utilises vaccinia promoter P7.5 for recombinant antigen expression (McShane et al., 
2002). The P7.5 construct showed potent immunogenicity in early clinical trials and 
demonstrated efficacy in pre-clinical testing. Modification/improvement of the construct 
may have initially been deemed unnecessary, but given the lack of efficacy observed in 
humans, rational optimisation might now be warranted. The impact of replacing P7.5 for 
mH5 should be determined in a manner consistent with assessing whether the efficacy of 
MVA85A, and other MVA-based TB vaccines, can be improved via optimisation of antigen 
expression.
5.1.3 Design and generation of rMVA for the current study
Vaccine candidate R vO lll has induced promising levels of protective efficacy in pre-clinical 
small animal models (see Section 1.4.2), but has unfavourable characteristics from a 
formulation perspective; the amino acid sequence of the protein contains 10 putative 
transmembrane domains (Vipond et al., 2006a; Vipond et al., 2006b). MVA is a potential 
vector for R vO lll delivery, but if confronted with stability issues the extent to which 
increased expression should be pursued is unclear. Therefore, a vaccinia promoter 
optimisation study for TB antigens is needed to clarify the potential benefits. The vaccine 
antigens selected for the current study were Ag85A and R vO lll. The vaccinia promoters 
selected for comparison were the promoter included in the current MVA85A clinical 
candidate and a promoter optimised for expression and stability - P7.5 and mH5, 
respectively.
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5.1.4 Evaluation of protective efficacy for novel TB vaccines
Pre-clinical evaluation of TB vaccines occurs through a hierarchy of animal models where 
immunogenicity testing is routinely performed in mice and preliminary efficacy studies in 
mice and guinea pigs (McShane and Williams, 2014). As discussed in Section 1.4.2, TB 
vaccines need to induce Th-1 immunity and so a key readout for murine immunogenicity 
studies is antigen-induced IFNy release. To evaluate protective efficacy, immunised animals 
are challenged with an aerosolised dose of M. tuberculosis (Mtb) and bacterial load in the 
lung and spleen determined at a set time point post-infection. Vaccine efficacy is measured 
according to the reduction in Mtb colony forming units (CFU) retrieved from the organs, 
relative to untreated and treated controls. The standard positive control in such tests is the 
current BCG vaccine. Dependent upon the requirements of the experiment, the test 
vaccine may be evaluated alone or as a booster vaccine to BCG. For ethical (and 
economical) reasons it is appropriate to restrict the pre-clinical efficacy testing of novel TB 
vaccines to those demonstrating adequate immunogenicity in a relevant model. The aims 
for this Chapter, described below, were implemented accordingly.
5.2 Chapter Aims
The objective for this Chapter was to test the hypothesis that vaccinia promoter selection 
can influence the immunogenicity and protective efficacy of TB vaccine antigens vectored 
by MVA. Specific objectives for this chapter were to:
For each pair of MVA:
>  Investigate relative levels of antigen expression.
>  Characterise viral fitness and stability.
>  Measure immunological potency.
>  Evaluate protective efficacy.
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5.3 Results
In order to make a head-to-head comparison of vaccinia promoter effects rMVA identical in 
every regard except for the vaccinia promoter driving transgene expression were required. 
This was achieved with respect to the configuration of promoters in relation to the inserted 
antigen; the early and late transcriptional start sites for P7.5 and mH5 were all within a 100 
bp of the Kozak sequence in which the translational start resides (detailed information 
regarding the sequence of each recombinant cassette is presented in Appendix III.). 
However, not all of the rMVA were able to be purified with the full length antigen 
sequence. The four rMVA vaccines constructed for the study were MVA-P7.5-Ag85A, MVA- 
mH5-Ag85A, MVA-P7.5-Rv0111 and MVA-mH5-Rv0111T, with the latter carrying a 
truncated R vO lll gene (described in Chapter 4).
5.3.1 rMVA expressing R vO lll under the control of P7.5 and mH5
MVA-P7.5-Rv0111 and MVA-mH5-Rv0111T antigen expression levels
Sucrose-cushion purified and titrated stocks of each of the above viruses were used to 
infect CEF cells at a range of concentrations. After two days, the cells were harvested in 
denaturing buffer for determination of antigen expression by dot blot (Section 2.3.4). The 
results demonstrated a dose dependent increase in the amount of V5 present in the 
infected cell lysate for each virus (Figure 5.1).
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Figure 5.1 Expression of R v O lll by rMVA. CEF cell monlayers were infected w ith 
rMVA in trip licate wells. A fter tw o days, cell lysate was transferred to  nitrocellulose 
fo r detection o f R v O lll using anti-V5 and anti-mouse-HRP. Following incubation 
w ith  ECL Plus chemiluminescent reagent, nitrocellulose was exposed to  Hyperfilm 
ECL and densitom etry performed to  measure spot volume using ImageQuant TL 
image analysis software (GE Healthcare). Results fo r spot volume minus background 
(mean +/- SEM) were plotted against the concentration o f infecting virus (PFU/well).
The relative expression levels o f the rMVA viruses were compared. There was clear 
separation o f the exponential region fo r each curve. The results provided evidence for 
MVA-mH5-Rv0111T being able to  achieve an equivalent level o f expression to MVA-P7.5- 
R v O lll after infection o f the cells w ith approximately 10 fold less virus. As stated above 
(Section 5.2), a comparison o f vaccinia promoter effects should ideally characterise rMVA 
viruses that are identical in every regard except fo r the prom oter under test. Therefore, 
the rate of viral replication was investigated to  determ ine w hether the increased 
expression observed fo r MVA-mH5-Rv0111T was due to  superior viral fitness, conferred by 
the expression o f a truncated R v O lll gene.
Relative fitness of MVA-P7.5-Rv0111 and MVA-mH5-Rv0111T
In the above experiment, an additional well o f CEF cells was infected w ith  each serial 
d ilu tion o f rMVA. When cells were harvested fo r analysis by dot blot, the additional well
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was harvested fo r titra tion  and determ ination o f rMVA concentration (PFU/ml). The results 
enabled dot b lot densitom etry data to  be re-plotted against PFU/well as measured at the 
end o f the incubation period (Figure 5.2).
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Figure 5.2 Amplification of rMVA expressing R vO lll. Data were as described fo r 
Figure 5.1. The densitometry results (mean ± SEM) were plotted against the 
concentration of infecting virus (solid line) and in addition, the viral titre  at the end of 
the experiment (dashed line).
A fter tw o days incubation, titra tion  o f the infected CEF cell lysate revealed tha t the 
number o f PFU per well had increased fo r both viruses across the range o f infecting 
concentrations. There was little  difference in the degree to  which each o f the viruses 
had been amplified. The average fold increase fo r MVA-mH5-Rv0111T and MVA-P7.5- 
R v O lll were similar (2.6 x 104 and 1.8 x 104, respectively).
The similar level o f amplification observed fo r MVA-mFI5-Rv0111T and MVA-P7.5-Rv0111
was inconsistent w ith  the observation that MVA-P7.5-Rv0111 plaques regularly appeared to
express more GFP (visualised during routine inspection o f the cell layer by inverted
fluorescent microscopy). By way o f a fu rthe r simple estimate o f viral fitness, titres  fo r
individual plaques were determined as reported fo r rMVA generated during the
development o f mFI5 (W yatt et at., 1996). Two representative plaques fo r each rMVA
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expressing R v O lll were isolated and diluted fo r determ ination o f PFU per plaque. The 
results confirmed that the growth rate fo r the tw o  rMVA was similar and tha t the rate o f 
replication fo r MVA-P7.5-Rv0111 m ight have been closer to  the parent virus (Figure 5.3).
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Figure 5.3 Plaque titre estimates for rMVA expressing R vO lll. CEF cells were 
infected w ith each o f the three viruses. Three days later, representative plaques 
were isolated and titra ted  fo r determ ination o f the ir concentration. Cell 
monolayers were immunostained w ith  anti-vaccinia to  make viral plaques visible 
fo r counting. Data are the mean fo r duplicate counts.
MVA-P7.5-Rv0111 and MVA-mH5-Rv0111T Th-1 immune responses
To investigate the impact o f transgene expression on antigen immunogenicity, mice were 
immunised w ith  each rMVA to determ ine antigen-specific Th-1 immune responses. A fter 
tw o doses o f MVA, splenocytes were harvested fo r restimulation ex vivo w ith  overlapping 
antigen-specific peptides representing R v O lllT  (as described in Sections 2.4.2 and 2.4.3). 
MVA-mH5-Rv0111T induced a measureable antigen-specific Th-1 response (Figure 5.4). 
Responses to  MVA-P7.5-Rv0111 were not significantly increased above background levels 
o f IFNy release.
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Figure 5.4 Immunogenicity of rMVA virus expressing R vO lll. Groups o f C57BI/6 
mice (n=5) were immunised intramuscularly w ith  rMVA at a dose o f 1 x 106 or 1 x 107 
PFU, tw ice, at tw o weeks apart. Two weeks after the final immunisation, splenocytes 
were harvested fo r restimulation w ith  overlapping peptides representing R vO lllT . 
The number o f cells induced to  release IFNy was measured by ELISpot assay 
(Mabtech). Results were plotted as the number of spot form ing units (SFU) per 
m illion cells (mean +/- SEM) after subtraction o f background, i.e. SFU/106 measured 
in the presence o f cell culture medium only.
No dose dependent effects were seen fo r the tw o  doses of MVA-P7.5-Rv0111 and MVA- 
mFI5-Rv0111T administered (1 x 106 and 1 x 107 PFU). Variability w ith in  the assay was 
greater than tha t seen on other occasions and a repeat assay would be required to 
determ ine w hether this observation was genuine. Poor antigen recall responses fo r MVA 
vectoring R v O lll under the control o f prom oter P7.5 had been seen previously; an rMVA 
construct prepared outside o f the current study was only measurably immunogenic when 
administered as part o f a heterologous prime-boost regimen (See Section 1.4.3, Table 1.5). 
The rationale fo r administering an MVA-only regimen in the present study was to  ensure 
tha t only MVA-induced and, thereby, promoter-mediated effects were investigated.
Given tha t MVA-P7.5-Rv0111 was so weakly immunogenic fo llow ing an MVA-only 
vaccination regimen, it was deemed inappropriate to  repeat the immunogenicity test, or 
progress this pair o f rMVA viruses to a protective efficacy study in which mice would be 
immunised and then infected w ith  M. tuberculosis.
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5.3.2 rMVA expressing Ag85A under the control of P7.5 and mH5
Recombinant MVA carrying the same Ag85A expression cassette were successfully isolated 
and purified. Subsequently, a more in-depth comparison o f the ir features was carried out. 
In the firs t instance, the expression and fitness experiment performed fo r rMVA expressing 
R v O lll was modified to  provide detailed time-course information. CEF were infected w ith 
rMVA expressing Ag85A to  enable the relationship between dose, fitness and expression to 
be defined.
Relative fitness o f MVA-mH5-Ag85A and MVA-P7.5-Ag85A
Purified stocks o f rMVA were diluted to  infect CEF cell monolayers at approximately 104 
PFU per well, equivalent to  an MOI of 0.1 PFU/cell. Sufficient m ulti-well plates were 
infected to  perm it harvesting o f cell lysate at set tim e points from  trip licate wells. One 
sample from  each tim e point, fo r both viruses, was titra ted  in parallel to  obtain 3 sets of 
viral growth data (Figure 5.5). The concentration of MVA (PFU/ml) was determined by 
counting GFP-expressing plaques (made possible because the selection marker had been 
inserted fo r stable expression).
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Figure 5.5 Growth curves for rMVA expressing Ag85A. CEF monolayers were 
infected w ith  MVA at an MOI o f 0.1 PFU/cell and then harvested at set tim e points in 
trip licate. The titre  o f each sample was determined by titra tion  on CEF cells and 
counting o f GFP-expressing plaques.
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Each pair of viral replication curves was very similar. Overall, the first set of titration data 
was lower. This was later attributed to a slight difference in the density of the CEF cells 
used for titration. The wider reaching implications for this observation are discussed in 
Section 5.4.1.
A statistical method for the comparison of viral growth curves was applied to investigate 
differences in the rate of viral replication for the two viruses (Wang and Bushman, 2006). 
In the first instance, the natural logarithm (In) of mean values for virus titre was calculated 
and plotted against time (Figure 5.6A). The exponential region of the curves was then 
selected, by eye, for analysis by linear regression. Data falling within the exponential region 
were replotted to permit the fitting of curves (Figure 5.6B). The slope of each curve was 
calculated and statistically compared (GraphPad Prism). The results confirmed that there 
were no statistically significant differences between the rates of replication for MVA-mH5- 
Ag85A and MVA-P7.5-Ag85A (summarised in Table 5.1).
Table 5.1 Analysis of viral replication by linear regression. Growth curves for rMVA 
expressing Ag85A (exponential region only) were analysed to find the line of best fit 
and to statistically compare the slopes (GraphPad Prism). Slope constants and 95% 
confidence intervals for the slope are shown. The slope was equivalent to the rate of 
change in virus titre per hour (ln(PFU/ml)/hr). Statistical comparisons were made 
between pairs of growth curves for which viral titres has been determined in parallel. 
None of the differences were statistically significant (P > 0.05).
MVA-
Ag85A
Slope
ln(PFU/ml)/hr
95% Confidence 
Interval
P value
Plot 1 (dotted line)
mH5 0.2568 0 .1537 -0 .3599 0.236
P7.5 0.3162 0 .1645 -0 .4678
Plot 2 (dashed line)
mH5 0.2218 -0 .0251 -0 .4687 0.185
P7.5 0.3142 0 .2854 -0 .3431
Plot 3 (solid line)
mH5 0.3285 0 .0917 -0 .5653 0.942
P7.5 0.3332 0.2207 -  0.4458
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Figure 5.6 Statistical comparison of viral growth curves for rMVA expressing Ag85A
A) The natural logarithm (In) o f virus titre  was calculated and plotted against tim e 
and then the exponential region o f the data was selected by eye (grey box). B) 
Individual replicates from  the exponential region were plotted fo r analysis by linear 
regression (GraphPad Prism). The line of best f i t  was added to each data set and 
statistical comparison carried out (Table 5.1).
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MVA-P7.5-Ag85A and MVA-mH5-Ag85A antigen expression levels
In parallel w ith  the comparison o f viral rates o f replication, samples were harvested for 
measurement o f Ag85A expression over time. Cell lysate samples were investigated for 
presence o f the V5 tag by dot blot, as described in Section 2.3.4.
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Figure 5.7 Expression of Ag85A by rMVA. CEF monolayers were infected w ith  MVA 
at an MOI o f 0.1 PFU/cell and then harvested at set tim e points. Cell lysate was 
transferred to  nitrocellulose to  create trip licate spots before im m unodetection w ith  
anti-V5 and anti-mouse-FIRP. Following incubation w ith  ECL Plus chemiluminescent 
reagent, nitrocellulose was exposed to Hyperfilm ECL and densitom etry performed to 
measure the mean optical density (OD) of each spot using Quantity One 4.6.9 ID 
analysis software (Bio-Rad). Results (mean +/- SEM) were plotted against the tim e of 
sample harvest.
From as early as four hours post-infection, MVA-mH5-Ag85A generated measurably more 
Ag85A than MVA-P7.5-Ag85A. Values fo r spot intensity (mean +/- SEM) were 0.171 + /- 
0.032 and 0.062 + /- 0.002, respectively. The difference between these values was 
statistically significant (T test, P = 0.03).
The expression o f Ag85A from both viruses appeared to  plateau at around 30 hours post­
infection. Viral concentration (PFU/ml) had been determ ined fo r a separate set o f samples 
tha t were infected and harvested in parallel (Figure 5.5 and Figure 5.6A). Growth curves
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had revealed tha t viral amplification had also reached, or was nearing, a plateau at 30 hours 
post-infection. To better understand the am ount of Ag85A produced in the context o f the 
amount o f virus present, the data were replotted against virus titre  (Figure 5.8). MVA-P7.5- 
Ag85A was able to  produce equivalent amounts o f recombinant antigen to  MVA-mH5- 
Ag85A when present at approximately a 10-fold greater concentration.
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Figure 5.8 Dose dependent expression of Ag85A by rMVA. Densitometry data are as 
described in Figure 5.7. The results were plotted against viral concentration 
(PFU/ml), equivalent to  to ta l PFU because the titra ted samples had a volume o f 1 ml.
MVA-P7.5-Ag85A and MVA-mH5-Ag85A Th-1 immune responses
The immunogenicity o f MVA-P7.5-Ag85A and MVA-mFI5-Ag85A were compared in mice. A 
vector-only control group was included in the study to  m onitor fo r MVA-mediated effects. 
Following immunisation, splenocytes were harvested fo r measurement o f antigen-specific 
Th-1 immune responses (Figure 5.9).
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Figure 5.9 Immunological potency of rMVA expressing Ag85A. Groups o f C57BI/6 
mice (n=5) were immunised intramuscularly w ith  rMVA (1 x 106 or 1 x 107 PFU) 
expressing Ag85A under the control o f vaccinia prom oter P7.5 or mH5. Another 
group o f mice received w ild-type MVA (1 x 107 PFU). All immunisations were given 
tw ice at an interval o f tw o  weeks. A fu rthe r tw o  weeks after the final immunisation, 
splenocytes were harvested fo r restimulation w ith  overlapping Ag85A peptides o f 15 
amino acids, overlapping by 10. Peptide pools representing the whole antigen (66 
peptides; amino acids 1-338) or sections from  the N to  C term inus were applied (up 
to  10 peptides). The number o f cells induced to  release IFNy was measured by 
ELISpot assay (Mabtech). Results were plotted as the number o f spot form ing units 
(SFU) per m illion cells (mean +/- SEM) after subtraction o f background, i.e. SFU/105 
measured in the presence o f cell culture medium only. Results were compared by t- 
test (*P < 0.05, * *  P < 0.01). The data are representative o f tw o  separate mouse 
experiments, one o f which was subjected to repeat analysis on cryopreserved cells 
(shown) to  confirm reproducibility o f the results.
Only groups receiving rMVA expressing Ag85A were able to  demonstrate Ag85A-specific 
immune responses. There was no detectable IFNy release in samples derived from  mice 
immunised w ith  w ild-type MVA (MVA 107). The highest responses overall (fractionally) 
were to  the 'Whole Antigen' peptide pool. Results fo r the other peptide pools provided 
evidence fo r at least three im m unodom inant epitopes residing w ith in  amino acids 301-338, 
101-160 and 251-310 (listed in decreasing order o f magnitude). Responses fo r each rMVA 
virus were generally dose dependent and higher where Ag85A was expressed under the
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control o f the mH5 promoter; the immunogenicity o f MVA-P7.5-Ag85A approached that o f 
MVA-mH5-Ag85A when used at a 10-fold higher dose.
In order to  investigate anti-vector T-cell responses, splenocytes were restimulated w ith 
Vaccinia virus imm unodominant CD8+ epitopes: B8R, A19L, A47L, A42R and K3L (Tscharke 
et o i,  2005). The peptides induced IFNy release and demonstrated dose dependent 
responses fo r the rMVA expressing Ag85A, which had been administered at tw o d ifferent 
doses (Figure 5.10).
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Figure 5.10 Immunes responses to vaccinia derived peptides. Groups o f C57BI/6 
mice (n=5) were immunised intramuscularly w ith  rMVA (1 x 106 or 1 x 107 PFU) 
expressing Ag85A under the control o f vaccinia prom oter P7.5 or mFI5. Another 
group o f mice received w ild-type MVA (1 x 107 PFU). All immunisations were given 
tw ice at an interval o f tw o weeks. A fu rthe r tw o weeks after the final immunisation, 
splenocytes were harvested fo r restimulation w ith  vaccinia derived peptides (8-10 
residues). The number o f cells induced to  release IFNy was measured by ELISpot 
assay (Mabtech). Results were plotted as the number o f spot form ing units (SFU) per 
m illion cells (mean +/- SEM) after subtraction o f background, i.e. SFU/106 measured 
in the presence o f cell culture medium only. The data are representative o f results 
observed fo r fresh and cryopreserved cells (shown).
Responses fo r mice immunised w ith  w ild-type MVA provided evidence fo r the actual dose 
given being closer to  106 PFU as opposed to the intended 107 PFU. Flaving confirmed that 
the four rMVA expressing Ag85A were all immunogenic and able to  induce Th-1 antigen- 
specific immune responses, the ir protective efficacy was evaluated in mice.
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MVA-mH5-Ag85A affords equivalent protection to MVA-P7.5-Ag85A at a 10 fold lower 
dose
Groups of C57BI/6 mice were immunised with rMVA and wild-type MVA as described 
above. Whilst a proportion of each group was used for antigen-recall studies (Figures 5.9 
and 5.10) the remainder went on to be challenged with an aerosolised dose of M. 
tuberculosis (Section 2.4.5). In addition to the groups immunised with recombinant and 
wild-type MVA, the study was set up to include unvaccinated and BCG controls, to provide 
negative and positive control data, respectively. A schematic of the study vaccination and 
challenge schedule is shown in Figure 5.11.
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Time (weeks) fn=5)
0 2 4 6
BCG Mtb Challenge
(105 CFU) (100 CFU)
M V A ----------- > MVA
(10® or 107 PFU)
Figure 5.11 Murine efficacy study schedule. Groups of C57BI/6 mice (n=8) were 
immunised intramuscularly with rMVA (1 x 106 or 1 x 107 PFU) or native MVA (1 x 107 
PFU), twice, at two weeks apart. Mice in the BCG control group were immunised 
subcutaneously with M. bovis BCG Danish (SSI, Denmark) at a dose of 1 x 10s CFU. Six 
weeks after the first immunisations, vaccinated and unvaccinated mice (n=8) were 
challenged with aerosolised Mtb to provide an inhaled retained dose of 
approximately 100 CFU. Four weeks after infection, the mice were necropsied and 
lung and spleen removed. Organs were processed for determination of Mtb bacterial 
load.
Lungs and spleens were harvested for determination of bacterial load at four weeks post­
challenge. The organs were processed for serial dilution and plating on selective medium 
as described in Section 2.4.5. Total CFU per organ was calculated for each animal and 
plotted against a log scale (Figure 5.12).
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Figure 5.12 Protective efficacy of rMVA expressing Ag85A. Groups of C57BI/6 mice 
(n=8) were vaccinated with M. bovis BCG Danish (SSI, Denmark), rMVA expressing 
Ag85A under the control of vaccinia promoter P7.5 or mH5, or wild-type MVA. MVA 
was given at a dose of 1 x 106 PFU or 1 x 107 PFU. Immunised mice were challenged 
with M. tuberculosis and four weeks later the bacterial load in the lung and spleen 
was determined. Results for individual mice and group median were plotted against 
a logarithmic scale. Statistically significant reductions relative to the unvaccinated 
control are highlighted (**P  < 0.01, ***p <  0.001; Mann-Whitney, GraphPad Prism).
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The data for the negative (unvaccinated) and positive (BCG) controls were as expected. 
There was a 1 -  2 log reduction in the median bacterial load for the BCG group compared to 
the unvaccinated group and in both organs this difference was statistically significant 
(Mann Whitney PcO.OOl). No statistically significant reductions were seen in the lung or 
spleen for the vector-only control group (wild-type MVA).
MVA-P7.5-Ag85A was able to induce modest reductions in the bacterial load of the lung 
and spleen and did so dose dependently. At a dose of 1 x 107PFU, a statistically significant 
reduction relative to unvaccinated controls was observed in the lung (Mann Whitney P = 
0.0011). MVA-mH5-Ag85A was able to achieve the same result using a dose that was 10 
fold lower (P= 0.0011). Curiously, in mice immunised with a higher dose of MVA-mH5- 
Ag85A (1 x 107 PFU), protective efficacy in the lung was reduced such that bacterial levels 
were equal to those seen in the unvaccinated control. However, there may have been 
reduced dissemination of Mtb to the spleen since the median value CFU was 0.6 logi0 lower 
in the MVA-mH5-Ag85A group than the unvaccinated control.
Stability of MVA-P7.5-Ag85A and MVA-mH5-Ag85A over multiple passages
To confirm that any benefits conferred by increased antigen expression were not offset by 
decreased stability of the recombinant cassette, the rMVA were characterised over an 
extended number of passages on CEF cells. The expression, fitness and immunogenicity of 
the MVA-P7.5-Ag85A and MVA-mH5-Ag85A, described above, had been evaluated after 10- 
11 passages, as this was the total number of passages required to purify and amplify the 
viruses (see Section 4.3.1, Table 4.5). Further passages were undertaken up to a total of 20. 
After each, analytical PCR of the insertion site (Figure 5.13) and Western blot for detection 
of the expression product (not shown) was performed. The results confirmed no change in 
the insert size or expression product.
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Figure 5.13 Analytical PCR of the Del III insertion site containing Ag85A. MVA- 
mH5-Ag85A and MVA-P7.5-Ag85A were passaged up to  20 times. A fter each 
passage a sample o f infected CEF cell lysate was subjected to  gDNA extraction and 
interrogation o f the insertion site via PCR. The PCR was performed using primers 
binding either side o f the insertion site. Amplicons were separated by gel 
electrophoresis. Transfer plasmid DNA was used in the positive control (+) 
reaction fo r each construct and gave a product of the expected size (MVA-mH5- 
Ag85A, 2680 bp; MVA-P7.5-Ag85A, 2863 bp). W ater was used in place o f DNA 
tem plate to  provide a negative control (-). A single band o f the same size in all 
reactions confirmed tha t the insert was present and had not been truncated.
5.4 Discussion
A head-to head comparison was undertaken fo r tw o pairs o f rMVA expressing a TB antigen 
under the control o f vaccinia prom oter P7.5 or mH5. MVA-P7.5-Rv0111 and MVA-mH5- 
R v O lllT  were compared, but w ith  the caveat tha t the expression products were not 
identical. The rMVA expressing the Ag85A gene were identical in every regard and so a 
more comprehensive comparison was undertaken.
5.4.1 Promoter effects on fitness and stability
As discussed above in Section 5.1, and in Section 1.2.4, vaccinia prom oter selection must 
balance optim ised expression w ith  stability o f the recombinant insert. Heightened levels of 
antigen expression may lead to  increased immunological potency, but this is only beneficial 
provided the vaccine is sufficiently robust fo r product-scale manufacture. M tb gene 
R v O ll l  was so unstable under the control o f mH5 that the desired recombinant could not 
be isolated. A truncated version o f the gene was stable and immunogenic and so may o ffer
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a viable alternative. Optimised expression for a truncated HIV antigen is being pursued as a 
clinical candidate (Wyatt et al., 2009; Wyatt et al., 1996). Expression of Ag85A under the 
control of mH5 did not impact negatively on viral fitness or on stability of the recombinant 
insert.
An important observation arising from the titration of viral samples was that differences in 
the estimated titre were most heavily impacted upon by technical variability in the plating 
of the virus, i.e. by differences in the cell monolayers upon which they were plated (Figure 
5.5). For this reason the viral titres of rMVA that were destined to be compared, in this 
Chapter and in Chapter 6, were always titrated in parallel.
5.4.2 Promoter effects on antigen expression
The first comparison of P7.5 with mH5 was made upon initial modification of the naturally 
occurring early/late promoter H5 and expression investigated using (3-galactosidase 
production by rW-LacZ (Wyatt et al., 1996). A five-fold increase in antigen expression was 
measured at a specified MOI, but not over a range of doses. Similarly, other published 
comparisons of P7.5 and mH5 have described expression following infection at one dose 
and over a time-course, e.g. as performed for expression of the luciferase reporter gene 
(Orubu et al., 2012) and the model antigen ovalbumin (Becker et al., 2014). In each of 
these examples the difference in expression was less pronounced, and it was not possible 
to gauge whether equivalent levels of expression might have been achieved by only a slight 
change in viral titre.
In the current study, antigen expression was investigated via dot blot to provide semi-
quantitative data; the amount of antigen expressed was not defined, but characterised for
each pair of rMVA in parallel to enable relative levels of antigen expression to be compared.
Further, results were obtained across a range of doses. Both MVA-mH5-Rv0111T and MVA-
mH5-Ag85A produced an equivalent amount of antigen to their P7.5 counterpart, but at a
10-fold lower concentration. In both cases, the rate of viral amplification was confirmed
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not to have influenced the result. The data provided evidence for optimised expression 
having the potential to provide optimal vaccine antigen delivery at a reduced dose of viral 
vector to an extent not previously reported. It should be noted that upon inoculation in 
vivo, rMVA expression will be limited to one round of viral protein production as the virus is 
replication deficient. However, relative differences in the strength of antigen expression 
are still expected to be manifest.
5.4.3 The correlation between in vitro expression and in vivo immunogenicity
The induction of Th-1 immunity in C57BI/6 mice was measured to assess the immunological 
potency of each rMVA. After two doses of rMVA, ex vivo antigen-recall responses were 
measured by murine IFNy ELISpot assay. The immunogenicity of each pair of rMVA viruses 
appeared to correlate with their relative levels of antigen expression. In each experiment, 
splenocytes were restimulated with overlapping peptides representative of the amino acid 
sequence of the recombinant antigen. Peptides were 15 residues in length and overlapped 
by 10 residues and so were designed to evoke CD4+ and CD8+ T cell responses (Rodda, 
2002).
Splenocytes from MVA-P7.5-Rv0111-immunised mice did not release IFNy in the presence 
of R vO lllT  peptides, but equivalent samples from MVA-mH5-Rv0111T-immunised mice 
demonstrated an antigen-specific recall response. Thus, evidence to support increased 
immunogenicity of the construct containing mH5 was obtained. The results highlighted the 
importance of including Vaccinia-derived peptides in future experiments, in order to 
demonstrate successful and equivalent delivery of the vector. Responses to rMVA 
expressing Ag85A were investigated more fully.
The number of antigen-responding T cells correlated with the immunising dose after
immunisation with MVA-P7.5-Ag85A and MVA-mH5-Ag85A. Consistent with the
observation that MVA-P7.5-Ag85A expressed an equivalent amount of recombinant antigen
to MVA-mH5-Ag85A when used at a 10 fold higher dose, the P7.5 and mH5 constructs
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induced a similar number of IFNy secreting cells after two inoculations with 107 and 106 
PFU, respectively.
The profile of the response to Ag85A was investigated using a whole-antigen peptide pool 
and sub-pools representing the length of the Ag85A amino acid sequence. The results 
provided evidence for at least three immunodominant epitopes which remained consistent 
between the two rMVA. The most immunogenic epitope was in the terminal region of the 
protein (amino acids 301-338) as has been reported previously for C57BI/6 mice immunised 
with an Ag85A vectored by plasmid DNA (D'Souza et al., 2003) and by Adenovirus 
(Radosevic et al., 2007).
Responses to Vaccinia peptides were measured to investigate vector immunity and provide 
confirmation of the doses of MVA given. All of the samples were induced to release IFNy in 
a pattern consistent with that reported previously for C57BI/6 mice (Cottingham et al., 
2008; Tscharke et al., 2005). The IFNy release data confirmed that the rMVA expressing 
Ag85A had been delivered at two different doses and that the doses of the two rMVA had 
been equivalent to one another; no statistically significant differences between MVA-P7.5- 
Ag85A and MVA-mH5-Ag85A at each dose were observed. Responses for mice inoculated 
with 107 PFU were approximately 30% higher than those measured in mice inoculated with 
106 PFU (this level of increase was also observed following restimulation with Ag85A 
peptides). The results provided evidence for the wild-type MVA group having been given a 
lower dose, closer to 106 PFU than the intended 107 PFU.
5.4.4 The impact of optimised expression on protective efficacy
Protective efficacy was investigated in C57BI/6 mice after challenge with M. tuberculosis.
All of the animals were infected as demonstrated by countable CFU in lung and spleen
samples at four weeks post-infection. Data for the control groups were as expected; BCG
vaccination led to a 1-2 logi0 drop in the bacterial load relative to the unvaccinated group
and this decrease was very highly significant in both the lung and the spleen (P = 0.0002
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and P = 0.0003, respectively). Mice immunised with wild-type MVA were not expected to 
be protected from initial infection or dissemination of disease and no statistically significant 
differences in bacterial load were observed for either tissue relative to the unvaccinated 
group.
The rMVA test groups were assessed for their ability to lower the bacterial load in the 
organs relative to the unvaccinated control. Protective efficacy better than BCG was not 
expected as the vaccines are TB sub-units designed to boost BCG. As discussed in Section 
1.4, BCG is a live, attenuated strain of M. bovis. It expresses multiple antigens and induces 
a relevant immune response for protection against TB, but requires improvement. Subunit 
vaccines are designed to be applied in the context of prior BCG vaccination, to boost 
responses to relevant antigens. Their efficacy can be evaluated in animal models in which 
BCG is used as the positive control, but it is often preferable to evaluate their effects 
relative to unvaccinated groups as BCG is very effective in small animal models making 
booting effects difficult to resolve.
Inoculation with MVA-P7.5-Ag85A at two doses of 106 PFU did not reduce the bacterial load 
in the lung relative to the unvaccinated control. However, the median logi0 CFU was 
reduced (-0.38) after two doses of 107 PFU, and the difference was statistically significant (P 
= 0.0011). In keeping with the observation that MVA-mH5-Ag85A could induce equivalent 
immune responses at a 10 fold lower dose, equivalent protection was observed following 
immunisation with two doses of 106 PFU; the median logi0 CFU was reduced (-0.40) and the 
difference was statistically significant (P = 0.0011). For both viruses there was a similar 
level of dissemination to the spleen which was not significantly different to the negative 
control. After immunisation with a higher dose, MVA-mH5-Ag85A was less protective and a 
possible explanation for this could be the strength of antigen delivery.
Successful vaccination is dependent upon the induction of immunological memory. As
outlined in Section 1.1.2, immunisation leads to the expansion of an antigen-specific T cell
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effector population (TE) which can then differentiate to provide a reservoir of memory cells. 
Circulating effector memory (TEM) cells provide immediate antigen recall, while central 
memory (TCM) cells reside in lymphoid tissues to mount a response upon interaction with 
infected APC (Sallusto et al., 2010). It is the TCM population in particular that is critical for 
vaccine induced T cell immunity.
It has been shown that excessive antigen stimulation can drive strong effector responses 
with the result that T cells are terminally differentiated and memory cell populations 
depleted (Masopust et al., 2006). Higher antigen doses and/or shorter intervals between 
priming and boosting immunisations can, therefore, reduce central memory and protective 
efficacy despite having induced stronger effector memory functions, such as those 
measured by IFNy ELISpot assay. Thus, vaccination must strike a balance between the 
expansion of TE cells and the retention of sufficient proliferative potential.
Excessive T cell differentiation may explain the lack of protection observed for the potently 
immunogenic MVA-mH5-Ag85A vaccine. The rMVA had been administered twice at two 
week intervals. In a clinical setting, a subunit vaccine would be given as a boost to BCG 
after a longer intervening period. A dose dependent reduction in protective efficacy has 
been reported for a novel TB vaccine tested in mice (Aagaard et al., 2009). Increased doses 
reduced the quality of the immune response with the result that protective efficacy was 
lost. This may have happened in this study and could be investigated by the assessment of 
further immune parameters, in particular by cytokine profiling of antigen-specific T cell 
subsets.
5.5 Conclusions
Pre-clinical efficacy for a rMVA-based vaccine was first demonstrated in mice following 
delivery of influenza virus antigens (Sutter et al., 1994). The study reported a correlation 
between the immunising dose of rMVA, levels of antigen-specific antibody subsequently
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induced and the resulting survival rates against influenza challenge. Studies performed 
since have provided further evidence for a positive correlation between antigen expression 
and immunogenicity, but the extent to which optimised expression can increase 
immunological potency and in turn protective efficacy is not always apparent. Two limiting 
factors are inadequate investigation of effects over a range of doses and the absence of 
efficacy data.
The results presented here have examined the relationship between rMVA titre, antigen 
expression, immunogenicity and efficacy. They support the view that optimisation of 
expression is of vital importance as it has the capacity to reduce the inoculating doses of 
rMVA required to achieve protection. This has the potential to reduce subsequent anti­
vector immune responses and may impact favourably on the cost per dose of the vaccine.
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Chapter 6 Do antigen fusions have the potential to make the immune 
response to rMVA-vectored TB antigens more diverse?
6.1 Introduction
Recombinant MVA viruses deliver vaccine antigens in the form of nucleic acid. Post­
immunisation, the antigen must be expressed before an immunological response can be 
evoked. In order to influence the way in which an MVA-vectored antigen is translated and 
processed, it is possible to genetically engineer a sorting signal to be fused to the amino (N) 
and/or carboxyl (C) terminus of the protein. This has the effect of influencing the manner 
in which the antigen is processed upon translation which in turn can influence the nature of 
the immune response that is stimulated. As summarised in Section 1.2.6, a number of 
antigen fusion sequences have been investigated for this purpose. The leader sequence 
most commonly used in TB vaccine research is the signal peptide from the human tissue 
plasminogen activator gene (TPA).
6.1.1 The TPA signal peptide
The first comparison of antigen delivery with and without a TPA leader was performed 
using plasmid DNA vaccines vectoring a malaria antigen (Haddad et al., 1997). The authors 
had speculated that direction of the gene product to the secretory pathway would increase 
humoral responses. Whilst TPA-dependent secretion via the endoplasmic reticulum (ER) 
was observed, increased antibody responses, however, were not. Conversely, TB antigen 
studies have demonstrated that fusion to the TPA leader sequence can increase murine 
humoral and cell-mediated immune responses. Evidence for increased expression and 
enhanced murine immunogenicity has been demonstrated for plasmid DNA vectoring 
Ag85A (Montgomery et al., 1997) and four other TB antigens (Li et al., 1999), as well as for 
rW  delivering Ag85A, Ag85B or Ag85C (Malin et al., 2000). Importantly, Li et al. also 
investigated protective efficacy. Following Mtb challenge, the bacterial load in the lung and
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spleen of immunised mice was consistently reduced for groups receiving TPA-antigen 
fusions as compared to their non-TPA counterparts (Li et al., 1999). The majority of 
recombinant TB vaccines researched since have employed a TPA leader sequence, including 
the clinical candidate MVA85A (McShane et al., 2002) and more recent plasmid DNA (Mir et 
al., 2009) and Adenovirus vaccines (Dicks et al., 2015; Mu et al., 2009).
6.1.2 Enhanced humoral immunity for novel TB vaccines
As discussed in Section 1.4.2, the induction of Th-1 immunity and IFNy release is considered 
central to the development of an improved TB vaccine. However, recent reports have 
highlighted the potential for antibody responses to contribute to TB protection and, in 
particular, the prevention of initial infection (Achkar and Casadevall, 2013; Andersen and 
Woodworth, 2014). Cell surface expression of an antigen following delivery by rMVA can 
lead to the induction of higher antibody titres (Wyatt et al., 2008a) and can be promoted by 
fusion of the antigen to membrane-anchoring sequences.
The Vesicular Stomatitis Virus (VSV) glycoprotein has been studied as a model integral 
plasma membrane protein. Initial reports of the protein's sequence suggested that a 
region at the C-terminus would be responsible for membrane anchoring - specifically, a 49 
amino acid sequence comprising a hydrophobic and cytosolic domain (Rose et al., 1980). 
This theory was supported by in vitro expression studies in which the C-terminus was 
removed; the glycoprotein was no longer observed to be membrane bound (Rose and 
Bergmann, 1982). Later, it was shown that the gene sequence for an otherwise secreted 
protein could be fused to the membrane-anchoring region with the result that the gene 
product would be cell surface expressed (Guan et al., 1988). Srinivasan et al. used this 
approach to enhance the immunogenicity of an rVV-based human chorionic gonadotrophin 
P (PhCG) subunit vaccine. Briefly, two rVV expressing phCG were generated - one with the 
VSV membrane-anchoring region (VSVg) and one without. High titres of anti-phCG 
antibodies were measured in animals immunised with the VSVg construct, whilst no phCG-
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specific antibody was detected in animals immunised with the native form of PhCG 
(Srinivasan eta l., 1995).
As discussed in Section 1.4.2, current TB vaccine strategies are primarily concerned with 
enhancing anti-mycobacterial T cell responses. However, there is a growing body of 
evidence to suggest that humoral immunity may also contribute to protection against TB 
(Achkar and Casadevall, 2013). Fusion of a TB antigen to the VSV glycoprotein membrane 
anchoring region (VSVg) may be an appropriate means of achieving enhanced antibody 
responses. Further, bilateral targeting of the same antigen to multiple pathways may 
diversify the immune response induced. In the current study, TPA and the VSVg were 
selected for comparison of their relative and combined effects.
6.1.3 A model antigen for proof of principle
The model antigen ovalbumin (OVA) was selected to be the test antigen for this aspect of 
the current study. OVA is well characterised and has been the subject of previous vaccine- 
related studies investigating immuno-potentiating factors, including endogenously 
expressed antigen fusions (Diebold et al., 2001), rMVA promoter selection (Baur et al., 
2010; Becker et al., 2014), novel adjuvants (de Cassan et al., 2011) and delivery systems 
(Huang et al., 2010). As demonstrated through these, and earlier reports, the OVA antigen 
is known to induce IgG isotypes associated with Th-1 (lgG2a, lgG2b and lgG3) and Th-2 
(IgGl) responses. The antigen also has restricted MHC Class I and MHC Class II epitopes 
through which to examine CD8+ and CD4+ T cell responses, respectively (Table 6.1).
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Table 6.1 Murine-restricted OVA immunological determinants. Sections of the OVA
385-amino acid sequence contain MHC Class I (OVA I) and Class II (OVA II) epitopes. 
The exact peptide sequence is shown using the single-letter amino acid code. The 
MHC molecules binding these antigens are encoded by H-2 genes, residing in 
different loci and on different alleles (haplotype).
MHC H-2 restriction 
Class Loci Haplotype
Reference
OVA 1: SIINFEKL (OVA257.264)
1 K b (Rotzschke et o/., 1991)
OVA II: ISQAVHAAHAE1NEAGR (OVAa^g)
II IA d (McFarland eta!., 1999)
The construction of rMVA expressing OVA using transfer plasmid methodology is described 
in Chapters 3 and 4. Transfer plasmids incorporating vaccinia promoter mH5 for regulation 
of antigen expression were selected to promote the induction of strong, measurable 
immune responses associated with different T cell subtypes. As discussed in Chapter 4, 
rMVA expressing a single copy of OVA were successfully isolated, but a double-recombinant 
expressing OVA fused to both TPA and VSVg, in separate insertion cassettes, could not be 
purified. The immunogenicity of the single rMVA was investigated to test the study 
hypothesis as far as possible and to inform the design of future studies.
6.2 Chapter Aims
The overall aim for this Chapter was to investigate the potential for diversifying the immune 
responses to an antigen through the use of multiple leader sequences, as per the study 
hypotheses outlined in Section 1.5. The immunogenicity of four rMVA viruses vectoring the 
Ovalbumin (OVA) gene was compared. Specific objectives were to:
>  Investigate antibody-mediated responses to OVA by measuring antigen-specific IgG 
isotypes.
>  Compare the cell-mediated response to OVA by measurement of antigen-recall 
cytokine release.
6.3 Results
6.3.1 rMVA for an investigation into leader sequence effects
Four rMVA viruses expressing OVA were purified as described in Chapter 4 (see Section
4.3.2). For each rMVA expressing OVA fused to  a leader sequence there was a 
corresponding 'no-leader' control virus. A diagram o f the expression product arising from  
each rMVA is presented in Figure 6.1. Detailed inform ation regarding the sequence o f each 
open reading frame is presented in Appendix III.
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Figure 6.1 Schematic representation of rMVA-OVA expression products. Each rMVA 
expressed OVA fused to N and/or C term inal fusions. Either side o f the OVA gene 
was a short sequence arising from  the presence o f the a tt recombination sites used 
in Gateway® cloning. The V5 tag was joined to  a linker sequence (zig-zag line) to  
ensure adequate presentation o f the B cell epitope. For each recombinant cassette 
incorporating a leader sequence, i.e. TPA-OVA-V5 and V5-OVA-VSVg, there was a no­
leader control, identical in every regard, including the site o f insertion. The start (•) 
and stop (♦ )  codons are shown. Numbers represent amino acid length.
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The immunogenicity o f the rMVA expressing OVA was investigated by immunising mice for 
subsequent evaluation o f humoral and cell-mediated immune responses. In the first 
instance, an ELISA was developed fo r the detection o f antigen-specific IgG isotypes.
6.3.2 Development of an ELISA for detection of mouse anti-OVA IgG isotypes
An indirect ELISA protocol was optim ised fo r the detection and measurement o f murine IgG 
isotypes. Biotinylated antibodies specific fo r murine IgG l, lgG2a, lgG2b and lgG3 were 
purchased (see Section 2.4.4) and investigated fo r the ir ability to  accurately discriminate 
between each isotype and were optim ised w ith  regards to  the ir concentration (described 
below). A suitable concentration o f OVA protein was then selected fo r coating m icrotitre  
plates, so that OVA-specific murine IgG could be captured from  serum samples and 
measured. In advance o f describing the assay optim isation undertaken, summaries o f the 
principal components o f the assay are presented (Figure 6.2).
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Figure 6.2 Indirect ELISA for detection of anti-OVA IgG isotypes. The main 
components of the assay are shown in one well o f a 96-well m icrotitre  plate. Plates 
were coated w ith commercially available murine IgG isotypes to  optim ise the 
protocol (left panel). Bound IgG was detected indirectly via the addition of 
biotinylated anti-mouse IgG followed by incubation w ith  streptavidin - horse radish 
peroxidase (HRP) conjugate. The amount o f IgG present was quantified by measuring 
HRP-mediated colour change o f the substrate 3,3',5,5'-tetramethylbenzidine (TMB). 
Later, plates were coated w ith  OVA protein and incubated w ith  mouse serum to 
allow anti-OVA IgG to  bind (right panel). The levels o f anti-OVA were then measured 
as described above, using biotinylated anti-mouse IgG to  detect specific isotypes.
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Isotype-specific detection of IgG
The specificity o f biotinylated antibodies raised against murine IgGl, lgG2a, lgG2b and lgG3 
was investigated, to  ensure that they would provide an accurate means o f measuring IgG 
isotypes (protocols and reagents are described in detail in Section 2.4.4). M icro titre  plates 
were coated w ith  IgGl, lgG2a, lgG2b or lgG3 at a range o f concentrations and then 
detection attem pted w ith  each biotinylated anti-mouse IgG (as described in Figure 6.3, left 
hand panel). The results confirmed tha t the biotinylated antibodies were isotype specific 
and tha t d iffe ren t concentrations o f coating IgG would be detected in a dose dependent 
manner (Figure 6.3). In this experiment, each o f the biotinylated anti-mouse IgG antibodies 
had been used at a d ilution o f 1 in 20,000. In the next round o f experiments the 
concentration o f anti-IgG would be optim ised.
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Figure 6.3 Isotype-specific detection of murine IgG. Plates were coated w ith  IgG l, lgG2a, 
lgG2b (not shown) or lgG3, as indicated by the legend. Isotype-specific b iotinylated an ti­
mouse IgG (raised in rabbit) was applied at a dilution o f 1:20,000 to  achieve indirect 
detection o f the coating IgG using streptavidin-FIRP and TMB reagents. Optical density (OD) 
was measured at 450 nm and was plotted after subtraction o f values fo r non-specific 
binding (NSB). Data points represent the mean o f duplicate wells.
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Optimisation of secondary antibody concentration
The product information supplied w ith  each o f the four biotinylated anti-mouse IgG 
specified a range o f dilutions at which they m ight be investigated fo r use in an ELISA. Four 
dilutions encompassing this range were selected fo r testing. M icro titre  plates were coated 
w ith  three concentrations o f each IgG isotype (0.003, 0.03 and 0.3 pg/m l) and were then 
incubated w ith the d ifferent dilutions o f biotinylated anti-mouse IgG. As before, the 
amount o f anti-IgG binding to  the plate was measured via the addition o f Streptavidin-HRP 
followed by TMB substrate. The OD data are summarised in Figure 6.4.
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Figure 6.4 Optimisation of secondary antibody concentration. M icrotitre  plates 
were coated w ith  one o f four IgG istoypes. The corresponding isotype-specific 
secondary antibody was applied at four d ifferent dilutions to  achieve indirect 
detection o f the coating IgG using streptavidin-HRP and TMB reagents. Optical 
density (OD) fo r trip licate wells (mean +/- SEM) was plotted after subtraction of NSB 
readings.
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The m ajority o f the biotinylated anti-mouse IgG concentrations tested were able to  detect 
the coating antibody and were able to  do so dose dependently. However, the sensitivity o f 
detection improved as the concentration o f biotinylated anti-IgG antibody was increased. 
The discrim inatory power to  measure 10-fold changes in coating-IgG concentration was 
poorest at a d ilu tion o f 1 in 250,000 and at its most sensitive at 1 in 8,000. The lowest 
dilution (1:8,000) was, therefore, selected fo r use in subsequent assays.
Previously, the specificity o f each o f the biotinylated anti-IgG antibodies was investigated at 
a d ilution o f 1 in 20,000 (Figure 6.3). To ensure tha t non-specific binding would not 
manifest at a higher concentration, isotype specificity was re-examined at the revised 
dilution o f 1 in 8,000. The results provided evidence fo r negligible cross-reactivity (Figure 
6.5) and so each o f the biotinylated anti-IgG antibodies was used at a d ilu tion o f 1 in 8,000 
in subsequent assays.
Specificity of anti-isotype IgG 
(1 in 8000)
Anti-IgG 1 
i i Anti-lgG2a
[Coating IgG] (0.3 jig/ml)
Figure 6.5 Specificity of secondary antibody at 1:8000. M icro titre  wells were coated 
w ith  one o f four IgG isotypes at a single concentration (0.3 pg/m l). Detection o f the 
bound IgG was then attempted using four isotype-specific b iotinylated anti-mouse 
IgG, as indicated by the figure legend. For each isotype o f coating IgG, detection was 
only achieved after addition o f the corresponding isotype-specific anti-IgG. OD fo r 
trip licate wells (mean +/- SEM) was plotted after subtraction o f non-specific binding 
(NSB).
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Selection of an ovalbumin concentration for plate coating
As summarised in Figure 6.2, OVA-specific IgG antibodies in mouse serum were captured 
fo r detection using m icrotitre  plates coated w ith  OVA protein. In order to  identify an 
optim al coating concentration o f OVA, m icro titre  plates were coated w ith  four d ifferent 
concentrations selected to fall w ith in  those reported fo r previous studies (Baur et a i,  2010; 
Bohnen et al., 2013). The binding o f antigen-specific IgG to  the coated plates was 
investigated using a commercially sourced preparation o f anti-OVA IgG. This was deemed 
preferable to  using mouse serum from  rMVA-OVA immunised mice, fo r which the anti-OVA 
IgG titre  was unknown. The commercially sourced anti-OVA IgG was serially diluted and 
applied to  the coated plates. Anti-OVA IgG binding curves were similar fo r all four coating 
concentrations o f OVA (Figure 6.6). At a dilution o f 1 in 100,000 (10~5), anti-OVA IgG 
binding increased dose dependently w ith  the coating concentration o f OVA and revealed 
tha t binding was nearing its maximum at 5 pg/m l. The concentration above this (10 pg/m l) 
was selected fo r use in the anti-OVA ELISA protocol.
Detection of OVA at various coating 
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Figure 6.6 Selection of an OVA concentration for plate coating. M icrotitre  plates 
were coated w ith  d ifferent concentrations o f ovalbumin and then ten-fold dilutions 
o f anti-OVA IgG were applied. Antibody binding was measured indirectly via the 
addition o f biotinylated anti-lgG l. Optical density (OD) fo r trip licate wells (mean +/- 
SEM) was plotted after subtraction o f NSB. At a d ilution o f 1 in 100,000, anti-OVA 
IgG binding correlated w ith  the coating concentration o f OVA.
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6.3.3 A mouse study for investigating rMVA-OVA immunogenicity
Groups of CB6F1 mice (5 per group) were immunised intramuscularly with each of the four 
rMVA expressing OVA, twice, at two week intervals (see Section 2.4.1). The dose of rMVA 
administered on each occasion was 1 x 107 PFU.
In order to ensure consistency between the doses of each rMVA vaccine, the viral stocks 
used for immunisation were titrated in parallel to determine their concentration (see 
Section 5.4.1). The viral stocks were then diluted in PBS to achieve the specified dose.
Two weeks after the final immunisation, whole blood and spleens were harvested for 
evaluation of humoral and cell-mediated immune responses, respectively.
6.3.4 Measurement of anti-OVA IgG isotypes in rMVA-OVA immunised mice
Serum from immunised mice was separated from whole blood as described in Section 2.4.4, 
and tested for the presence of anti-OVA IgG isotypes, as described in Section 2.4.4 and 
above. Throughout, samples of test serum were evaluated in parallel with control serum to 
monitor for the specificity of any 'anti-OVA' IgG detected. The control serum was obtained 
from CB6F1 mice immunised with plasmid DNA vectoring various TB antigens (pooled stock 
from multiple studies). No cross-reactivity with OVA was expected and this was confirmed 
in preliminary studies in which control serum was serially diluted and incubated in OVA- 
coated plates; there was evidence for only limited binding at the highest serum 
concentrations. Representative data for control serum are presented in Figure 6.7 and are 
plotted as the mean plus three standard deviations. Test-serum OD values above this 
threshold were interpreted to represent positive responses.
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Figure 6.7 Measurement of anti-OVA IgG isotypes in rMVA immunised mice.
Groups of CB6F1 mice (n=5) were immunised intramuscularly w ith  rMVA expressing 
OVA (1 x 107 PFU), twice, at tw o week intervals. Two weeks after the final 
immunisation, serum was harvested fo r measurement o f anti-OVA IgG. Two serum 
samples were selected fo r a prelim inary assessment o f the ir anti-OVA IgG titres by 
ELISA. Sample IB  was from  a mouse immunised w ith rMVA-TPA-OVA-V5. Sample 4B 
was from  a mouse immunised w ith  rMVA-V5-OVA. Both were selected on account of 
having ample volume. Optical density (OD) was measured at 450 nm in duplicate 
wells and the mean value plotted after subtraction of NSB. Control serum was 
evaluated in parallel. Data were plotted after calculation o f the mean plus 3 
standard deviations.
Prelim inary studies were performed to  investigate the presence o f anti-OVA IgG in serum 
derived from  rMVA-OVA immunised mice. Two samples o f the test serum were 
investigated over a dilution series and anti-IgG was detected in some o f the samples in a 
dose-dependent manner. Representative data are shown in Figure 6.7. The results were 
interrogated fo r the ir ability to  yield reliable endpoint titre  values, as this is the method 
most commonly applied to  the measurement of antibody titres in the absence o f a positive 
control (Miura et al., 2008). The data confirmed that fo r many samples there would be 
insufficient IgG present to  implem ent this approach reliably. All o f the test samples were 
subsequently investigated at a d ilution of 1 in 100 as has been reported fo r o ther IgG- 
isotype studies involving mice (de Cassan et al., 2011) and humans (Biswas et al., 2014). All
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o f the serum samples were tested in parallel, w ith  one another, and w ith  control serum. 
The results are shown in Figure 6.8.
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Figure 6.8 Anti-OVA IgG induced by rMVA immunisation. Groups o f CB6F1 mice 
(n=5) were immunised intramuscularly w ith  rMVA expressing OVA (1 x 107 PFU), 
tw ice, at tw o week intervals. Two weeks after the final immunisation, serum was 
harvested fo r measurement o f anti-OVA IgG by ELISA. Serum samples were diluted 1 
in 100 and added to duplicate wells. Control serum was diluted 1 in 100 and added 
to  four wells divided between tw o m icro titre  plates. Mean OD values were 
calculated after subtraction o f NSB. The rMVA vaccine groups are labelled according 
to  the expression product delivered. Data are shown fo r individual mice (n=5) and 
the group mean. Dotted lines represent the threshold fo r positive responses and are 
equal to  the control serum mean plus three standard deviations. For each IgG 
isotype the difference between groups was examined by one-way ANOVA and by 
post hoc Tukey's m ultiple comparison tests. Significant differences are highlighted 
(*P<0.05, **P<0.01, ***P<0.001).
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For each IgG isotype, it was deemed important to compare test serum results with control 
serum data obtained within the same assay in order to control against inter-assay 
variability. Whilst the majority of the serum samples passed the threshold for positive 
responses, this was not the case for any of the lgG3 measurements and for many of the 
lgG2b readings. However, the control serum mean value may have been slightly higher for 
lgG2b and lgG3 than seen on other occasions (see Figure 6.7).
Only a few of the anti-OVA IgGl measurements were below the threshold for a positive 
response and it was noted that this would not have been the case had the threshold been 
set to the mean plus two standard deviations. Statistical analysis was applied to all the data 
sets despite the failure of some samples to pass the threshold for a positive response, but 
later, the results would be interpreted with due reference to the relative magnitude of the 
IgG levels detected.
Analysis of the data by one-way ANOVA revealed statistically significant differences 
between the groups for each of the IgG isotypes (IgGl, P = 0.0248; lgG2a, P = 0.0008; lgG2b, 
P = 0.0025; lgG3, P = 0.0482). The difference between individual groups was further 
examined by post hoc Tukey's multiple comparison tests. Statistically significant 
differences are highlighted in Figure 6.8. The induction of anti-OVA responses in mice 
immunised with each of the 'no leader' control rMVA might have been expected to be 
similar to one another. However, rMVA expressing OVA-V5 inserted into Deletion site III 
generally induced higher IgG levels than rMVA expressing V5-OVA inserted into Deletion 
site II, and for anti-OVA IgGl, this difference was statistically significant (P < 0.05).
Relative to their corresponding 'no leader' controls, rMVA vectoring OVA fused to either 
TPA or VSVg evoked higher Th-1 associated IgG responses (lgG2a and lgG2b). These 
increases reached statistical significance for VSVg enhancement of anti-OVA lgG2a (P < 
0.01) and TPA enhancement of anti-OVA lgG2b (P < 0.05). Relative to their respective
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controls, there was no difference in the ability o f the tw o  leader-sequence constructs to  
modulate the levels o f Th-2 associated IgGl.
The ratio o f lgG2a to  IgGl, based upon group means, was compared as an indicator o f the 
balance between Th-1 and Th-2 immunity, as has been reported previously (de Cassan et 
al., 2011). The results confirmed tha t all o f the groups were skewed towards a Th-1 type 
response, but tha t rMVA employing insertion site Del III m ight have been less biased on 
account o f the ir higher IgG l levels (Figure 6.9A).
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Figure 6.9 Anti-OVA IgG Isotype summary data. A) The Th-l:Th-2 balance o f the IgG
levels reported in Figure 6.8 were investigated by calculating the ratio o f lgG2a: IgG l. 
The data are the ratio o f group means. B) The to ta l amounts o f IgG induced were 
plotted according to  all o f the OD values. The contributing totals fo r each isotype are 
shown, as indicated by the figure legend.
Finally, the IgG data were summarised by plotting the sum o f the responses (Figure 6.9B). 
Fusion o f OVA to  either TPA or VSVg increased the to ta l levels o f IgG induced relative to  
data fo r the corresponding 'no-leader' control. As already noted, the induction o f anti-OVA 
humoral responses appeared to  be higher fo r rMVA expressing OVA inserted into Deletion 
site III.
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6.3.5 Measurement of OVA-specific IFNy release
Splenocytes from  immunised mice (see Section 6.3.3) were harvested fo r IFNy ELISpot 
assay, as described in Section 2.4.2. Cells were incubated w ith  whole OVA protein and non- 
OVA protein to  investigate the induction o f antigen-specific cytokine release. Tuberculin 
purified protein derivative (PPD) was added at a concentration routinely observed to  induce 
cytokine release after BCG vaccination (10 pg/m l), but did not increase the number o f IFNy- 
releasing cells above background levels (Figure 6.10). Whole OVA protein, meanwhile, did 
evoke an increase in the number o f responding cells enumerated fo r each group. Further, 
the splenocytes were incubated w ith  tw o concentrations o f whole OVA protein (10 and 50 
pg/m l) to  test whether the number o f cells induced to  release IFNy would vary dose 
dependently. The results confirmed antigen-specific, dose-dependent stimulation.
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Figure 6.10 Whole OVA IFNy responses. Groups o f CB6F1 mice (n=5) were 
immunised intramuscularly w ith  rMVA expressing OVA (1 x 107 PFU), twice, at tw o 
week intervals. Two weeks after the final immunisation, splenocytes were harvested 
fo r restimulation w ith  whole OVA protein or tuberculin purified protein derivative 
(PPD). The number o f cells induced to  release IFNy was measured by ELISpot assay. 
Results were plotted as the number o f spot form ing units (SFU) per m illion cells 
(mean +/- SEM) after subtraction o f background, i.e. SFU/106 measured in the 
presence o f cell culture medium only. No statistically significant differences between 
groups were observed (one-way ANOVA).
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The number of cells induced to release IFNy after restimulation with whole OVA protein 
was compared between the groups. No statistically significant differences were detected at 
either of the whole OVA concentrations tested (one-way ANOVA, P = 0.5429 and P = 
0.6489, for 10 and 50 pg/ml, respectively).
Within the same assay, OVA-specific cellular responses were further dissected after 
incubation of the splenocytes with MHC Class I and MHC Class II OVA-restricted peptides 
(see Section 6.1). Peptides OVA I and OVA II stimulate CD8+ and CD4+ T cells, respectively, 
thereby enabling the number of anti-OVA responding cells to be enumerated for each 
subtype. Incubation of the splenocytes with either OVA I, or OVA II, led to an increase in 
the number of cytokine releasing cells. For each of the groups, there were more CD8+ 
responding T cells than there were CD4+ T cells (Figure 6.11).
The number of splenic T cells responding to stimulation with the OVA peptides was 
compared between the groups. There were no statistically significant differences between 
group means for the number of CD4+ cells induced to release IFNy by peptide OVA II. The 
number of CD8+ responding cells, meanwhile, did appear to differ according to the rMVA 
used for immunisation (one-way ANOVA, P = 0.0118). Further examination of the group 
means by post hoc Tukey's multiple comparisons tests revealed that there were no 
differences in the number of CD8+ cells stimulated to release IFNy following immunisation 
with each of the no-leader control viruses. This was in contrast to the data collected for 
humoral responses where rMVA vectoring OVA-V5 inserted into Del III had induced higher 
Th-l-associated IgG levels than rMVA vectoring V5-OVA inserted into Del II. In terms of 
CD8+ cytokine response, the results were slightly lower for OVA-V5 (Del III) than they were 
for V5-OVA (Del II), i.e. the opposite of what had occurred in terms of IgG induction
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Figure 6.11 IFNy responses to MHC Class I and MHC Class II restricted OVA peptides.
Groups of CB6F1 mice (n=5) were immunised intramuscularly w ith  rMVA expressing 
OVA (1 x 107 PFU), twice, at tw o week intervals. Two weeks after the final 
immunisation, splenocytes were harvested fo r restimulation w ith  OVA I or OVA II. 
The number o f cells induced to  release IFNy was measured by ELISpot assay. Results 
were plotted as the number o f spot form ing units (SFU) per m illion cells (mean +/- 
SEM) after subtraction o f background, i.e. SFU/106 measured in the presence o f cell 
culture medium only. For each OVA peptide the difference between groups was 
examined by one-way ANOVA. Differences between the responses to OVA I were 
statistically significant (P = 0.0118) while differences between OVA II responses were 
not (P = 0.5417). Post hoc evaluation by Tukey's m ultiple comparison tests revealed 
differences reaching statistical significance and these are highlighted (*P<0.05).
Relative to  the corresponding no-leader control, there were no measurable differences in
the number o f CD4+ or CD8+ responding T cells induced fo llow ing fusion o f OVA to  VSVg.
The impact o f fusing OVA to  TPA, meanwhile, was to  decrease the number o f antigen-
specific CD8+ IFNy-releasing splenic T cells. The differences between the group mean for
TPA-OVA-V5 and the group means fo r V5-OVA-VSVg and V5-OVA were statistically
significant (P < 0.05). An outcome o f the weaker CD8+ response fo r the TPA-OVA-V5 group
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was that the ratio of CD8+ to CD4+ responding cells was more balanced than it had been for 
the other groups. Thus, fusion of the transgene to TPA appeared to reduce the CTL 
dominance of the anti-OVA immune response evoked by rMVA, as measured by IFNy 
ELISpot assay.
6.3.6 Measurement of OVA specific IL-4 and IL-17 release
ELISpots for IL-4 and IL-17 release were conducted in parallel with assays for IFNy. None of 
the restimulating proteins or peptides induced responses above background release. This 
remained the case upon repeat testing where the restimulation period was increased from 
overnight to two, and then five days (data not shown).
6.4 Discussion
The primary objective for this Chapter was to compare the immunogenicity of rMVA 
incorporating TPA and VSVg leader sequences, with a view to investigating the potential for 
leader sequence combinations to diversify the immune response to an MVA vectored 
antigen. Four rMVA expressing OVA were generated and evaluated for their 
immunogenicity in CB6F1 mice. Differences in humoral and cell-mediated immune 
responses were observed, confirming the potential for antigen fusions to modulate 
antigen-specific immunogenicity.
6.4.1 Measurement of anti-OVA IgG
An ELISA panel was developed for the detection of anti-OVA IgG isotypes. In the absence of
a positive standard, it was not possible to create standard curves through which to
interpret OD values. Instead, control serum was tested within each assay to monitor for
positive responses. Experimental immunisation studies are commonly without a positive
standard control and so quantitative analyses are performed on the basis of results for a
negative control, typically by determination of reciprocal endpoint titre. Endpoint titre is
determined from a full dilution curve of the test sample. It is equivalent to the highest
dilution giving an OD reading two or three standard deviations above the negative control.
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In instances where there are low antibody titres, dose curves are difficult to define and 
readings at a single dilution may be compared (Biswas et al., 2014; de Cassan et al., 2011). 
This was the approach applied in this study.
The limitations of assessing IgG levels at a single dilution must be noted. Chiefly, it is 
unclear where on the titration curve the OD value is taken from; the relative differences 
between readings are less meaningful if not from the linear region. However, the relative 
magnitude of the values remains informative.
6.4.2 Measurement of cytokine responses
Splenocytes were restimulated to measure antigen-specific cytokine responding cells via 
ELISpot assay. Th-1 immunity was investigated via enumeration of cells secreting IFNy. 
ELISpot assays for IL-4 and IL-17 release were implemented to explore Th-2 and Th-17 
responses, respectively.
The ELISpot assays for IL-4 and IL-17 were performed in parallel with the IFNy tests and 
were implemented using the same methodology (MAbtech). Positive control wells were 
restimulated with PMA/I (as described in Section 2.4.2) and were induced to release IL-4 
and IL-17. However, there were markedly lower SFU as compared to the IFNy assay. Lack 
of sensitivity may, therefore, have been the root cause of the failure to detect measureable 
responses. Humoral responses for all of the vaccines had demonstrated skewing towards 
Th-1 immunity.
6.4.3. The design and evaluation of vaccine antigen fusions
Leader sequences have the potential to modulate the immunogenicity of virally vectored 
antigens. Complicating the selection of a sorting signal are conflicting reports about their 
expected impact on antigen immunogenicity and/or gaps in our understanding of their 
mechanism of action. For example, the MHC Class ll-binding invariant chain (li) would be 
expected to target antigens towards CD4+ T cell stimulation (Holst et al., 2008), but has
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been found to enhance CD8+ responses to both rAd and rMVA vectored antigens 
(Mikkelsen et al., 2011; Spencer et al., 2014). The TPA signal sequence is expected to 
modify antigen immunogenicity by targeting the protein towards the ER for increased 
secretion (Haddad et al., 1997). However, TB antigens fused to TPA are also more highly 
expressed (Li et al., 1999; Malin et al., 2000) and the relative contribution of expression to 
immune-potentiating effects, versus intracellular trafficking, has yet to be assessed.
Another consideration in the design of vaccine antigen fusions is whether to include the 
native sorting signal, should one be present. Both prokaryotic and eukaryotic genes can 
contain a signalling peptide at the N-terminus to direct the translated protein into the cell 
membrane or ER membrane, respectively, and both signals are recognised in eukaryotic 
cells (Hall et al., 1990). The TB vaccine antigen, Ag85A, is a secreted protein and has a 
signal peptide at its N-terminus. The clinical candidate MVA85A expresses the full length, 
native protein fused TPA (McShane et al., 2002). Previous studies have demonstrated that 
mature Ag85A, full length Ag85A and mature Ag85A fused to TPA become progressively 
more immunogenic (Huygen et al., 1996; Montgomery et al., 1997).
The OVA gene has an N-terminal signal peptide and this too was retained in the current 
study. This was important given that the VSVg membrane anchoring region would be 
dependent upon direction of the antigen to the ER in the first instance for co-translational 
membrane insertion (Lodish et al., 2000). For consistency, the same full length OVA gene 
was included in each of the rMVA evaluated. The presence of two ER-targeting sorting 
signals in TPA-OVA-V5 is not anticipated to be detrimental and, coincidentally, mirrors the 
'signalling content' of MVA85A.
Ultimately, for each novel antigen fusion it may be necessary for (a) the
immunomodulatory effects conferred by a particular leader sequence to be empirically
investigated and (b) that experiments testing the influence of the antigen fusion be robustly
controlled. Consequently, in the current study, the two rMVA-OVA constructs
177
incorporating a cell sorting signal were matched with a corresponding no-leader control 
virus.
6.4.4. The impact of rMVA insertion site on the immunogenicity of the transgene
The panel of rMVA generated for the present study carried recombinant cassettes at one of 
two insertion sites -  Deletion site II (Del II) or Deletion site III (Del III). The insertion site had 
not been anticipated to impact upon the immunogenicity of the transgene, OVA, and T cell 
responses for the no-leader control viruses were not significantly different. However, the 
levels of IgG induced by OVA-V5 (Del III) were generally higher than V5-OVA (Del II) and 
achieved statistical significance for IgGl (P < 0.05).
When the rMVA were generated there was some evidence to suggest that Deletion site II 
may have conferred inferior stability (see Section 4.4.3). Future experiments should 
continue to monitor for insertion site effects and be extended to include characterisation of 
viral fitness and antigen expression (as performed for MVA expressing Ag85A in Chapter 5). 
Extended characterisation of the rMVA should also be complemented with repeat 
measurements of the immune responses induced; current observations have been made on 
the basis of one study. Measurement of anti-vaccinia responses should also feature to 
ensure successful and equivalent delivery of rMVA vaccines.
6.4.5 The impact of TPA and VSVg on cell mediated immunity
Fusion of OVA to VSVg was expected to lead to cell surface expression and the induction of 
higher antibody levels. The TPA signal sequence was expected to direct antigen to the ER 
and/or increase antigen expression with the result that antibody responses would be 
enhanced. Both VSVg and TPA increased anti-OVA IgG levels relative to their corresponding 
control viruses and by a similar order of magnitude.
Cytokine responses were measured after restimulation of splenocytes with either whole 
OVA protein or MHC-restricted OVA peptides. Whole protein is a less sensitive inducer of T
cell responses as it must first undergo internalisation and processing by APC in order to be 
presented to T cells. Peptides, meanwhile, can bind directly to MHC on the surface of APC 
in an ELISpot assay, leading to efficient and sensitive measurement of T cell responses 
(Schmittel et al., 2001). A peptide panel of 15-20 mers offset by 1-5 amino acids is advised 
for detection of CD4+ and CD8+ responses based upon the average epitope length for MHC 
Class I and II molecules -  8 -1 1  and 11 -  25 mers, respectively (Rodda, 2002). MHC Class I 
and MHC Class II restricted epitopes have been defined for OVA (summarised in Table 6.1) 
and were used in this study. Comparison of leader sequence effects was made on the basis 
of peptide-induced cytokine release. Cell-mediated antigen recall responses were 
investigated via IFNy ELISpot assay; there were no measureable increases in the number of 
cells secreting IL-4 and IL-17.
In the current study, fusion of OVA to VSVg did not lead to detectable differences in the 
number of antigen-specific CD4+ or CD8+ IFNy-secreting T cells. The effect of VSVg fusion 
on cell mediated immunity was previously unknown. The induction of T cell responses was 
not reported following delivery of rVV vectoring (3hCG fused to VSVg (Srinivasan et al., 
1995). The immunogenicity of an rMVA virus promoting cell surface expression of an HIV 
antigen was reported to be enhanced, but was confined to increased humoral responses; 
the levels of splenic CD8+ cells induced to release cytokine upon restimulation with the 
vaccine antigen were investigated and found to be unchanged (Wyatt et al., 2008a).
In contrast to the results obtained with V5-OVA-VSVg, immunisation with TPA-OVA-V5 
induced the lowest number of splenic CD8+ and CD4+ IFNy-releasing cells. In particular, the 
CD8+ response was reduced meaning that the skewing towards CTL-dominant immunity, 
observed for the other rMVA, was reduced. Novel TB vaccines are concerned with the 
induction of strong cellular immunity and so the expected effect of fusing OVA to TPA, a 
leader sequence commonly used in the TB vaccine field, might have been to enhance T cell 
responses. In the limited number of reports describing head-to-head comparison of TB
179
antigen delivery, with and without an N-terminal TPA leader sequence, murine splenic 
cytokine release studies have been performed. However, these reports, which suggest T 
cell responses might have been unchanged (Li eta l., 1999), or moderately enhanced (Malin 
et al., 2000), are difficult to interpret as short-term cytokine release was investigated using 
purified whole mycobacterial proteins. As demonstrated here, this may have compromised 
the ability to accurately investigate the impact of TPA fusion on cell-mediated immunity.
In the current study, fusion to either TPA or VSVg enhanced the levels of lgG2a and lgG2b in 
particular, indicating that a Th-1 biased response had been induced, and all of the rMVA 
were biased towards the induction of CD8+ T cell responses. Both of these observations 
are consistent with viral vector delivery of the antigen.
6.5 Conclusions
The impact of TPA and VSVg leader sequences on OVA humoral and cell-mediated immune 
responses was investigated. The results have confirmed the potential for antigen fusions to 
modulate the immune response evoked by the antigen to which they are fused.
The original aim of this study had been to compare single rMVA expressing OVA with a 
double-recombinant containing both the TPA-OVA-V5 and V5-OVA-VSVg cassettes. This 
was not achieved on account of the instability encountered with the double-recombinant 
virus (see Section 4.3.3). The combined effects of multiple leader sequence on a single 
antigen are still worthy of investigation and insertion of recombinant cassettes into 
alternative insertion sites, including intergenic regions (see Section 1.2.7), may support 
improved stability.
The capacity for sorting signals to direct different antigens to different pathways to avoid 
competition and/or promote the induction of favourable antigen-specific immune 
responses may also form part of future investigations. Recombinant MVA expressing 
multiple antigens in the same insertion site could be expediently created for these studies.
The current study has developed tools with which to expedite future work. Transfer 
plasmids were generated and are available for assessment of further antigens, which can 
be inserted by Gateway® cloning. Should the transfer plasmids need to be modified, they 
have been rendered amenable to alteration by restriction enzyme digest (see Section
3.4.3). An in-house panel of ELISA assays was developed in preference to purchasing 
commercially available ELISA kits. The protocol developed was less expensive to implement 
and remains available for other immunisation studies investigating TB antigens; only the 
plate-coating protein would need to be replaced. Other parameters would remain 
unchanged and the specificity of isotype detection would have already been confirmed.
Viral vectors are a promising delivery strategy as they induce strong cellular immunity 
comprising CD8+ as well as CD4+ responses (Rollier et al., 2011). Hence, they are being 
developed for vaccination against important diseases requiring T cell immunity such as HIV, 
malaria and TB. The manner in which TPA reduced OVA-specific T cell response was not 
expected. Mice immunised with MVA vectoring TPA-fused Ag85A are reported to yield a 
balanced T-helper/CTL response, i.e. the numbers of Ag85A-specific CD4+ and CD8+ 
cytokine releasing T cells are similar (Spencer et al., 2012), but the extent to which TPA 
might be limiting the induction of T cell immunity has not been previously tested.
Protection against Mtb infection is believed to require both CD4+ and CD8+ T cell immunity 
(Andersen and Woodworth, 2014). Should the role of TPA be to balance the relative 
magnitude of these two arms of defence then an ability to induce fewer CD8+ reactive T 
cells may be advantageous, but this should be explored more fully and then either 
purposefully implemented or otherwise, further optimised. The potential for leader 
sequences to improve vaccines required to induce T cell immunity was more recently 
exemplified by fusion of a malaria antigen to the MHC-II binding invariant chain (Spencer et 
al., 2014). Similar studies are required in the TB field of viral vaccine vector development.
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Chapter 7 General Discussion
Recombinant MVA is a promising strategy for the development of novel vaccines; there are 
many clinical trials ongoing for viral, bacterial and parasitic diseases, and for cancer 
immunotherapies. The attributes of MVA include an extensive safety profile, large capacity 
for foreign DNA and the ability to induce potent humoral and cell-mediated immune 
responses. There are many factors to consider when constructing rMVA vaccines 
(described in full in Section 1.2), but therein lies an opportunity to apply rational 
optimisation for improved vaccine antigen delivery. The current study investigated the 
potential for vaccinia promoter selection and antigen fusions, or 'leader sequences', to 
enhance the immunological potency of rMVA delivering TB antigens.
7.1 Construction and characterisation of novel rMVA
7.1.1. Transfer plasmid methodology
As discussed in Section 1.3, there are two main approaches to rMVA construction - transfer 
plasmid and BAC methodology. Transfer plasmid methodology was applied in the current 
study because of the ease of set up; it is less technically demanding to implement and there 
were existing transfer plasmids available for use.
Transfer plasmids serve as a shuttle-vector for insertion of recombinant cassettes into the 
MVA genome. As demonstrated in Chapter 3 (see Section 3.3), they can be modified using 
standard cloning techniques to achieve any recombinant design. This has the potential to 
be an efficient process but, where more complex alterations are required, custom synthesis 
of plasmids and/or DNA fragments may be preferable. During the course of this study, the 
preparation of custom synthesised DNA has become more advanced and affordable and 
would be put to greater use in future work, for example, by custom synthesising 
recombinant cassettes in their entirety, for insertion into the plasmid DNA vector. 
Establishing the BAC system would not have negated the requirement to create the
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required recombinant cassettes by conventional cloning, or by custom synthesis, but might 
have expedited rMVA isolation.
7.1.2 Generation and isolation of rMVA
The rMVA viruses evaluated in the current study were isolated by plaque purification. 
Generally, this was an expedient process and rMVA were purified away from the parent 
virus in less than five passages (see Sections 4.3.1 and 4.3.2). However, genetically unstable 
or otherwise unwanted recombinant populations could lengthen the process. This was 
found to occur after the insertion of recombinant cassettes designed for transient GFP 
expression; a population containing the selection marker alone could be created and had to 
be distinguished from the desired recombinant viral population (see Section 4.3.2).
The application of BAC technology might have circumvented the issue of unwanted 
recombination events, but would not have resolved issues associated with genetic 
instability. In support of the plaque purification process, examination of MVA gDNA by 
analytical PCR provided a practical and effective means of achieving routine interrogation 
of the viral samples. Thus, future studies would continue to utilise transfer plasmid 
methodology and an extended panel of tools has been made available for this purpose by 
the current project.
7.1.3 An improved rMVA vaccine for TB
Until recently, the most advanced clinical candidate under development for use against TB 
was based on MVA vectoring a single TB antigen -  Ag85A (see Section 1.4.3). MVA85A 
became the first TB vaccine to enter an efficacy trial since BCG studies performed over 40 
years prior, but was unable to improve upon the effects observed for the placebo control in 
BCG vaccinated infants (Tameris et al., 2013). MVA85A has since been evaluated in clinical 
studies investigating aerosol delivery (Satti et al., 2014), Adenovirus boosting (Sheehan et 
al., 2015) and fusion of the TPA-Ag85A to a C-terminal oligomerisation domain (Minhinnick 
et al., 2016). It has been concluded that additional vaccine antigens and immune-
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enhancing strategies are still required. The current study undertook to assess how the 
underlying rMVA design might be improved, in advance of applying additional measures.
During the period of this study, pre-clinical evaluation of another novel rMVA targeting TB 
was reported. Candidate MVATG18377 is based on rMVA vectoring 14 TB antigens for 
prevention or treatment of active, latent and reactivating TB disease (Leung-Theung-Long 
et al., 2015). The vaccine incorporates three antigen strings under the transcriptional 
regulation of three different vaccinia promoters. One string has an N-terminal signal 
peptide derived from measles virus F protein; another has an N-terminal signal peptide and 
a C-terminal transmembrane anchoring domain, both of which were derived from rabies 
virus, while the third string has no antigen fusions. The design was reportedly optimised on 
the basis of bioinformatics and a review of the biochemical properties of each antigen. 
Thus far, the antigen-specific immune response to each gene vectored by MVATG18377 is 
variable, in mice and non-human primates (NHP). Vaccine candidate R vO lll has been 
included in the construct and is expressed under the control of vaccinia promoter P7.5, 
along with three other antigens. As demonstrated in the current study, this may not confer 
optimal expression and immunogenicity and could explain the weak responses induced 
against these antigens following delivery in MVATG18377.
7.2 The study hypotheses
7.2.1 Vaccinia promoter selection
The current study sought to address whether vaccinia promoter selection could influence
the immunogenicity and protective efficacy of TB vaccine antigens vectored by MVA. It was
shown that increased expression could improve immunological potency and efficacy. This
improvement was to an extent that would be relevant to the conservation of vaccine dose.
Products based on rMVA can induce anti-vector immune responses and so reduced doses
are preferable. Lower doses are also beneficial from the perspective of vaccine
manufacture and product cost; viral vectored vaccines are propagated on live cells and
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must be produced according to stringent regulatory (GMP) conditions. As stated in Section 
1.1.4, there are established processes for rMVA production, but strategies for improving 
viral yields and lowering vaccine cost should always be pursued. An optimised vaccine 
offering equivalent protection for one tenth of the dose would serve to increase product 
yields, in terms of the number of doses per manufacturing batch, and would reduce vaccine 
cost, in terms of cost per dose. This is particularly pertinent for vaccines sponsored by 
non-profit organisations for use in the developing world.
7.2.2 Leader sequence immunomodulatory effects
It was hypothesised that the type of immune response evoked by an MVA-vectored antigen 
could be altered by the addition of particular leader sequences, and that by targeting the 
antigen to multiple pathways the immune response could be made more diverse. Leader 
sequence effects were demonstrated for a single model antigen, OVA, and highlighted the 
potential for antigen-fusions to optimise transgene immunogenicity. An unexpected 
outcome was that the specific leader sequence used in several recombinant TB vaccines, 
TPA, served to reduce antigen-specific CD8+ T cell responses. This is a significant finding as 
there is evidence to support the view that novel TB vaccine strategies should be optimised 
for the induction of both CD4+ and CD8+ mediated anti-mycobacterial responses (Behar et 
a!., 2007; Ryan etal., 2009).
7.3 Future work
7.3.1 Efficient construction of rMVA
In the course of generating markerless rMVA (see Section 4.3.2) it was apparent that an 
unwanted population, expressing the GFP marker alone, was liable to be selected. It was 
also speculated that an antigen-only population could arise. The frequency of this 
occurrence could be investigated to gauge the impact on the efficiency of rMVA 
production, and to explore measures that might reduce it. An expedient means of 
achieving this would be to perform the infection-transfection (l/T) step after replacing the
gene of interest with a second marker gene, e.g. mCherry, which encodes a red fluorescent 
protein. Upon plating of the l/T harvest, viral plaques containing the selection marker (GFP) 
only, the antigen (mCherry) only, or both could then be enumerated according to the 
presence of green, red or red & green fluorescent protein.
7.3.2 Vaccinia promoter optimisation
Vaccinia promoter selection was able to enhance the immunological potency and efficacy 
of MVA-mH5-Ag85A, but at a higher dose the protective effect was lost. This was 
speculated to have occurred following immunisation with an excessive antigen dose, 
leading to terminal differentiation of effector T cell subsets with the loss of memory cell 
populations. This phenomenon was possibly confounded by the short time interval 
between the prime and boost immunisations applied in the experimental setting of the 
current study (described in full in Section 5.4.4). Detailed immunological analyses should 
be undertaken to determine if this was indeed due to a reduction in the quality of the 
immune response. In particular, T cell subsets including those associated with memory 
should be studied for antigen-specific induction of cytokine release. Multi-parameter flow 
cytometry would be a suitable approach (Aagaard et a i,  2009) and could be performed on 
murine peripheral blood mononuclear cells (PBMCs) over a time course following 
immunisation. In the first instance, a panel of cellular markers and antibodies for 
intracellular cytokine staining (ICS) would need to be established to distinguish effector T 
cell and memory T cell subsets. Detailed immunological studies should also investigate 
alternative vaccination schedules, to examine how the benefits conferred by an rMVA 
optimised for expression might be harnessed in a clinical setting, for example, by testing 
single doses of rMVA administered after a priming immunisation with BCG.
7.3.3 The influence of TPA on TB antigen immunogenicity
Studies comparing TB antigen delivery with and without a TPA signal sequence have been 
reported, but the influence on T cell immunity after ex vivo restimulation with overlapping
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peptides as opposed to whole protein should be reassessed (see Section 6.4.5). In the 
current study, TPA served to significantly lower the number of antigen-specific CD8+ 
responding T cells. MVA85A has a TPA leader sequence and is reported to primarily induce 
potent and enduring antigen-specific CD4+ T cell responses (Tameris et al., 2014). The 
impact of TPA on the immunogenicity of TB antigens, including Ag85A, should be examined 
in a properly controlled study, i.e. after antigen delivery in rMVA that are identical in every 
regard except for the presence of the leader sequence.
7.4 Conclusions
The advent and evolution of vaccinology research is captured within the history of Vaccinia 
virus. In 1796, cowpox lesion matter, a close relative of Vaccinia virus, was administered in 
the first vaccination study ever to be undertaken. In the 1970's the virus was attenuated by 
serial passage to create a safer, live vaccine and today, MVA is subject to development as a 
recombinant viral vaccine vector using the latest molecular biology, vaccine evaluation and 
product manufacturing techniques.
There are many aspects of rMVA design to consider when generating novel rMVA-based 
vaccines. This presents an opportunity to undertake rational optimisation for the induction 
of potent and long-lasting immune responses that are appropriate for the target disease. 
As such, it is insufficient to report that a given MVA-antigen combination is or is not 
effective. As demonstrated in the current study, efficacy is intrinsically linked to the precise 
nature of the rMVA vaccines' construction. A recent human efficacy study for MVA85A was 
unsuccessful, but factors such as vaccinia promoter selection and leader sequence 
optimisation may provide a means of improving future constructs which will need to deliver 
several antigens in order to target multiple stages of disease.
The value of vaccinia promoter selection may be to reduce the dose and thereby the cost 
and anti-vector effects of rMVA vaccines. Leader sequences represent an opportunity to 
further explore and enhance TB antigen immunogenicity. The rational selection of an
appropriate leader sequence may result in a more diverse immune response to an antigen, 
or help to explore changes in the quality of the immune response and their impact on 
protective efficacy. Vaccinia promoter selection and leader sequence optimisation should 
be a feature of future rMVA TB vaccine development.
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Appendix I
Transfer plasmids designed to  insert OVA into the MVA genome were sequenced across the 
open reading frame to  obtain continuous data fo r one or both strands. The sequenced 
region is indicated by a green arrow. The position of restriction enzyme recognition sites 
utilised in the cloning process is also highlighted. The plasmids maps were generated in 
SeqBuilder DNA Lasergene 11.
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Appendix II
A transfer plasmid designed to  insert a truncated version o f R v O lll (R vO lllT ) into the 
MVA genome was sequenced across the open reading frame to obtain continuous data for 
one or both strands. The sequenced region is indicated by a green arrow.
i. pTBDl-RvOlllT
Nsrt
pTBD1-Rv0111T
Sbfi
SnaBl
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Appendix III
The pTBD plasmid series are E. coli cloning vectors incorporating an Ampicillin resistance 
gene (see Section 2.1.4). The sequence of each recombinant cassette is as follows:
i. pTBDl-RvOlllT
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -14 93 39
Promoter P l l 948 - 978 TTTCATTTTG1 1 1 1 111CTATGCTATAAATG
GFP 976 -1695 JQ693016.1
Promoter mH5 1717 -1786 AAAAATTG AAAATAAATACAAAGGTT CTT G A 
GGGTTGTGTTAAATTGAAAGCGAGAAATAAT 
CATAAATA
Optimised Kozak 1795 -1804 GCCACCATGG
TPA 1801 -1908 X13097.1; 109 -  216
RE site/Gateway attB l 1909 -1941 CCCAT CAAACAAGTTT GTACAAAAAAG CAG G 
CT
R vO lllT 1942 - 2913 CP003248.2; 135031 -136002
Gateway attB2/RE site 2914 - 2946 ACCCAG CTTT CTT GTACAAAGT GGTTCGATGG 
G
Linker 2947 - 2970 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 2971 - 3012 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3028 - 3549 U94848.1; 149345-149866
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ii. pTBD2-Rv0111
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413-149339
Promoter P l l 948 - 978 TTT CATTTT GTTTTTTT CTAT G CTATAAATG
GFP 976 -1695 JQ693016.1
Promoter 7.5 1704 -1975 AY243312.1; 190028 -190295
Optimised Kozak 1978 -1987 GCCACCATGG
TPA 1984 - 2091 X13097.1; 1 0 9 -2 1 6
RE site/Gateway attB l 2092 - 2124 CCCAT CAAACAAGTTTGTACAAAAAAG CAG G 
CT
R vO lll 2125-4176 CP003248.2; 133951 -136002
Gateway attB2/RE site 4177 - 4209 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGG
G
Linker 4210 - 4233 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 4234 - 4278 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 4291-4812 U94848.1; 149345 -1 4 9 8 6 6
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iii. pTBDl-Ag85A
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -14 93 39
Promoter P l l 948 - 978 TTTCATTTTG1 11 1 1 1 1CTATG CTATAAATG
GFP 976 -1695 JQ693016.1
Promoter mH5 1717 -1786 AAAAATT G AAAATAAATACAAAG GTTCTT G A 
G G GTTGT GTTAAATT G AAAG CG AG AAATAAT 
CATAAATA
Optimised Kozak 1795 -1804 GCCACCATGG
TPA 1801 -1908 X13097.1; 1 0 9 -2 1 6
RE site/Gateway attB l 1909 -1941 CCC AT CAA AC AAGTTT GTACAAA A AAG CAG G 
CT
Ag85A (Rv3804c) 1942 - 2955 CP003248.2; 4266836 - 4265823
Gateway attB2/RE site 2956 - 2988 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGG
G
Linker 2989 - 3012 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3013 - 3057 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3070 - 3591 U94848.1; 149345-149866
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iv. pTBD2-Ag85A
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -14 93 39
Promoter P l l 948 - 978 TTTCATTTTGTTTTTTTC1ATGCTATAAATG
GFP 976 -1695 JQ693016.1
Promoter 7.5 1704 -1975 AY243312.1; 190028 -190295
Optimised Kozak 1978 -1987 GCCACCATGG
TPA 1984 - 2091 X13097.1; 1 0 9 -2 1 6
RE site/Gateway attB l 2092 - 2124 CCC AT CAAAC AAGTTT GTACAAA AAAG C AG G 
CT
Ag85A (Rv3804c) 2125 - 3138 CP003248.2; 4266836 - 4265823
Gateway attB2/RE site 3139-3171 ACCCAGCTTT CTT GTACAAAGT G GTTCG ATG G 
G
Linker 3172 - 3195 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3196 - 3240 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3253 - 3774 U94848.1; 149345 -1 4 9 8 6 6
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v. PTBD5-0VA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -14 93 39
Promoter P l l 948 - 978 TTT CATTTT G TTTT1TTCTATG CTAT AAAT G
GFP 976 -1695 JQ693016.1
MVA Del III Direct repeat 1702 -1983 U94848.1; 149058 -149339
Promoter mH5 2015 - 2084 AAAAATT G AAAATAAATACAAAG GTT CTT GAG 
GGTTGTGTTAAATTGAAAGCGAGAAATAATCA 
TAAATA
Optimised Kozak 2093 - 2102 GCCACCATGG
TPA 2099 - 2206 X13097.1; 1 0 9 -2 1 6
RE site/Gateway attB l 2207 - 2239 G ATAT CAAAC AAGTTT GTACA AAAAAG CAG G C
T
Ovalbumin 2240 - 3394
1
NM_205152.1; 68-1222
Gateway attB2/RE site 3395 - 3427 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGGG
Linker 3428 - 3451 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3452 - 3496 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTC
GATTCTACGTAA
MVA Del III Right flank 3509 - 4030 U94848.1; 149345 -14 98 66
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vi. pTBD6-0VA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -14 93 39
Promoter P l l 948 - 978 TTT C ATTTT G TTTTTTT CT AT G CTATAAATG
GFP 976 -1695 JQ693016.1
MVA Del III Direct repeat 1702 -1983 U94848.1; 149058 -149339
Promoter 7.5 1997 - 2264 AY243312.1; 190028 -190295
Optimised Kozak 2271 - 2280 GCCACCATGG
TPA 2277 - 2384 X13097.1; 109 -  216
RE site/Gateway attB l 2385 - 2417 G ATAT CAAAC AAGTTT GTACA AA AA AG C AG G 
CT
Ovalbumin 2418 - 3572 NM_205152.1; 68 -1222
Gateway attB2/RE site 3573 - 3605 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGG
G
Linker 3606 -3629 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3 6 3 0 -3 6 7 4 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3687 - 4208 U94848.1; 149345 -14 98 66
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vii. pTBD9-0VA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 -9 3 3 U94848.1; 148413-149339
Promoter P l l 948 - 978 TTTCATTTTG1I I'll 1 1 ClATGCTATAAATG
GFP 976 -1695 JQ693016.1
MVA Del III Direct repeat 1702 -1983 U94848.1; 149058 -149339
Promoter mH5 2015 - 2084 AAAAATTG AAAATAAATACAAAGGTT CTT G A 
GGGTTGTGTTAAATTGAAAGCGAGAAATAAT 
CATAAATA
Optimised Kozak 2093 - 2102 GCCACCATGG
RE site/Gateway attB l 2099 - 2134 ATG G ATAT C AAACAAGTTTGTACAAAA AAG C 
AGGCT
Ovalbumin 2135-3289 NM_205152.1; 68 -1222
Gateway attB2/RE site 3290 - 3322 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGG
G
Linker 3323 - 3346 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3347 - 3391 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3404 - 3925 U94848.1; 149345 -14 98 66
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viii. pTBDlO-OVA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del III Left flank 7 - 9 3 3 U94848.1; 148413 -1 4 9 3 3 9
Promoter P l l 948 - 978 TTTCATTTTG1 1 1 1 1 11C 1 ATG CTATAAATG
GFP 976 -1695 JQ693016.1
MVA Del III Direct repeat 1702 -1983 U94848.1; 149058 -149339
Promoter 7.5 1997 - 2264 AY243312.1; 190028 -190295
Optimised Kozak 2271 - 2280 GCCACCATGG
RE site/Gateway attB l 2277 -2312 ATG GATAT CAA ACAAGTTT GTACAAAA AAG C 
AGGCT
Ovalbumin 2313 - 3467 NM_205152.1; 68- 1222
Gateway attB2/RE site 3468 -3500 ACCCAG CTTT CTT GTAC AAAGT GGTTCGATGG 
G
Linker 3501 -3524 GATCTAGAGGGCCCGCGGTTCGAA
V5 tag/Stop 3525 -3569 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACGTAA
MVA Del III Right flank 3582 - 4103 U94848.1; 149345-149866
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ix. pTBDll-OVA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del II Right flank 17 - 583 U94848.1; 21284-20719
Promoter P l l 601 - 631 TTTCATTTTG1 11 1 1 1 1C1ATGCTATAAATG
GFP 629 -1348 JQ693016.1
MVA Del II Direct repeat 1355 -1571 U94848.1; 20935-20719
Promoter mH5 1596 -1665 AAAAATT G AAAATAAATACAAAG GTT CTTG A 
GGGTTGTGTTAAATTGAAAGCGAGAAATAAT 
CATAAATA
Optimised Kozak 1674 -1683 GCCACCATGG
V5 tag 1683 -1724 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACG
Linker 1725 -1748 GATCTAGAGGGCCCGCGGTTCGAA
RE site/Gateway attB l 1749 -1781 GATAT CAAACAAGTTT GTACAAAAAAG CAG G 
CT
Ovalbumin 1782 -2936 NM_205152.1; 68 -1222
Gateway attB2/RE site 2937 -  2984 ACCCAG CTTT CTT GTACAAAGTG GTTCG AT G G 
GGATCTAGAGGGCCCG
VSVg/Stop 2985 - 3134 GU177825.1; 1387 -1536
MVA Del II Left flank 3148 - 3842 U94848.1; 20666-19972
206
x. PTBD12-0VA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del II Right flank 1 - 5 6 7 U94848.1; 21284-20719
Promoter P l l 585 - 615 TTTCATTTTG 1 111111C1 ATGCTATAAATG
GFP 613 -1332 JQ693016.1
MVA Del II Direct repeat 1339 -1555 U94848.1; 20935-20719
Promoter 7.5 1562 -1829 AY243312.1; 190028 -190295
Optimised Kozak 1836 -1845 GCCACCATGG
V5 tag 1845 -1886 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACG
Linker 1887 -1910 GATCTAGAGGGCCCGCGGTTCGAA
RE site/Gateway attB l 1911 -1943 GATAT CAAACAAGTTT GTACAAAAAAG CAG G
CT
Ovalbumin 1944 - 3098 NM_205152.1; 68 -1222
Gateway attB2/RE site 3099 - 3146 ACCCAG CTTTCTTGTACAAAGTGGTTCGATGG
GGATCTAGAGGGCCCG
VSVg/Stop 3147 - 3296 GU177825.1; 1387 -1536
MVA Del II Left flank 3310 - 4004 U94848.1; 20666-19972
207
xi. pTBD13-0VA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del II Right flank 17 - 583 U94848.1; 21284-20719
Promoter P l l 601 - 631 TTTCATTTTG 1 11 1 1 1 1C1 ATGCTATAAATG
GFP 629 -1348 JQ693016.1
MVA Del II Direct repeat 1355 -1571 U94848.1; 20935-20719
Promoter mH5 1596 -1665 AAAAATT G AAA ATAAATACA AAG GTT CTT G A 
G G GTTGT GTTAAATTG AAAG CG AG AAATAAT 
CATAAATA
Optimised Kozak 1674 -1683 GCCACCATGG
V5 tag 1683 -1724 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACG
Linker 1725 -1748 GATCTAGAGGGCCCGCGGTTCGAA
RE site/Gateway attB l 1749 -1781 GAT AT CAAACAAGTTT GTACAAAAAAG CAG G 
CT
Ovalbumin 1782 -2936 NM_205152.1; 68 -1222
Gateway attB2/RE 2937 -  2987 ACCCAGCTTTCTTGTACAAAGTGGTTCGATGG
site/Stop GGATCTAGAGGGCCCGTAA
MVA Del II Left flank 3001 - 3695 U94848.1; 20666-19972
208
xii. pTBD 14-OVA
Feature Plasmid bases GenBank Accession No./Sequence
MVA Del II Right flank 1 -5 6 7 U94848.1; 21284-20719
Promoter P l l 585 - 615 TTT CATTTT GTTTTTTT CT AT G CTAT AAAT G
GFP 613 -1332 JQ693016.1
MVA Del II Direct repeat 1339 -1555 U94848.1; 20935-20719
Promoter 7.5 1562 -1829 AY243312.1; 190028 -190295
Optimised Kozak 1836 -1845 GCCACCATGG
V5 tag 1845 -1886 GGTAAGCCTATCCCTAACCCTCTCCTCGGTCT
CGATTCTACG
Linker 1887 -1910 GATCTAGAGGGCCCGCGGTTCGAA
RE site/Gateway attB l 1911 -1943 G ATAT CAAACAAGTTT GTACAAAAAAG CAG G 
CT
Ovalbumin 1944 - 3098 NM_205152.1; 68 -1222
Gateway attB2/RE 3099 - 3149 ACCCAG CTTT CTT GTACAAAGT G GTT CG ATG G
site/stop GGATCTAGAGGGCCCGTAA
VSVg/Stop 3147 - 3296 GU177825.1; 1387 -1536
MVA Del II Left flank 3310 - 4004 U94848.1; 20666-19972
209
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